November 2026 Volume 18 Issue 11 IRISHPHARMACYNEWS.IE
THE INDEPENDENT VOICE OF PHARMACY
Scan for Digital Version
In this issue: NEWS: Welcome for Pharmacist Prescribing Page 5
REPORT: The Case for a Pharmacy Deprivation Payment Page 8
CORPORATE PROFILE: In Conversation with Graham Stafford Page 20
SEASONAL: What’s in your Pharmacy ‘Stocking’? Page 38
CPD: Management of Oncology Pain Page 41
SPECIAL FOCUS: Why Ireland Must Rethink Men's Health Page 46
TEAM TRAINING: Cough, Cold & Flu Page 72 This Publication is for Healthcare Professionals Only
Re-Evaluate Rinse
®
Evidence-Based. Patient-Focused.
Range of tastes tailored to help with patient compliance. While every patient’s mouthwash preference is unique, recommendations should always be evidence-based. Recommend the 3rd essential step, formulated with 4 Essential Oils.
It’s Time For An Evidence-Based Recommendation. FIND OUT MORE UK-LIS-2025-268193
3
Contents
Foreword
Page 5: Retail Excellence for Ryan’s Pharmacy
There is a recurring theme throughout this month's edition of Irish Pharmacy News: the growing importance of community pharmacy within Ireland's healthcare system, and the need to ensure that the profession has the support, resources and recognition to fulfil its expanding responsibilities.
Page 6: Pharmacies Score High for Customer Service Page 8: Special Report on Pharmacy Deprivation Payments Page 14: McCabes Launch New Digital App
5
Page 16: Medication Safety Week recognises Pharmacy Page 18: Ten Cyber Security Steps to Protect your Pharmacy Page 20: Changing the Conversation around Fertility Nutrition
8
Page 26: Polypharmacy and the Role of the Team
EDITOR Kelly Jo Eastwood: +44 787654 8989 kelly-jo@ipn.ie
14
Patient safety is another important focus this month. We examine Medication Safety Week and the practical steps pharmacies can take to strengthen their systems and protect patients. Our feature on cyber security also highlights an increasingly important area of business resilience, offering ten practical steps to help pharmacy owners safeguard their operations.
With winter approaching, our Team Training feature on coughs, colds and flu provides timely guidance for pharmacy teams preparing for one of their busiest periods. We also highlight the profession's contribution to preventative healthcare, including the new community pharmacy initiative supporting participation in the national BowelScreen programme. What emerges from these stories is a profession that continues to evolve, innovate and respond to the changing needs of patients. Yet progress must be accompanied by meaningful investment, appropriate recognition and policies that support sustainable pharmacy practice.
SALES DIRECTOR Debbie Graham debbiegraham@ipn.ie +353 8727 99317 MARKETING AND EDITORIAL MANAGER Anna Hadfield Office: +353 (01) 2339121 Mobile: +353 89 947 7171 anna@ipn.ie
This is particularly evident in our special report on pharmacy deprivation payments, beginning on page 8. The report examines an issue that goes to the heart of equitable healthcare provision. Pharmacies serving disadvantaged communities often face additional pressures, yet their role in providing accessible, trusted healthcare services is especially important. Ensuring their long-term sustainability must remain a priority if we are to avoid widening existing inequalities in patient access and care.
Elsewhere, we explore polypharmacy and the valuable contribution of the wider pharmacy team in supporting patients managing multiple medicines. Our CPD feature examines cancer pain, while our men's health coverage considers issues extending beyond the familiar November focus on moustaches, including hair loss and its wider implications for wellbeing.
PUBLISHER: IPN Communications Ltd. 77 Camden Street Lower, Dublin D02 XE80 Office: +353 (01) 2339121 MANAGING DIRECTOR Natalie Maginnis natalie@ipn.ie
As expectations around clinical services, medicines optimisation and patient access continue to increase, questions surrounding the sustainability of community pharmacy have become more pressing than ever.
Community pharmacy has demonstrated time and again its ability to adapt and deliver. The challenge now is ensuring that the structures and resources are in place to allow it to continue doing so.
46
I hope you enjoy the issue.
CONTRIBUTORS Darren Scully | Dave Buckley Jessica Egerton | Wen Yan Low Tomás Cahill | Nessa Keane Dr Dmitri Wall | Amy Doyle Dr Susan Brannick | Elaine Buckley Edward Murphy | Aishling Sheridan Shane O’Donnell | Tiernan McCann Dr Jordan Kirwan | Noof Albannai Professor Karen Ryan Professor Naishadh Patil
DESIGN DIRECTOR Ian Stoddart Design IRISHPHARMACYNEWS.IE
Irish Pharmacy News IRISH PHARMACY is circulated to all NEWS independent, multiple Pharmacists and academics in Ireland. All rights reserved by Irish Pharmacy News. All material published in Irish Pharmacy News is copyright and no part of this magazine may be reproduced, stored in a retrieval system or transmitted in any form without written permission. IPN Communications Ltd. has taken every care in compiling the magazine to ensure that it is correct at the time of going to press, however the publishers assume no responsibility for any effects from omissions or errors.
Regulars CPD: CANCER PAIN
P41
MEN’S HEALTH: BEYOND THE MOUSTACHE
P46
MEN’S HEALTH: HAIR LOSS
P52
TEAM TRAINING: COUGH, COLD & FLU
P72
@Irish_PharmNews IrishPharmacyNews
IRISHPHARMACYNEWS.IE
4
News
Community Pharmacies to Support National BowelScreen Initiative Community pharmacy teams across Ireland are taking on an enhanced role in promoting participation in the HSE's national BowelScreen programme, as part of a new initiative introduced under the Community Pharmacy Agreement 2025. The initiative, recently launched by the Minister for Health, is being delivered in collaboration with the Irish Pharmacy Union (IPU) and the HSE and aims to increase awareness and uptake of bowel cancer screening among eligible patients.
programme or request a home screening kit.
trusted conversations during routine pharmacy visits.
The initiative provides an opportunity for community pharmacists and their teams to use their regular contact with patients to encourage greater participation in preventative healthcare services.
Participating community pharmacies will provide information about BowelScreen, address patient queries and encourage eligible individuals to register for the programme and complete their free home screening test.
Pharmacy teams taking part have completed dedicated training developed jointly by the HSE and IPU, equipping them with the information needed to explain the screening process, answer common questions and signpost patients to appropriate resources.
The programme also reflects the expanding role of community pharmacy in public health promotion, with pharmacists increasingly contributing to vaccination, screening awareness and preventative healthcare initiatives.
As part of the initiative, pharmacy teams will attach specially designed promotional stickers to prescription bags dispensed to patients within the eligible age group. Each sticker features a freephone number and QR code, enabling patients to check their registration status, register for the
The IPU highlighted that many eligible individuals intend to participate in bowel screening but may delay completing their test, forget to return their kit or remain uncertain about the process. Community pharmacy teams are well positioned to address these barriers through accessible,
Bowel cancer remains a significant public health concern in Ireland, ranking as the second most common cancer in men and the third most common invasive cancer in women, with approximately 2,800 new diagnoses each year. Through this initiative, community pharmacies will provide an additional point of contact for eligible patients, complementing existing HSE screening communications and supporting increased engagement with the national programme.
Chemist Warehouse Open 19th Store Chemist Warehouse Ireland has continued its retail expansion with the opening of its 19th store, located in the ILAC Shopping Centre in Dublin 1. established everyday low-price retail proposition. Situated in one of Dublin's prominent city-centre shopping destinations, the new store provides Chemist Warehouse with an additional opportunity to reach shoppers and strengthen its visibility within the capital's competitive pharmacy retail market.
The new outlet strengthens the pharmacy retailer's presence in Dublin city centre and represents another milestone in the company's ongoing growth across the Irish market. The store officially opened its doors to customers this week, with Chemist Warehouse reporting strong activity and enthusiasm on the shop floor from the outset. The company highlighted the collaborative effort involved in bringing the new location into
IRISHPHARMACYNEWS.IE
operation, acknowledging the contributions of teams across property, construction, operations, merchandising, buying and marketing.
The opening brings the company's Irish store network to 19 locations, reflecting its continued investment in expanding its physical retail footprint.
Chemist Warehouse also thanked its suppliers and brand partners for their continued support in preparing the new store for opening.
For the wider community pharmacy sector, the latest opening highlights the ongoing development of Ireland's pharmacy retail landscape, with larger operators continuing to invest in new locations, product ranges and customer accessibility.
The ILAC Centre location will offer customers access to the retailer's extensive range of pharmacy, healthcare, beauty and personal care products, alongside its
Chemist Warehouse has welcomed the opening as another important step in bringing its brands, product selection and pricing proposition to a broader customer base.
EMA Recommends Six Medicines The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended six medicines for European Union marketing authorisation following its October 2026 meeting, including new treatments for pancreatic cancer, obesity and type 2 diabetes. Among the recommendations is Rasonque (daraxonrasib), intended for adults with metastatic pancreatic adenocarcinoma who have received at least one previous treatment. The medicine underwent a phased review after being identified as a high-priority treatment under the EMA's Cancer Medicines Pathfinder initiative, reflecting the significant unmet medical need in advanced pancreatic cancer. The committee also issued positive opinions for Foundayo (orforglipron), for adults with obesity and type 2 diabetes, and Kizfizo (temozolomide), for adults with glioblastoma multiforme and children with malignant glioma. Kizfizo was assessed through a hybrid application incorporating evidence from an existing authorised reference medicine alongside additional data. A further positive recommendation was issued for Yuviwel (navepegritide), for the treatment of achondroplasia in children. Two biosimilars also received positive opinions: Fovlussea (ranibizumab), for several retinal conditions including wet age-related macular degeneration and diabetic macular oedema; and Neuzafy (filgrastim), for neutropenia in adults and children. The CHMP comprises scientific experts from EU Member States, Iceland, Liechtenstein and Norway, with Ireland represented by experts from the Health Products Regulatory Authority (HPRA). Its recommendations follow scientific assessment of medicines' quality, safety and efficacy. Final decisions on centralised EU marketing authorisations rest with the European Commission.
News Over ¤10 million to Expand Mental Health Services
5
Retail Excellence for Ryan’s Pharmacy Ryan's Pharmacy in Edenderry, County Offaly, has been named Pharmacy of the Year at the Elavon Retail Excellence Ireland Awards 2026.
Minister for Mental Health, Mary Butler TD, has announced a major package of investment under Budget 2027 to strengthen specialist and forensic mental health services, including over ¤10 million in annual recurring funding for the continued rollout of National Clinical Programmes and the expansion of highly specialised community-based mental health services across the country. The investment will support the establishment of three new specialist clinical teams, expand services experiencing significant growth in demand, and continue the development of Ireland's national forensic mental health service. As part of the package, Budget 2027 will provide funding for: • A new Early Intervention in Psychosis (EIP) Team in Donegal, a county with a rate of prevalence 50% higher than the national average • The final Eating Disorder Team required to complete the national rollout of the Adult Eating Disorders Programme, serving the Mid-West • A new Dual Diagnosis Team in Dublin South West (Tallaght) to support people experiencing both mental health difficulties and addiction • Additional medical and clinical capacity within Adult ADHD services to respond to increasing referrals and demand for assessment and treatment • Enhanced staffing for specialist Perinatal Mental Health Services, bringing each regional spoke-site team to a minimum of 2.0 wholetime equivalent clinical staff, strengthening supports for women during pregnancy and the first year following birth The investment builds on the significant progress made in recent years under the National Clinical Programmes and further advances the Government's commitment to providing timely, evidence-based specialist mental health care closer to home.
The pharmacy received the prestigious accolade at an awards ceremony held on Saturday, 10 October, at the Lyrath Estate Hotel in Kilkenny, attended by more than 500 executives and representatives from across Ireland's retail sector. Organised by Retail Excellence Ireland, the annual awards recognise outstanding achievement, innovation and high standards across the Irish retail industry. The Pharmacy of the Year award represents a significant achievement for Ryan's
Pharmacy, highlighting the continued importance of independent community pharmacy within Ireland's competitive retail landscape. Commenting on the awards, Jean McCabe, CEO of Retail Excellence Ireland, praised the exceptional standard of entries and the commitment demonstrated by participating retailers.
She also acknowledged the challenges facing retailers, particularly persistently high operating costs, while expressing optimism about the sector's outlook for 2027. Established in 1997, the Retail Excellence Ireland Awards promote best practice and celebrate businesses demonstrating excellence across the country's retail sector.
“The standard across this year's submissions has been exceptional, and our panel of judges found it incredibly difficult to choose the final recipients,” she said.
For Ryan's Pharmacy, the national recognition marks an important achievement and places the Edenderry business among Ireland's award-winning retailers.
Pharmacy Contraception Services Community pharmacists are set to take on an expanded role in contraceptive care, with work progressing on a new pharmacist-led prescribing service under the Community Pharmacy Agreement 2025. Pharmacists have supplied emergency hormonal contraception without a GP prescription for more than a decade, providing an established, accessible service for patients requiring time-sensitive treatment. Emergency contraception is currently available free of charge through participating pharmacies to eligible individuals aged 17 to 35 under the HSE's Free Contraception Scheme. Medicalcard holders can also access emergency contraception directly from pharmacies without a GP prescription. Attention is now turning to the next phase of pharmacy-based contraceptive care. The proposed Contraception Prescribing Service will enable pharmacists to issue prescriptions
for specified short-acting contraception to patients meeting defined clinical criteria who have previously received a prescription. The Health (Provision of Contraception Prescribing Service in Retail Pharmacy Businesses) Bill 2026 was published in June, providing a legislative pathway for the new service. Speaking exclusively to Irish Pharmacy News, Ireland's new Chief Pharmaceutical Officer, Cora O'Connell, confirmed that the service could be introduced in early 2027, subject to the necessary approvals. She described contraception prescribing as the next step in the pathway towards greater pharmacist prescribing responsibilities, with autonomous prescribing planned initially for
secondary care before extending into primary care. Turn to page 8 for the full interview. Implementation work is progressing, with clinical protocols, professional guidance and training requirements forming part of preparations for the service. The development builds on community pharmacy's established role in reproductive healthcare and represents another step towards integrating pharmacists more fully into the delivery of accessible primary care services. While the proposed service will initially operate within defined prescribing criteria, it is expected to help establish the foundations for further expansion of pharmacists' clinical responsibilities in the coming years.
IRISHPHARMACYNEWS.IE
6
News
Pharmacies Among Ireland’s Top Customer Performers Life Pharmacy and McCabes Pharmacy have secured places among Ireland’s top ten brands for customer experience, reinforcing the strong performance of the pharmacy and health retail sector in the latest annual Customer Experience (CXi) survey. Life Pharmacy achieved second place overall, while McCabes Pharmacy ranked seventh, placing two pharmacy and health retail brands among the country's highest-rated organisations. The findings, published on 13 October 2026, highlight the continued importance of personal service and customer relationships at a time when businesses across Ireland are increasingly exploring artificial intelligence and digital solutions to improve customer engagement. Now in its eleventh year, the CXi report assesses more than 150 leading Irish brands based on consumers' experiences. Conducted by Amárach Research, the latest survey found that Ireland's overall customer experience score increased by 3%, reaching its highest level in nine years.
Some 64% of Irish companies and organisations recorded improvements in their CX scores, contrasting sharply with the United States, where just 6% of companies experienced an increase over the same period. According to Michael Killeen, report author and Chairman of the CX Academy, Ireland's improving customer experience performance reflects the continued preference among Irish consumers for meaningful human interaction rather than technology-led solutions alone. The findings are particularly relevant to community pharmacy, where face-to-face advice, professional expertise and established relationships with patients remain central to service delivery. While digital innovation and artificial intelligence offer opportunities to streamline
operations and improve accessibility, the report suggests that technology alone cannot replace the value customers place on personal engagement. For community pharmacy operators, the results underline the commercial and reputational importance of maintaining high standards of customer service alongside the sector's expanding clinical responsibilities. The strong rankings achieved by Life Pharmacy and McCabes demonstrate the pharmacy sector's ability to compete with leading brands across financial services, retail, travel and other consumer-facing industries. For Ireland's community pharmacy sector, the latest CXi findings provide further evidence of the importance of trusted, accessible and personalised service.
Théa Pharma All-Star Award Théa Pharma Ireland has been recognised as Business All-Star Mayo Champion Enterprise 2026 by the All-Ireland Business Foundation, acknowledging the company's contribution to ophthalmic healthcare and the wider business community in County Mayo. Diarmuid Gavin Accepting the award on behalf of the company, Country Manager Diarmuid Gavin said, “At the heart of this achievement is a shared commitment to improving eye health, supporting the healthcare professionals who place their trust in us and contributing to the community we call home. This award belongs to our people, whose expertise, dedication and teamwork make that commitment a reality every day.”
The award recognises Théa Pharma Ireland's commitment to innovation, quality and leadership within Ireland's eye health sector, alongside its continued support for healthcare professionals and patients.
IRISHPHARMACYNEWS.IE
The All-Ireland Business Foundation described Théa Pharma Ireland as “a company that has become synonymous with innovation, quality and leadership within Ireland’s ophthalmic healthcare sector.”
The company also highlighted its strong connections to County Mayo, emphasising its commitment to contributing to the region's economic and professional development. Théa Pharma Ireland thanked the All-Ireland Business Foundation for the recognition, describing the award as a reflection of the dedication and collective efforts of its team.
Minster for Health at WHO Session Minister for Health, Jennifer Carroll MacNeill TD, has recently travelled to Copenhagen to attend the 76th session of the World Health Organisation (WHO) Regional Committee for Europe, underlining Ireland’s commitment to strong international cooperation on health. The WHO Regional Committee for Europe serves as the primary decision-making body for the WHO European Region, which comprises 53 countries, including the 27 EU Member States. It provides a platform for countries to discuss public health priorities, review progress, and make decisions that guide WHO’s work in the region. Minister Carroll MacNeill will deliver a statement at the WHO on behalf of the 27 EU Member States, as part of Ireland’s role as President of the Council of the European Union – the Minister will also attend several bilateral meetings. Speaking ahead of the WHO Regional Committee, Minister Carroll MacNeill said, “I am honoured to deliver a statement on behalf of the European Union at the WHO Regional Committee for Europe. At a time of growing pressure on global health, Ireland and our EU partners stand firmly behind a strong, effective World Health Organisation, with predictable funding to deliver where it matters most - to build more resilient, equitable and sustainable health services. “Ireland will continue to engage closely with the WHO Regional Office for Europe and regional partners to ensure collaboration on issues including health emergencies, universal health coverage and health inequalities. “I commend the vital support that the WHO office is providing to Ukraine and applaud the unwavering commitment of WHO in alleviating the immense suffering of people in Gaza. “Healthcare workers, patients and hospitals must be protected in every conflict, and humanitarian assistance must reach those who urgently need it.”
SUPPORT YOUR BODY
– with just one tablet daily HAIR1,4 NAILS1,4 SKIN1 METABOLISM 4 IMMUNE SYSTEM1,2,3,4 ENERGY 2,3 BioActive® Selenium+Zinc is one of the most rigorously tested selenium supplements on the market. In the last 30 years it has changed the lives of millions of consumers in more than 45 countries worldwide. Contains the patented SelenoPrecise yeast (organic selenium), which is widely known for its superior bio-availability (89% absorption) and safety records.
Contributes to the maintenance of normal hair1,4. Helps maintain normal skin1. Contributes to the maintenance of normal nails 1,4. Supports a normal thyroid function4. Supports normal function of the immune system1,2,3,4. Contributes to the reduction of tiredness and fatigue2,3. 1: Zinc / 2: Vitamin C / 3: Vitamin B6 / 4: Selenium
Visit: www.pharmanord.ie to find out more about BioActive® Selenium + Zinc and our full range of high quality supplements. You can also sign up to our newsletters and stay informed on the latest health headlines.
8
Report
Unequal Need, Unequal Resources: The Case for a Pharmacy Deprivation Payment As the Irish Pharmacy Union calls for a €2.295 million Health Equity Payment for pharmacies serving disadvantaged communities, Irish Pharmacy News examines the pressures facing frontline providers, the evidence linking deprivation with medicines-related risks, and the Government's existing approach to funding general practice. In a community pharmacy on Dublin's Pearse Street, the changing face of the capital is impossible to ignore. Technology companies, modern office developments and an expanding commuter population have transformed the surrounding area. Yet behind the commercial regeneration, many longstanding residents continue to experience financial pressures and complex healthcare needs.
resources to community pharmacies in disadvantaged areas. “The Government has previously recognised that community pharmacies serving disadvantaged communities required dedicated additional resources to improve health outcomes. The principle was right then, and the evidence for acting on it is even stronger today. “If Government is serious about reducing health inequalities, we must protect access to healthcare in the communities where the need is greatest.”
For pharmacist Tomás Conefrey, whose family pharmacy has served the area for more than seven decades, the contrast is striking.
Caoimhe insists the proposal should be viewed through the lens of healthcare access rather than simply commercial support.
“We are a family pharmacy on Pearse Street in Dublin 2. The business was founded by my father around 71 years ago. My mother subsequently ran it, and I have been working there for about 28 years. “I have seen enormous changes in the area. There are now major offices, technology companies and new developments, with many people commuting in to work. At the same time, there is still a strong local community, including longestablished residents and families.” Despite the area's transformation, approximately 80% of the pharmacy's monthly claims are made under the General Medical Services (GMS) scheme. That experience provides a practical illustration of the issues behind a new call from the Irish Pharmacy Union (IPU) for
Tomás Conefrey
communities where healthcare needs are greatest.
dedicated funding for pharmacies serving areas of significant social deprivation.
The proposal raises a fundamental question: should pharmacies caring for populations with greater health and social needs receive additional resources to reflect the demands placed upon them?
In September, the IPU urged Government to introduce a targeted Health Equity Payment through Budget 2027, seeking ¤2.295 million to help protect access to pharmacy services in
“There is only so much time in the day, and the workload keeps increasing. If extra support could fund somebody to help with the work, or allow us to delegate appropriate tasks, that would be a substantial help,” Tomás Conefrey IRISHPHARMACYNEWS.IE
A Commitment Yet to Be Delivered The IPU argues that pharmacies in disadvantaged communities often face pressures that are not adequately recognised within existing funding arrangements. These can include higher volumes of patients with complex healthcare needs, additional time spent supporting patients with limited health literacy, greater operational costs and fewer opportunities to supplement dispensing income through retail activity. IPU President Caoimhe McAuley points to a commitment contained in the 2020 Programme for Government, Our Shared Future, to provide dedicated additional
“This is not simply about supporting individual pharmacy businesses. It is about protecting a highly accessible part of our primary care infrastructure and ensuring that the move towards delivering more care closer to home benefits every community,” she has said. The IPU has also highlighted an existing precedent: the Social Deprivation Grant available to eligible GMS general practices. The Reality Behind the Dispensary Counter For Tomás, the financial circumstances of patients can influence everyday decisions about medicines and pharmacy services. He cites the example of children prescribed melatonin for sleep difficulties, including some children with ADHD, where reimbursement arrangements can leave families facing additional costs. Depending on prescribing circumstances and approval, he says, some families may face a cost of approximately ¤40 per month. Another challenge is the provision of medicines in blister packs. “We have around 50 patients receiving medicines in blister packs. Roughly half pay for the service and half do not. We introduced a charge for certain
9
“Further research is needed to better understand these socioeconomic differences in higher-risk prescribing and polypharmacy and to determine whether they reflect appropriate prescribing in response to greater clinical need or inequities in care that increase the risk of medication-related harm,” Dr Caitriona Cahir Dr Caitriona Cahir
patients because preparing the packs takes time and resources, and we need to cover those costs,” he says. Tomás acknowledges that blister packs can be particularly valuable for patients managing multiple medicines. However, he believes the service must be appropriately targeted, with alternatives considered where suitable. The pharmacy has also experienced shoplifting and intimidating incidents, adding to the pressures facing staff. Conefrey stresses that protecting employees must always take priority over preventing stock losses. Beyond dispensing, his team provides informal health advice, blood pressure checks, vaccination information and bowel screening awareness. These interactions may be brief, but they can help patients identify concerns and seek appropriate care.
working as the only pharmacist, there are so many demands competing for attention. People ring for advice, prescriptions still have to be dispensed, and there are follow-up tasks and other services to manage. “There is only so much time in the day, and the workload keeps increasing. If extra support could fund somebody to help with the work, or allow us to delegate appropriate tasks, that would be a substantial help,” he told us. The Evidence Linking Deprivation and Medicines Risk The case for additional support is not limited to the financial pressures experienced by individual pharmacies. Research conducted by Dr Caitriona Cahir, Senior Lecturer in
the Data Science Centre at RCSI's School of Population Health, has identified associations between socioeconomic disadvantage and potentially higher-risk prescribing among older adults. Using linked data from The Irish Longitudinal Study on Ageing and HSE pharmacy claims records, the research examined 1,401 adults aged 70 and over during a two-year follow-up period. More than half had at least three chronic conditions, while 41% were prescribed ten or more different drug classes. Dr Cahir explains, “We found that participants with lower socioeconomic status, measured by educational attainment, household income, and private health insurance status, were more likely to be prescribed higher-risk medications and
experience polypharmacy, with the strongest association observed for psychoanaleptic medications.” Importantly, the findings do not establish that prescribing was inappropriate. Greater medicines use may reflect greater clinical need, differences in healthcare access or a combination of factors. “Further research is needed to better understand these socioeconomic differences in higher-risk prescribing and polypharmacy and to determine whether they reflect appropriate prescribing in response to greater clinical need or inequities in care that increase the risk of medicationrelated harm,” she acknowledges. Dr Cahir identifies several potential contributors, including multimorbidity, fragmented healthcare, limited access to
The expansion of pharmacy services presents further opportunities, although Tomás says the Common Conditions Service has required considerable explanation to patients, particularly where a consultation results in referral rather than a prescription. Time remains one of the greatest constraints. Asked whether a deprivationrelated grant could make a difference, he identifies staffing as the clearest potential benefit. “It could make a real difference if it helped pay for another member of staff or additional pharmacist time. At times, particularly when I am
IRISHPHARMACYNEWS.IE
10
Report Lewis Byrne
the community: when people struggle to afford a GP appointment or face difficulties accessing one, they may feel they have little choice but to turn to cheaper, more readily available alternatives.” His work demonstrates the value of trusted, accessible conversations about health. Participants in Mind Yourself have subsequently reported seeking medical advice sooner, sometimes resulting in potentially serious conditions being identified earlier. The experience reinforces a wider point: reducing health inequalities requires more than the availability of clinical services. People must also feel able, informed and supported to use them. What the HSE Already Funds
non-pharmacological services and difficulties understanding complex treatment regimens. “In addition, lower health literacy, financial constraints, and limited social support may make it more difficult for individuals to understand medication regimens, navigate healthcare services, communicate concerns about side effects, or actively participate in medication reviews and deprescribing decisions.” Her findings strengthen the argument for targeted interventions, although they do not, in themselves, establish which funding model would be most effective. Dr Cahir suggests that improved access to pharmacistled medication reviews, integrated care and health literacy support could help address inequalities. She points to the iSIMPATHY project, which delivered personcentred medication reviews to approximately 6,481 patients across Ireland, Northern Ireland and Scotland. According to the figures she provided, medication appropriateness improved in 92% of reviewed cases, with more than half of participants experiencing a reduction in prescribed medicines. “Building on these initiatives, the HSE could prioritise medication review services for socioeconomically disadvantaged older adults, embed pharmacists within primary care teams serving areas of greater deprivation, and develop targeted medication literacy programmes for patients with lower educational attainment,” she adds. Such measures, she believes, could improve medicines safety and reduce inequalities in prescribing and polypharmacy.
IRISHPHARMACYNEWS.IE
When Access to Healthcare Becomes a Barrier The challenges associated with deprivation extend well beyond medication management. Lewis Byrne, a Community Health Worker and Social Prescribing Link Worker with Dublin City Community Cooperative, has spent more than five years supporting people in Dublin's north inner city. His experience highlights how financial pressures, appointment availability and difficulties accessing primary care can discourage people from seeking help. “Long waiting lists for procedures and busy GP practices can make people feel discouraged from even attempting to make an appointment in the first place. Poverty and lack of fees to access GP services are just some of the obstacles that can prevent people from looking after their own health,” he says. Lewis also points to the difficulties experienced by people working full-time who cannot easily attend appointments during conventional working hours. Some residents struggle to find GP practices accepting new medical-card patients, leaving them travelling outside their communities or waiting for a place to become available. He describes this as a form of “GP limbo”. These experiences underline the importance of accessible, community-based healthcare services, including pharmacies, although Byrne's interview focused on broader barriers to healthcare rather than the specific proposed pharmacy payment. Through the Mind Yourself programme, Lewis also works to
encourage men to engage more confidently with their health. He has observed growing interest in preventative healthcare, but also increasing exposure to misleading online health information, unregulated products and the use of artificial intelligence tools in place of professional advice. “Another emerging concern is the use of AI tools as a substitute for professional medical advice,” he notes. “Some people are turning to AI chat platforms to check their symptoms and decide whether they need to visit their GP at all. While these tools may offer accessible information, they cannot replace a proper medical assessment.” For Lewis, the problem is closely connected to access. “I think this also highlights a wider issue within
In response to questions from Irish Pharmacy News, the HSE confirmed that its Social Deprivation Grant for general practice was introduced in 2020 under the 2019 GP Agreement. The scheme uses geocoding analysis to identify GMS GP panels serving populations experiencing the greatest social deprivation. Rather than allocating funding solely according to the location of a practice, the methodology examines the populations served by individual GP panels. The HSE explained, “The purpose of the Social Deprivation Grant is to improve healthcare access, supports and health outcomes for socially deprived populations attending GP practices. The funding enables practices to
“In the context of these ongoing programmes of work, the HSE will continue to work with the relevant stakeholders to explore and progress future opportunities for community pharmacy to improve health equity and access to services, and to support pharmacists to use their full range of skills and expertise to improve both population health and health outcomes for individual patients.” HSE
Collagen Complex Gift Set 4 FREE Hydrogel Face Masks
Worth €79.95, Only €59.95 30 Collagen Complex Sachets
Supports Healthy Looking Skin*
4 FREE Hydrogel Face Masks
The Ultimate Self-Care Gift Set
091 769803
customerservice@reviveactive.com
Or contact your local area sales representative. *Niacin, Biotin & Zinc contribute to the maintenance of normal skin.
12
Report
provide additional clinical and support resources to meet the increased needs often associated with deprivation.” Examples include additional GP hours, nursing support, key worker services, counselling and other clinical resources. The HSE confirmed that 81 GPs are receiving the grant during the 2025–2027 funding period. Of these, 28 are in Dublin and Midlands, 22 in Dublin and North East, 11 in the Mid-West, ten in the South West, and five each in Dublin and South East and West and North West. The figures demonstrate that a targeted, population-based deprivation funding mechanism already exists within Irish primary care. They also raise questions about how a comparable approach could be designed for pharmacies, including how eligible patient populations would be identified, what additional services would be funded and how outcomes would be measured. Will Pharmacy Receive Equivalent Support? The HSE did not announce a commitment to introduce the IPU's proposed Health Equity Payment in its response. It did, however, acknowledge the role of community pharmacies in reaching vulnerable and marginalised populations. “Due to the reach and coverage of pharmacies across the country, their accessibility and the fact that they are rooted and established in local communities, they already play an important role in supporting those who are vulnerable, in marginalised groups or disadvantaged communities, and those who may
IRISHPHARMACYNEWS.IE
not routinely engage with other healthcare services.” The HSE pointed to work under the Community Pharmacy Agreement 2025, including developments in health promotion, sexual health and screening, alongside existing vaccination, opioid substitution treatment and HIV pre-exposure prophylaxis services. It added, “In the context of these ongoing programmes of work, the HSE will continue to work with the relevant stakeholders to explore and progress future opportunities for community pharmacy to improve health equity and access to services, and to support pharmacists to use their full range of skills and expertise to improve both population health and health outcomes for individual patients.” That response signals continued engagement, but leaves the central funding question unresolved. From Recognition to Resources Taken together, the perspectives gathered by Irish Pharmacy News illustrate several dimensions of healthcare inequality. Tomás describes the practical pressure of meeting patients' needs within a busy community pharmacy. Dr Cahir's research identifies socioeconomic differences in complex prescribing and potential opportunities for more targeted medication support. Lewis demonstrates how deprivation can affect whether patients access professional healthcare at all. The HSE, meanwhile, has confirmed that additional resources are already being directed towards general practices serving disadvantaged populations. For the IPU, Budget 2027 represents an opportunity to extend that principle to community
pharmacy. “The commitment to provide additional resources to pharmacies in disadvantaged communities has already been made,” Caoimhe said. “Budget 2027 is an opportunity to deliver on it and ensure that pharmacies in these areas can continue providing accessible care to the patients and communities who depend on them.” Whether the proposed ¤2.295 million payment would provide
sufficient support, and how it should be distributed, remain questions for policymakers. What emerges clearly is that the needs of disadvantaged communities are not always reflected in the resources available to those providing their care. As Ireland seeks to expand community-based healthcare, the challenge will be ensuring that the pharmacies serving patients with the greatest needs have the capacity to deliver it.
IPU Statement in Full The IPU is calling for the introduction of a targeted Health Equity Payment for pharmacies operating in areas of significant social deprivation, with ¤2.295 million sought in Budget 2027 to fund the measure. Importantly, the principle is not new. The 2020 Programme for Government, Our Shared Future, committed to providing community pharmacies with dedicated additional resources in disadvantaged communities, focused on improving health outcomes and informed by strong data. Commenting, IPU President Caoimhe McAuley said, “The Government has previously recognised that community pharmacies serving disadvantaged communities required dedicated additional resources to improve health outcomes. The principle was right then, and the evidence for acting on it is even stronger today. If Government is serious about reducing health inequalities, we must protect access to healthcare in the communities where the need is greatest. “This is not simply about supporting individual pharmacy businesses. It is about protecting a highly accessible part of our primary care infrastructure and ensuring that the move towards delivering more care closer to home benefits every community.” The case for action is further reinforced by the approach already taken in general practice. Government provides a Social Deprivation Practice Grant for GMS general practices, using the Pobal HP Deprivation Index to direct additional resources towards practices serving disadvantaged populations. Ms McAuley concluded, “The commitment to provide additional resources to pharmacies in disadvantaged communities has already been made. Budget 2027 is an opportunity to deliver on it and ensure that pharmacies in these areas can continue providing accessible care to the patients and communities who depend on them.”
Preservative-free NOT ALL DRY EYE DROPS HAVE CLINICALLY PROVEN EFFICACY
THEALOZ DUO DOES! Phosphate-free Hypotonic Osmoprotective
Relative change in Tear Film Thickness (%)
Thealoz® Duo relieves the signs and symptoms of Dry Eye Disease1
130
# # #
*
120
#
#
* 110
*
#
100 0 0
20
40
60
80
100
120
140
160
180
200 220 240
Timepoint (minutes) Thealoz ® Duo
# * Significant change from baseline
Sodium chloride
Sodium hyaluronate
p<0.0001 n=60 patients
See the difference:
EUROPE’S
TOP 100 PHARMACY PRODUCTS
2025/2026
1 drop of Thealoz® Duo lasts for up to 4 hours1
DRY EYE The increase in TFT with Thealoz® Duo was significantly eatment of mild DROPnon-infectious allergic or inflammatory conjunctival diseases. Posology: The recommended dosa longer than with HA (p<0,01). With Thealoz® Duo the effect remained over 240 min.in order to avoid of 14 days. Gradual tapering off up to one administration every other day statistically may be significant recommended bstance or to any of the excipients; Known glucocorticosteroid-induced ocular hypertension and other forms of oc pt when combined with specific chemiotherapeutic agents for herpes virus), conjunctivitis with ulcerative keratitis years Products Educating vitis and purulent blepharitis, stye 150 and herpes may be masked or aggravated by anti-inflammatory that are 100% of knowledge & infection that & empowering preservative free expertise in eye care professionals glucocorticoids are excreted in breast milk and may cause suppression of growth or of endogenous corticosteroid ourstinging. eyes Cort fants cannot be excluded. Undesirable effects: Hydrocortisone: Eye disorders: Not let’s known:open Burning, ticosteroids. Eye disorders: Not known: Allergic and hypersensitivity reactions, delayed wound healing, posterior uveitis, changes in corneal thickness, crystalline keratopathy, blurred vision. Cases of corneal calcification have b 2
Reference: 1. Schmidl D1, Schmetterer L et al. Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease. Cornea. 2015 Apr;34(4):421-6. 2: 8. 2. IQVIA Consumer Health Customized Insights for the period 2024, volume and value sales in Euros PUB, limited to IQVIA CHC3 07A3 Artificial Tears and Ocular Lubricants, reflecting estimates of real-world activity in these countries: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, UAE (United Arab Emirates), UK. Copyright IQVIA. All rights reserved. TP25015
14
News
McCabes Pharmacy's Digital Evolution: Brian O'Keeffe on the Launch of McCabes PLUS McCabes Pharmacy has taken a significant step in its digital development with the launch of a new app and McCabes PLUS loyalty programme, bringing prescription management, healthcare bookings, online shopping and customer rewards together in one platform. McCabes Pharmacy Managing Director Brian O’Keeffe celebrates the launch of the new McCabes Pharmacy app, and McCabes PLUS loyalty programme with the McCabes Pharmacy Dundrum Shopping Centre team
For Brian O'Keeffe, the initiative is about much more than introducing a loyalty scheme. It represents an opportunity to build on the relationships McCabes Pharmacy has established with patients and communities while making everyday healthcare more accessible and convenient. “Our customers rely on us for much more than purchasing products. They come to us for prescriptions, healthcare services, advice and support,” he explains. “The three things we really wanted to achieve were greater value, encouraging a more proactive approach to health, and making everyday healthcare more convenient. That thinking sits at the heart of both McCabes Pharmacy PLUS and the new app.” More Than a Traditional Loyalty Programme While customers can earn points on eligible health and wellbeing purchases, Brian emphasises that McCabes Pharmacy PLUS was deliberately developed as part of a broader healthcare offering. “We wanted to create much more than a traditional loyalty programme. McCabes Pharmacy is a healthcare business, so it was important that the digital experience reflected the wider role we play in our customers’ lives.” The app allows customers to select their preferred McCabes Pharmacy, manage and track prescriptions, book healthcare appointments, shop online, access Click & Collect services and manage their McCabes Pharmacy PLUS rewards. Brian believes integrating these functions into a single
IRISHPHARMACYNEWS.IE
platform offers customers greater convenience while reinforcing the pharmacy's role in supporting their ongoing healthcare needs. “We’re not simply rewarding someone for making a purchase; we’re helping them manage their health while giving them greater value along the way.” An important element of the initiative is encouraging customers to engage more proactively with their health. Alongside prescription services, the app facilitates access to flu vaccinations, blood pressure checks and other pharmacy services, including Common Conditions Service consultations. “There is a real opportunity for community pharmacy to play a greater role in preventative healthcare, and we want the new app and McCabes Pharmacy PLUS to support that.” Bringing Digital Healthcare Together Delivering an integrated digital experience across a national network of 112 pharmacies presented a considerable operational undertaking. Brian explains that the priority was ensuring the technology remained straightforward for customers, despite the complexity involved in connecting the different services and systems. “This was a significant project for McCabes Pharmacy, particularly because we were bringing together a number of different elements of the customer experience across all 112 of our pharmacies as well as our online website.” The app incorporates DigiScript, enabling customers to order repeat prescriptions online, alongside
prescription tracking that provides visibility from submission through to collection. Through its MY Health section, customers can also book healthcare appointments and access relevant services. For Brian, the combination of practical healthcare functions and customer rewards is what distinguishes the platform from a conventional digital loyalty card. “We wanted the app to have genuine everyday usefulness,” he says. Achieving this required extensive planning, coordination and system integration, as well as ensuring the technology complemented the experience customers receive in-store. Supporting Pharmacy Teams While digital innovation is central to the initiative, Brian is clear that pharmacy teams remain fundamental to its success. “Our pharmacy teams have been an important part of the rollout because they are at the heart of the customer relationship.” Supporting staff throughout the introduction of McCabes Pharmacy PLUS was therefore a priority, ensuring teams understood the programme, its benefits and how the app connects with the services available in their pharmacies. “The technology is there to make the experience easier, but we never lose sight of the fact that community pharmacy is ultimately about people. The advice and expertise provided by our pharmacy teams remain fundamental to the McCabes Pharmacy experience.” Looking Beyond App Downloads Although the initial response has been encouraging, Brian believes the real measure of success will be how customers incorporate the platform into their everyday healthcare routines. “The launch has generated a very positive response, and we're encouraged by the level of interest in both the app and McCabes Pharmacy PLUS.”
However, he is keen to look beyond early registrations and downloads to understand how customers engage with the app's different functions over time. “For us, success isn't simply about how many people download the app. It's about whether we're genuinely making healthcare easier, more convenient and more rewarding for our customers.” One of the most important lessons from the rollout, he adds, has been the need to keep the experience simple. With a broad range of features available, the approach has been to provide customers with a clear reason to download the app while allowing them to discover its additional benefits gradually. The Next Stage of Digital Engagement Looking ahead, Brian sees McCabes Pharmacy PLUS and the new app as an important foundation for the pharmacy group's continued development. Customer and pharmacy team feedback will inform future improvements, while personalisation is expected to remain a key focus. Members already have access to personalised offers, exclusive vouchers, member-only promotions and birthday rewards, with opportunities to make these benefits increasingly relevant to individual customers. “We see McCabes Pharmacy PLUS and our new app as an important part of the future of McCabes Pharmacy. The launch gives us a strong platform to build on.” For other community pharmacy businesses considering investment in digital engagement, Brian's advice is to begin with the needs of the customer rather than the technology itself. “Digital has enormous potential to make healthcare more accessible and convenient, but it has to solve a genuine problem or add genuine value.” Ultimately, he believes digital innovation should strengthen rather than replace the trusted relationships that underpin community pharmacy. “Community pharmacy already has an incredibly important relationship with patients. The opportunity with digital is to strengthen that relationship and make it easier for people to access the care, advice and services they need.”
Available in packs of 7s , 14s & 28s. Medicinal product not subject to medical prescription. For further information refer to SPC available at www.hpra.ie Adverse events should be reported. Reporting forms and information can be found on the HPRA website (www.hpra.ie) or by emailing adverse.event.ireland@sandoz.com Marketing Authorisation Holder : Rowex Ltd., trading as Sandoz. Further information and SPC are available from: Rowex Ltd., trading as Sandoz, Regus City Gate, Building 1000, Units 1201 & 1202, City Gate, Mahon, Cork, T12 W7CV. Freephone 1800 83 20 83. E-mail: mi.ireland@sandoz.com MLR ID: MLR-0239-IE Date of prep: (09.2026)
16
Medicines Safety
Don’t ignore side effects. Report them This #MedSafetyWeek, 2–8 November, the HPRA is recognising the important contribution pharmacists and other healthcare professionals make to medicines safety, with this year’s campaign carrying a simple message: “Don’t ignore suspected side effects. Report them.” Written by Darren Scully, Pharmacovigilance Risk Communication & Assessment Manager, HPRA The HPRA recognises that reporting is one of many demands on healthcare professionals working in busy practice settings. We greatly value the time that pharmacists and other healthcare professionals already give to reporting suspected adverse reactions and the contribution those reports make to the wider medicines safety system. #MedSafetyWeek is a global medicines safety campaign. This year, more than 130 organisations across over 120 countries will take part, sharing the campaign message in more than 60 languages. At the heart of the campaign is the importance of reports of suspected adverse reactions. These reports contribute to the ongoing monitoring of medicines in clinical use, adding to knowledge about known adverse reactions and helping to identify previously unrecognised safety issues. Medicines undergo extensive testing before they are authorised for use. However, clinical trials can only involve a limited number of participants and take place under controlled conditions. Once a medicine is used by larger and more diverse patient populations in everyday practice, additional information about its safety profile can emerge. Ongoing reporting of suspected adverse reactions therefore provides important realworld information that contributes to medicines safety monitoring and patient safety. The important contribution of pharmacists Pharmacists have a particularly valuable perspective on medicines safety. Through their knowledge of medicines and regular contact with patients, they can be among those who hear directly about a patient's experience with a medicine, whether during dispensing, medicines advice or other interactions. These conversations can provide valuable insights into patients’ experiences with medicines and contribute to the identification and reporting of suspected adverse reactions.
IRISHPHARMACYNEWS.IE
That contribution is important because our understanding of the safety of medicines continues to develop as they are used in everyday clinical practice. Reports of suspected adverse reactions provide information from that real-world experience and, when considered alongside other reports and sources of safety information, can help identify potential issues that may warrant further investigation. In 2025, the HPRA received 8,598 reports of suspected adverse reactions. Each report adds to the information available to support the ongoing monitoring of medicines. There does not need to be certainty that a medicine caused a suspected reaction for it to be reported. As the #MedSafetyWeek campaign highlights, suspected side effects can take different forms. Some may appear suddenly, while others develop gradually or following longer-term use. This is also why individual reports remain valuable. What may appear to be an isolated experience can contribute to a broader body of information when considered alongside other reports. As this year's campaign emphasises, every report matters. Supporting ongoing medicines safety monitoring Reports of any suspected adverse reaction are welcomed. There are also circumstances in which reports can be particularly valuable, including those involving serious suspected reactions, newly authorised medicines, vaccines and medicines subject to additional monitoring. Medicines marked with an inverted black triangle (▼) are subject to additional monitoring,
and reporting suspected adverse reactions associated with these medicines is especially valuable. Reports relating to the use of medicines during pregnancy or breastfeeding, as well as suspected reactions associated with medication errors, misuse, overdose, addiction, dependence or withdrawal, can also provide important information for ongoing safety monitoring. Importantly, the absence of complete information should not be a barrier to making a report. Providing as much relevant information as is available helps support assessment, but further information can be provided where it becomes available. Information received through adverse reaction reports contributes to national, European and international medicines safety monitoring activities. When combined with data from other sources, reports can help regulators better understand how medicines are being used in practice and whether additional risk minimisation measures, updates to product information or further investigation may be required. Reporting to the HPRA The HPRA offers several options for reporting suspected adverse reactions. The online reporting system is available at www.hpra.ie/report. Reports can also be submitted by email to medsafety@hpra.ie, with further reporting options and contact details available on the HPRA website. For healthcare professionals submitting a report, useful information includes details of the suspected medicine and reaction, relevant information about the patient and clinical circumstances, and the reporter's contact details. Patients can also report suspected adverse reactions directly to the HPRA. Pharmacists can therefore have an important role in the reporting system both through reports arising from their own professional practice and through their conversations with patients about medicine safety and suspected side effects.
Encouraging conversations with patients about suspected side effects, including awareness that these can be reported, makes an important contribution to the overall reporting system. These conversations can provide valuable information about patients’ experiences with medicines and help ensure that suspected adverse reactions are captured and contribute to ongoing safety monitoring. Every report matters #MedSafetyWeek offers an opportunity to recognise and reinforce the contribution that pharmacists and other healthcare professionals already make to medicines safety. The HPRA sincerely thanks pharmacists for the time and professional expertise they contribute to suspected adverse reaction reporting. Collectively, these reports help build our knowledge of medicines in everyday use and contribute to the continued monitoring of their safety. While a single report may seem small in isolation, its value lies in its contribution to the wider picture of medicines use and safety. Reports submitted by pharmacists across the country help strengthen the evidence available to support regulatory decision-making and ultimately contribute to the safe and effective use of medicines for patients. That is the message at the heart of #MedSafetyWeek 2026: don’t ignore suspected side effects. Report them. Further information, including the HPRA's online reporting system, is available at www.hpra.ie/report.
NEW
RECOMMEND THE ALL-IN-ONE RANGE TREATS ANY COUGH AND SORE THROAT*
MEDICAL DEVICE
Also available in 250ml
COOLS THE THROAT FAST** FOOD SUPPLEMENTS *BENYLIN® All-In-One Cough & Sore Throat Syrup is a medical device for dry or chesty coughs. **BENYLIN® All-In-One Non-Medicated Lozenges are food supplements and should not be used as a substitute for a varied and balanced diet and a healthy lifestyle. ALWAYS READ THE LABEL. IE-BYL-2026-356196
18
Cyber Security
Ten Cyber Security Steps every Community Pharmacy Can Take this Month Practical measures that protect your patients, your stock and your ability to keep dispensing, from Cork IT security specialist Dave Buckley. Written by Dave Buckley, Founder, IT Operations and Security EX, Treora Dave Buckley is a Cork-based IT operations and security leader with more than 20 years' experience across multinational and regulated businesses, including leading ISO 27001 certification and PCI DSS audits. He is the founder of Treora Technologies (treora.ie), which provides written cyber security policies for small businesses.
Two-step login, where a code on a phone is needed as well as the password, stops most of those attacks on its own. Start with email, then online banking, PCRS online services, wholesaler ordering portals and your accounts package. Where you have the choice, use an authenticator app rather than text messages. And make sure everyone knows one rule: never approve a login prompt on your phone that you did not start yourself. An unexpected prompt means someone else has the password.
what if a record is changed or something goes wrong. Give every pharmacist, technician and locum their own account, and remove access the day someone leaves. The same thinking applies to suppliers. If your system supplier or IT company connects remotely for support, find out how that access is protected, and make sure it cannot happen without someone in the pharmacy knowing about it.
3. Stop sharing logins on dispensary terminals
Counter and consultation room screens are often visible to customers. Set screens to lock after a few minutes, get into the habit of locking them when you step away, and angle or shield any screen that shows patient records.
One shared login on a busy dispensary PC is common, and understandable, but it means nobody can tell who did
Most pharmacists can tell you exactly what they would do if the fridge failed overnight. Far fewer could say what happens if the dispensing system locks up on a Monday morning with a queue at the counter, or if the pharmacy's email account starts sending fake invoices to every supplier in the contacts list. Neither scenario is far-fetched. The ransomware attack on the HSE in May 2021 showed how quickly health services stall when the computers stop, and community pharmacies hold exactly the kind of information criminals want: names, addresses, medication histories and payment details, along with supplier accounts that move real money every week. Smaller businesses are rarely well prepared. Research published last December by Munster Technological University and the National Cyber Security Centre, covering almost 900 Irish small and medium businesses, found that two in three had no written cyber security policy, and more than three-quarters had no plan for what to do if they were hacked. Pharmacies are an attractive target for reasons that have little to do with technology. The team is busy and often interrupted. Dozens of emails arrive each day from wholesalers, prescribers, the PCRS and patients, so one more unexpected message does not stand out. New services such as
IRISHPHARMACYNEWS.IE
the Common Conditions Service and the contraception service have added booking systems, online forms and consultation records, and each one brings another login to protect. Staff and locums change, and the systems that matter most are usually run by outside suppliers who connect remotely to provide support. None of that is a criticism; it is simply how community pharmacy works, and criminals know it. The steps that make the biggest difference are cheap, and none of them needs an IT department. Here are ten you can put in place this month. 1. Plan for a day without the dispensing system Ask yourself how you would dispense, label and record supplies if your PMR system was unavailable for two days. Keep a short written downtime procedure in the dispensary: how to record what was supplied so it can be entered later, where the blank labels are, and the support number for your system supplier. Run through it once with the team so it is not being invented on the day. It is also worth knowing which tasks could carry on from a single working laptop or phone, and which could not. 2. Turn on two-step login everywhere it is offered A stolen password is the most common way into a business.
4. Lock screens and keep them out of view
19 5. Retire unsupported computers Microsoft stopped providing security updates for Windows 10 in October 2025. If a dispensary PC, or the one in the back office running the accounts, is still on Windows 10 without extended support, it is no longer receiving fixes for new weaknesses. Check every machine, turn on automatic updates, and plan to replace anything that cannot be updated. Do not forget the phones and tablets used for work, and the router, which also needs updates from time to time. 6. Ask your system supplier about backups, and test one It is easy to assume this is taken care of. Ask your PMR supplier where your data is backed up, how often, and when a restore was last tested. Do the same for anything kept locally, such as the accounts, staff files and rotas. At least one copy should be kept separate from your main systems so that ransomware cannot reach it. 7. Phone before you change any bank details FraudSMART, the awareness campaign run by Banking & Payments Federation Ireland,
reported in March that Irish small businesses had lost almost ¤19 million to email scams in two years. If a wholesaler, landlord or supplier emails to say their bank details have changed, ring them on a number you already have before paying anything. Treat any unexpected request to pay urgently the same way. A newer version of the same trick targets payroll: an email, apparently from a member of staff, asking for their salary to go to a new account. A quick word with the person in question is all it takes to check. 8. Treat unexpected attachments with suspicion Pharmacies receive a steady flow of emailed documents, which makes them an easy target. The same goes for requests arriving by WhatsApp or online forms. Be wary of anything unexpected: a "prescription" or "patient letter" from an unfamiliar address, a delivery notice from a courier you were not expecting, or a message claiming to be from the PCRS or the Revenue asking you to log in. If in doubt, contact the sender using details you already have.
9. Separate the customer Wi-Fi If you offer Wi-Fi to customers, it should never be on the same network as the dispensary computers. Most business routers can create a separate guest network in a few minutes. Change the router's default admin password while you are at it. 10. Write it down and brief the team One page is enough to start: who to call if something goes wrong (your system supplier, IT support, bank and insurer), what not to do (such as switching off an infected machine before advice is given), and the rule that a breach involving patient data may need to be reported to the Data Protection Commission within 72 hours. Spend fifteen minutes going through it with the team, including counter staff and regular locums, and repeat it once a year. Make it clear that anyone who clicks on something they should not have will not be blamed for saying so. The sooner a mistake is reported, the easier it is to contain. Where to start If ten steps feels like too many for one month, start with three: turn
on two-step login for email, agree the rule that bank details are never changed without a phone call, and ask your system supplier how your data is backed up. Those three alone close off the most common ways small businesses lose money and data. Free help is also available. The National Cyber Security Centre publishes practical guidance for small businesses at ncsc.gov.ie, the Data Protection Commission's website explains when and how to report a breach, and FraudSMART (fraudsmart.ie) publishes regular alerts about the scams currently doing the rounds in Ireland. It is easy to think of cyber security as something for the HSE or the large pharmacy groups, with their own IT departments, to worry about. But an independent pharmacy depends on the same things they do: a working dispensing system, an email account suppliers and prescribers can trust, and accurate patient records. When attacks on small pharmacies succeed, it is usually through something ordinary: a shared password, an unchecked invoice or a backup nobody tested. Fix those, and your pharmacy will be far harder to catch than most.
IRISHPHARMACYNEWS.IE
20
Corporate Profile
Proceive: The Irish Brand Changing the Conversation Around Fertility Nutrition From an idea sparked by two friends undergoing fertility treatment to an internationally recognised nutrition brand, Proceive has built its success on research, innovation and a longstanding partnership with Irish pharmacy. Graham Stafford, founder of Ocean Healthcare and the driving force behind Proceive, speaks to Irish Pharmacy News about the brand's journey, the growing awareness of male fertility and why scientific development remains central to its ambitions.
"The challenge we had was an awareness one, not only for preconception nutrition, but actually for the men," Identifying an Unmet Need Graham approached a nutritionist specialising in reproductive nutrition and began examining the scientific evidence surrounding fertility. One of his earliest discoveries was the importance of recognising male fertility. "When you look at the issue of infertility, a third of it is women, a third is men, and a third is unexplained," Graham explains. "Basically, the issues between men and women are equal." This established an important principle for the emerging brand: fertility nutrition should address the needs of both partners. Graham Stafford, founder of Ocean Healthcare
When Graham Stafford established Ocean Healthcare in 2003, his focus was on bringing innovative consumer healthcare products to the Irish market. Working across over-the-counter medicines, cosmetics and nutritional supplements, he developed an understanding of the pharmacy sector and its opportunities. More than two decades later, one of his most significant
IRISHPHARMACYNEWS.IE
achievements has been Proceive, a specialist fertility and pregnancy nutrition brand that has expanded from Ireland into international markets. The idea began with conversations between Graham and two friends undergoing fertility treatment. "Both of them told me the same thing, that they had to go off and get like five or six supplements, a very high dosage," he recalls. Graham was struck by the need to source multiple individual supplements rather than one comprehensive nutritional product. It prompted a simple question: "Why doesn't this exist?"
The development team, which included a reproductive nutrition specialist and a doctor, examined products internationally but struggled to identify a comprehensive formulation that met its objectives. "There was nothing. There was no one product that had everything you need." Several years of research followed. Graham says approximately 600 clinical studies were referenced during development. "We wanted to deliver every nutrient as close as we could to therapeutic dosage," he explains. In 2017, Proceive launched its first four products: two for men and two for women.
A Different Approach to Fertility Nutrition At the time, pregnancy supplements were already established in Irish pharmacy, but Graham identified an opportunity to focus on the period before conception. "If you went into a pharmacy, you would see a number of pregnancy supplements, but there wasn't really anything for preconception," he says. Importantly, Proceive was not intended exclusively for people experiencing fertility difficulties. "It shouldn't, it doesn't have to be a problem-solutionits for all men and women trying to conceive that want to ensure they are taking all the right nutrients." Graham explains. The objective was to encourage greater awareness of nutritional preparation before conception, recognising supplementation as one element of broader reproductive health. Following its Irish launch, Proceive entered the UK market approximately a year later, subsequently expanding into other European countries, China and the Middle East, including the UAE. Despite this international growth, the business has remained independently funded.
21
"We wouldn't have the brand without the support of the pharmacy" "We've been self-funded from the start. So we've been, let's say, slow and steady, but we've over time built a really nice business." Today, its main team operates from Sandyford, Dublin, alongside a growing UK operation. Science at the Centre of Innovation A defining feature of Proceive's strategy has been its commitment to reviewing formulations as scientific understanding develops. Graham explains that products are typically reassessed every 18 months to two years. "It's not the same formula for the last nine years. We're probably on the fifth or sixth iteration at this point. We're continuously striving to have the best-in-class product always," he adds. Around five years after launching its fertility range, Proceive began developing pregnancy-specific products, prompted partly by customers asking whether they could continue taking their preconception supplements after becoming pregnant. The company returned to research and development, identifying differences in nutritional requirements throughout pregnancy. "We identified that the nutritional demands are different by trimester." This resulted in separate formulations for the first, second and third trimesters. "We're very about the stagespecific product. This is the right one for you right now. It's not a one-size-fits-all." The portfolio subsequently expanded into breastfeeding and post-pregnancy nutrition, creating what Graham describes as a journey from "preconception to after pregnancy." More recently, Proceive introduced a dedicated Myo-Inositol product containing four grams of myoinositol, positioned particularly towards women with polycystic ovary syndrome (PCOS). Bringing Male Fertility into Focus With November placing renewed attention on men's health,
Graham believes the changing conversation around male fertility is particularly significant. Although Proceive launched with products for both sexes, the male range initially took longer to establish itself. "The challenge we had was an awareness one, not only for preconception nutrition, but actually for the men," he explains. Historically, fertility discussions and purchasing decisions have frequently been driven by women, despite male factors contributing to a substantial proportion of fertility difficulties. Education therefore became an important part of Proceive's strategy. The company developed educational resources for healthcare professionals and consumers, while its nutritionists began visiting fertility clinics throughout Ireland to deliver presentations and lunch-and-learn sessions. Graham believes attitudes are changing. "On the men's side, it's developing more now. There's more awareness. People are more open to discussing it." This has also been reflected commercially. "We've seen a big increase in the last couple of years in particular in the rate of sale of our men's products." One of the company's earlier innovations was a combined male-and-female fertility pack, providing a one-month supply for both partners. "Generally it's the woman who's buying it, but it's getting the man on the product," Graham explains. For him, the growing recognition of male fertility represents an important development. "The whole men's space is very interesting. It's developing, the awareness is growing." He also points to increasing scientific research into male reproductive health and sperm quality, reinforcing the importance of education and evidence-informed nutritional preparation.
Nutrition as Part of the Bigger Picture Despite Proceive's specialist focus, Graham is careful not to overstate supplementation's role. "At the end of the day, this is a supplement," he says. The company emphasises that nutritional preparation must sit alongside wider lifestyle considerations. "You need to eat well, you need to exercise, you can't smoke, you need to cut down on the alcohol." Graham believes supplementation should be understood as one element of a broader approach rather than a solution to fertility difficulties. "This is one thing you can do to tick the box for your nutrition, but you have plenty of other areas that you also need to consider as well." This philosophy extends to the company's communication, particularly given the emotional sensitivity surrounding fertility. "It's a sensitive area, so we're very careful with how we deliver our communication, our messages." Proceive bases its product messaging on authorised nutrient health claims and has deliberately resisted expanding into unrelated supplement categories. "We've become the experts in fertility and pregnancy nutrition. And that's where we're staying." Pharmacy: The Foundation of the Brand Throughout Proceive's development, community pharmacy has remained central to its success. "We wouldn't have the brand without the support of the pharmacy," Graham says. Independent pharmacies, regional groups and larger pharmacy businesses have all contributed to building awareness and making the products accessible. Pharmacy also provides consumers with trusted healthcare advice, particularly when discussing sensitive subjects such as fertility. Graham acknowledges that some customers prefer the anonymity of larger stores but emphasises the longstanding support of independent pharmacy. Distribution across Irish pharmacies has expanded considerably, and Graham says Proceive is now Ireland's number-one brand in its category, according to the latest IQVIA data available to the business.
"We've got to a point now where the awareness is there. I think there's a little bit less of a taboo about it." Expansion into pregnancy and post-pregnancy nutrition has also changed how consumers perceive Proceive. "We're not seen as a fertility supplement anymore. It's that end-to-end nutritional supplement." Building a Responsible Business Proceive has recently achieved B Corp certification, marking another milestone in its development. For Graham, the significance lies not simply in certification but in the improvements encouraged throughout the process. "It's not a one-off certification. It's continuous improvement. And that's what B Corp is." Quality and safety remain equally important priorities. All Proceive products are manufactured in the UK through a longstanding manufacturing partner which, Graham says, holds an MHRA manufacturing licence and GMP certification. "Quality for us is number one," he explains. Looking to the Future With Proceive continuing to grow internationally, Graham sees further opportunities within fertility and pregnancy nutrition. The company is currently undertaking an Irish clinical study involving Proceive Max Women, working with an Irish clinical research organisation. "We've a clinical study ongoing at the moment, which is really exciting and interesting," he says. "Further investment in research, brand awareness, geographical expansion and team development is also planned. "The business is growing quite fast, but we're reinvesting all the time." While new products may emerge where genuine gaps are identified, Graham remains committed to maintaining a focused and understandable portfolio. Nearly a decade after Proceive launched, his ambition remains centred on improving formulations, supporting healthcare professionals and encouraging a more informed conversation around reproductive health. And as male fertility becomes an increasingly important part of men's health discussions, Proceive's original commitment to recognising the needs of both partners remains particularly relevant.
IRISHPHARMACYNEWS.IE
22
News
UD Talks: Keeping Community Pharmacy Informed Through Expert Conversations Since its launch, United Drug’s UD Talks podcast has established itself as a platform for accessible, informative conversations on the issues shaping community pharmacy and the wider healthcare landscape. Denis O’Driscoll, Superintendent Pharmacist, McCabes Pharmacy
overdose awareness and updates in this critical area, highlighting the importance of accessible information and awareness in supporting better outcomes.
Hosted by Denis O’Driscoll, Superintendent Pharmacist for McCabes Pharmacy, the series brings together leading voices from across pharmacy, healthcare and patient support to explore topics that matter to pharmacists and the communities they serve. From developments in pharmacy practice and public health awareness to weight management, overdose prevention and entrepreneurship, UD Talks aims to make expert knowledge accessible, helping pharmacy
professionals stay informed and better equipped to engage in meaningful conversations with their patients. Recent episodes have continued to reflect the breadth of the profession and its evolving role in healthcare. Joanne Kissane has shared her insights on pharmacy and the direction of the profession, while Donal O’Shea has explored weight management, an increasingly important area of public health and patient care. An episode with Jenny Smyth examined
The series has also explored the personal journeys behind careers in pharmacy. Laura Dowling, widely known as the Fabulous Pharmacist, joined Denis to discuss her journey through pharmacy, her experience as an entrepreneur and how she has built a recognisable public profile through health education and communication. Her story offers a different perspective on the opportunities available to pharmacists and the many ways their expertise can reach beyond the traditional pharmacy setting. These conversations build on the podcast’s wider coverage of subjects including Naloxone use, sepsis awareness, long
COVID, sexual health, and the future of pharmacy. By addressing both clinical and broader professional topics, UD Talks recognises the diverse demands placed on community pharmacists and the importance of keeping knowledge current in a changing healthcare environment. At its heart, UD Talks is about supporting pharmacists with relevant information, fresh perspectives and the confidence to have informed conversations with patients. By bringing experienced professionals and subject matter experts together in an accessible format, the podcast provides an opportunity for continued learning that fits around the realities of busy pharmacy practice. As the role of community pharmacy continues to evolve, UD Talks will continue to explore the issues, ideas and experiences that matter to the profession, celebrating the expertise of pharmacists while supporting their contribution to patient care. Listen to UD Talks on Spotify and Apple Podcasts. For more information, contact the United Drug marketing team at UDWMarketing@united-drug.com.
Ireland joins Global Medicines Safety Campaign As part of #MedSafetyWeek (2-8 November), the Health Products Regulatory Authority (HPRA) is encouraging patients and healthcare professionals to report suspected side effects from medicines directly to the HPRA. This year's campaign highlights the message, “Don’t ignore side effects, report them,” and the important role that reporting throughout the year plays in the continuous monitoring of medicine safety. The global campaign, the largest to date, will see more than 130 organisations across 120 countries take part, with the message shared in 60 languages. While medicines provide significant benefits for millions of people worldwide, side effects can occur and are an important aspect of ongoing medicines safety monitoring. Some side effects appear suddenly, while others develop gradually and even after long-term use. Some may be clearly noticeable, while others are only detected from tests. The HPRA calls on all patients and healthcare professionals to stay alert to all types of side effects and report them when they occur. In 2025, the HPRA received over
IRISHPHARMACYNEWS.IE
8,500 reports of suspected side effects. These reports provide important information about the safety of medicines and help regulators like the HPRA identify and respond to any potential risks. ‘Reports from the public and healthcare professionals have a vital role in helping us monitor the safety of medicines. Every report matters. By taking the time to report a suspected side effect, people contribute to a better understanding of medicine safety and help us identify and manage potential risks. This information
can help protect others and improve patient safety,’ says Dr Darren Scully, Medicines Safety Manager at the HPRA.
at hpra.ie/report or by email to medsafety@hpra.ie. Further reporting options are available on the HPRA website.
‘Side effects may be more likely to occur when starting a new medicine, changing the dose, or when also taking other medicines. Always take the time to read the information leaflet that comes with your medicine and remember to discuss any questions you have with a healthcare professional.’
The HPRA is encouraging everyone to support the campaign by sharing information through their websites, newsletters and social media channels, and by joining the conversation using the #MedSafetyWeek hashtag. A range of campaign materials and resources, including posters, email signatures and video backgrounds, is available from the HPRA’s website.
Suspected side effects can be reported via the HPRA website
The Go-To Pharmacy Podcast!
Listen on spotify:
Listen on the go and enhance your professional knowledge at your convenience. Expert Insights
Practical Knowledge
Tailored for you
Stay ahead with in-depth interviews and discussions led by industry experts
Gain actionable knowledge on patient care and best practice
Specifically designed for pharmacists to elevate their expertise
For more information and to subscribe to UD Talks contact the United Drug Marketing Department on udwmarketing@united-drug.com
24
News
HPRA Publishes Annual Report The HPRA has published its 2025 annual report, outlining a year of significant achievement across its regulatory remit and marking the successful conclusion of the organisation's Strategic Plan 2021-2025. Grainne Power, Chief Executive of the HPRA
The HPRA continued its active contribution at European and international level throughout 2025, including: • Acting as rapporteur or corapporteur for 13 centrally authorised human medicines and being assigned a further seven centralised assessment roles during the year. The HPRA was also the co-ordinator of 54 scientific advice requests via the European Medicines Agency (EMA) across a broad range of conditions.
The report highlights the HPRA's continued contribution to protecting public and animal health through the regulation of medicines, medical devices and other health products, while responding to a complex and evolving national and European regulatory environment. It also reflects the organisation's role in strengthening Ireland's regulatory capacity, supporting access to safe and effective health products, and contributing to the work of the wider European regulatory network. During 2025, the HPRA’s key activities included: • Authorisation of 473 new human medicines following assessment of their safety, quality and effectiveness. • Issuing 95 authorisations for clinical trials of human medicines under the EU Clinical Trials Regulation. • Continuing the assessment of veterinary medicines, with 1,966 authorised medicines for animal use on the Irish market at year-end.
IRISHPHARMACYNEWS.IE
• Receipt of 8,565 suspected adverse reaction reports for human medicines. • Receipt and assessment 4,638 medical device vigilance reports, in addition to undertaking 564 market surveillance cases. • Completion of 108 good manufacturing practice (GMP) inspections at sites producing human medicines or active substances, and 11 GMP inspections of veterinary medicines manufacturers. • Undertaking 191 market surveillance cases relating to cosmetic products. • Coordinating 54 recalls of medicines, comprising 41 human medicines and 13 veterinary medicines. • Detention of 763,027 dosage units of falsified and other illegal medicines, while securing the amendment or shutdown of 4,762 websites, e-commerce listings and social media pages associated with the sale of illicit medicinal products.
• Serving as rapporteur or corapporteur for six centrally authorised veterinary medicines and acting as co-ordinator or joint co-ordinator for nine EMA scientific advice procedures relating to veterinary medicines. • Playing a leading role in European initiatives addressing medicines shortages, including contributions to the European Shortages Monitoring Platform and the EMA Medicines Shortages Steering Group. • Contributing to the IncreaseNET Joint Action, which aims to strengthen the capacity and capability of medicines regulators across Europe. Grainne Power, Chief Executive of the HPRA, reflected on 2025 as a pivotal year for the organisation. “The publication of our 2025 Annual Report marks the conclusion of the HPRA’s Strategic Plan 2021–2025, a period during which the organisation delivered an ambitious programme of work while responding to significant external challenges. Throughout this period, our focus remained firmly on protecting public and animal health with strong collaboration across the Irish and European regulatory systems.
Ms Power also pointed to 2025 as a year of significant achievement, underpinned by continued investment in the organisation’s people, capabilities and digital infrastructure. “The availability of medicines remained a priority during 2025, with ongoing global supply pressures highlighting the importance of robust regulatory systems, strong partnerships and coordinated action. Through our contribution to medicines availability initiatives, crisis preparedness activities and regulatory policy development, we continued to strengthen our ability to anticipate, prevent and mitigate potential disruptions for patients and healthcare professionals. “We completed a highly successful Benchmarking of European Medicines Agencies assessment, continued our participation and influence across the European regulatory network and broader international regulatory initiatives, and launched the new HPRA website as part of our ongoing digital transformation programme. Internally, we introduced a Career and Capabilities Framework for staff and launched a new learning and development platform, further strengthening our capacity to meet future challenges and opportunities. Ms Power also acknowledged the significant contribution of Dr Lorraine Nolan, whose decade as Chief Executive helped strengthen the HPRA’s regulatory impact, organisational capability and standing both nationally and internationally across Europe. “As we move into the next phase for our organisation under the HPRA Strategic Plan 2026–2029, we do so from a position of strength. The regulatory environment continues to evolve rapidly, driven by advances in science and technology and by significant updates to national and European regulatory frameworks across health products. The HPRA remains committed to ensuring that Ireland benefits from a trusted, responsive and effective regulator that supports and embraces innovation while safeguarding public and animal health.”
26
Polypharmacy
Polypharmacy: The Role of the Community Pharmacy Team in Supporting Medication Safety Polypharmacy is an important consideration in healthcare, particularly as people live longer with multiple longterm conditions. For community pharmacy teams, it highlights the value of listening to patients, recognising potential concerns and ensuring relevant information reaches the appropriate healthcare professional. Written by Jessica Egerton, Founder, Pharmacy Standard
Recognising the limits of the role and communicating concerns appropriately helps ensure patients receive the right support. Knowing when to escalate The Pharmaceutical Society of Ireland (PSI) states that pharmacy technicians and general pharmacy counter assistants work under the guidance and supervision of a pharmacist.2 Clear responsibilities and effective communication are therefore essential to safe practice. Staff should understand how to escalate concerns, whom to approach and what information needs to be communicated. Appropriate training and clear pharmacy procedures can help team members feel confident about raising concerns while remaining within their role.
Polypharmacy is commonly defined as the use of five or more regular medicines.1 An Irish study examining General Medical Services (GMS) pharmacy claims data found that polypharmacy among GMS (medical card) patients aged 65 and over in the former Eastern Health Board region increased from 17.8% in 1997 to 60.4% in 2012.1 These figures illustrate how common polypharmacy became in this population. The authors also suggested that a threshold of five medicines alone may no longer identify those at greatest risk, as polypharmacy has become more widespread.1 There is a distinction between appropriate and inappropriate polypharmacy. Multiple medicines may be necessary to manage complex conditions and maintain quality of life. The concern is not simply how many medicines a person takes, but whether their treatment remains appropriate and whether they can manage it safely. Recognising potential concerns Patients may raise concerns about their medicines during routine pharmacy interactions. They might report unexpected symptoms, difficulty remembering doses, uncertainty about why a medicine has been prescribed or challenges managing a complicated regimen. These conversations should not be used to draw clinical conclusions independently. However, they
IRISHPHARMACYNEWS.IE
may identify issues that warrant further attention. Listening carefully and recognising when to refer a concern to the pharmacist are practical ways the pharmacy team can support medication safety. The pharmacy technician’s contribution My experience across community pharmacy and residential care pharmacy has reinforced how essential communication is between healthcare professionals. In residential care, medicinesrelated concerns can involve pharmacy teams, nursing staff and GPs working together to share relevant information and ensure concerns receive appropriate attention. In community pharmacy, technicians can contribute through everyday interactions. For example, if a patient collecting a prescription mentions missing doses or difficulty managing their medicines, the technician can listen, clarify the information in line with pharmacy procedures and pass the concern to the pharmacist. Accurate communication allows the pharmacist to determine whether further assessment or action is appropriate. This is information-gathering, not clinical assessment. A technician should not determine whether a medicine is responsible for a symptom or recommend changes to treatment.
Concerns about possible side effects, difficulties managing medicines or changes in a patient's circumstances should be referred to the pharmacist. If a patient describes potentially urgent symptoms, the pharmacy's established procedures for obtaining urgent clinical assistance should be followed. Patients should also be encouraged to discuss concerns about their treatment with their pharmacist or GP. They should not stop or alter prescribed medicines without appropriate professional advice. A team approach to safer medicines use Medication safety depends on effective collaboration.
Pharmacists may work with GPs and other prescribers when reviewing treatment, particularly where changes to prescribed medicines are being considered. Decisions should take account of the patient's clinical needs, circumstances and preferences. For community pharmacies, an important practical question is whether every team member knows how to recognise and communicate a concern. Regular training, clear escalation pathways and a supportive team culture can help ensure patients' questions are heard and relevant information is not overlooked. Polypharmacy is complex, and the number of medicines alone does not determine whether treatment is appropriate. By listening carefully, communicating accurately and recognising when further professional input is needed, pharmacy technicians can support pharmacists and help make medication safety part of everyday, person-centred care. References 1. Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. BMJ Open. 2015;5(9). doi:10.1136/ bmjopen-2015-008656. 2. Pharmaceutical Society of Ireland. Pharmaceutical Assistants. Available at: https://www.psi.ie/registration/ pharmaceutical-assistants. Accessed 26 October 2026.
Small in size, rich in nutrition, great in taste. No Online PCRS Approval Required
High protein, low volume ONS comparison Fresubin® PRO COMPACT Drink
Fortisip® Compact Protein1
Volume (ml)
125
125
Energy (kcal)
300
306
Protein (g)
18 (24% energy)
18.3 (24% energy)
Leucine (g)
1.8
1.6–1.7 (depending on flavour)
Vitamin D (µg)
6.3
2.6
Calcium (mg)
438
438
Fresubin® PRO COMPACT Drink and Fortisip® Compact Protein are low volume ONS (125ml) with the same energy density (2.4 kcal/ml) and protein content (24% energy from protein)
Scan the QR code to order samples Intended for use in Republic of Ireland ONS- Oral Nutritional Supplement
IE-FreONS-2600008 | Date of Preparation: February 2026
28
News
Minister Questioned Over Fairness of Drugs Payment Scheme for Single-Person Households The fairness of Ireland's Drugs Payment Scheme (DPS) has been raised in the Dáil, amid concerns that people living alone face the same monthly medicines expenditure threshold as couples and families. Minister for Health, Jennifer Carroll MacNeill TD
General Medical Services scheme, alongside wider measures to improve access to healthcare. She also emphasised the State's investment in new medicines, noting that additional funding had supported the reimbursement of 276 medicines, including treatments for cancer and rare diseases.
In a parliamentary question on 6 October 2026, Deputy Brian Brennan asked Minister for Health Jennifer Carroll MacNeill whether she would review the application of a uniform monthly threshold, particularly for widowed and single-person households. The question raises concerns about the financial burden on individuals who must meet the same threshold from one household income, compared with larger households whose eligible medicines expenditure can be combined.
In her written response, the Minister confirmed that the Government remains committed to improving the affordability of medicines, including through ongoing reviews of community drug schemes. However, she did not indicate whether a specific review of the threshold's impact on single-person households would be undertaken. The Minister highlighted previous reductions in the DPS threshold and prescription charges under the
The DPS is available to people ordinarily resident in Ireland and is not means-tested. It limits eligible monthly expenditure on approved prescribed medicines and certain medical appliances, with expenditure above the applicable threshold covered under the scheme. “The Drug Payment Scheme (DPS) provides for the refund of the amount by which expenditure on approved prescribed medicines or medical and surgical appliances exceeds a named threshold in any calendar month. The DPS is not means tested and is available to anyone ordinarily resident in Ireland. The DPS significantly reduces the cost burden for
LEAN Award for United Drug Congratulations to United Drug on being recognised with a Kaizen LEAN Award from the Kaizen Institute. This award marks an important milestone in United Drug’s continuous improvement journey with the Kaizen Institute, recognising the dedication of their people to driving positive change across the business. By embracing Kaizen principles, United Drug teams have identified smarter ways of working, improved efficiency, and enhanced the service they provide to customers every day. As one of Ireland’s leading healthcare distributors, supplying more than 50% of the Irish pharmaceutical market and delivering over 85 million units annually, continuous improvement plays a vital role in helping us deliver health and support better outcomes across the healthcare system.
Stakeholder Briefing As Ireland navigates an increasingly competitive and rapidly changing global landscape, maintaining our position as a leading destination for investment, innovation and enterprise has never been more important. The Pharmaceutical Managers’ Institute is delighted to welcome Peter Burke, Minister for Enterprise, Tourism and Employment, for a Stakeholder Breakfast briefing on November 11th. This timely discussion will explore the role of the healthcare and pharmaceutical sector in Ireland’s economic and international success, the opportunities presented by Ireland’s Presidency of the Council of the European Union, and what Ireland must do to continue attracting investment, fostering innovation and strengthening its position on the global stage. The event will be held from 8-9.30am in the Clayton Hotel, Liffey Valley, Dublin. Visit www.thepmi.com for further information.
IRISHPHARMACYNEWS.IE
families and individuals with ongoing expenditure on medicines. “There has been a significant focus in recent years on improving access to, and the affordability of, healthcare services. “This includes reductions in the Drugs Payment Scheme threshold, reductions in the prescription charges per item and maximum monthly prescription charges under the GMS scheme, expansion of access to free GP care, and the abolition of all public in patient hospital charges for children and adults. These measures continue to support affordable access to quality healthcare,” she said. For community pharmacists, the issue highlights the importance of medicines affordability, particularly for older patients, people living alone and those managing multiple chronic conditions. The Minister stated that any future changes to medicines eligibility would be considered in the context of healthcare priorities and available budgets. No specific commitment to introduce a different threshold for single-person households was announced.
The next generation of pharmacy performance reporting Understand dispensary and retail performance, identify opportunities and make more informed decisions with connected reporting from Navi. Where is performance improving? Which categories need attention? Where are purchasing opportunities being missed? For pharmacy owners and managers, reporting is most useful when it helps answer these questions and decide what to do next. Navi has launched iGnite360, the upgrade to its iGnite Business Intelligence solution. Bringing together dispensary and Epos data, it gives owners a connected view of dispensing activity and retail sales, with insights to support day-to-day management and commercial decisions. For many Irish pharmacies, iGnite has been the place to go for a clearer picture of the business. iGnite360 takes that further. Rebuilt around how owners and managers actually work, it connects DispenSense dispensary data and TillSense retail data, so the two halves of the pharmacy can finally be seen side by side.
See where to focus your attention Dispensary performance reporting helps owners review dispensing activity, trends and performance over time. Epos reporting provides visibility of retail sales and category performance, helping managers identify areas of growth and categories that need closer attention. Viewing these insights together helps owners set priorities across the dispensary and shop floor, then review performance as changes are introduced. Pharmacy benchmarking: Understand performance across your pharmacy or group For multi-store owners, comparisons across stores help highlight performance gaps and identify where additional support may be needed. Employee-level reporting across dispensary and retail also supports coaching and training conversations. Used alongside an understanding of roles and workload, these insights help managers recognize contributions and focus development. Use purchasing insights to inform decisions Margin tools highlight missed discounts and purchasing opportunities, while order management helps pharmacies review purchasing history against their chosen criteria. This gives owners a basis for reviewing buying habits and making more informed purchasing decisions. Automatic PCRS payment file download PCRS payment files now download automatically into iGnite360, building on its existing claims functionality and removing a manual download task from the team’s routine.
What’s new in iGnite360: • • •
•
Connected reporting: dispensary and retail data in one view DispenSense reporting: dispensary performance, benchmarking & team insights TillSense reporting: sales performance, category analysis, benchmarking and team sales insights Purchasing tools: order management and margin maximisation
Dispensary data
Reporting grounded in your own transactions iGnite360 uses your pharmacy’s dispensing and sales transactions to show performance within your business. Dispensary reporting draws on DispenSense data, while retail reporting draws on TillSense data; the connected view depends on the systems integrated with your pharmacy. See what iGnite360 could show you Book a 20-minute demo to explore dispensary and retail reporting, purchasing insights and automatic PCRS payment file download. Existing iGnite customers can contact Navi customer service or there Business Development manager for full details.
info@navi.ie | 01 443 3884
iGnite360. Your pharmacy, connected.
Connected insights, smarter decisions
Retail data
30
Winter Skin
Winter-Proof Skin Sales in your Pharmacy Atopic eczema can run in families and frequently occurs alongside other atopic conditions, including hay fever and asthma. Symptoms include red, dry, itchy skin, which can sometimes weep, become blistered, crusted and thickened. However, the appearance of eczema and the locations of the body affected can vary greatly depending on the age of the person affected. Atopic eczema has been described as the ‘itch that rashes’. Itch is an unpleasant sensation which activates the desire to scratch. The desire to scratch can be so intense that people can sometimes scratch until the skin becomes painful and bleeds. Occasionally, this can lead to cuts, abrasions and skin infections. Dry Skin If the skin’s water content drops below 10%, the enzymes responsible for corneocyte desquamation no longer function properly. The corneocytes shrink reducing levels of NMF and the lipid lamellae appears broken (analogous to crumbling mortar in an old brick wall). These will create breaches in the skin’s barrier, allowing for greater water loss. Clinically, xerotic skin appears rough and flaky, with white patches (which represent adherent corneocytes due to reduced desquamation) that is both uncomfortable and pruritic. Dry skin is commonly seen on the lower legs, the trunk, forearms, hands and face. The feet are normally less prone to dryness, being protected by socks and tights, but dryness can be problem for those who walk barefoot or wear sandals. Left untreated, xerotic skin becomes red, dull and rough, and ultimately starts to crack. These cracks deteriorate over time and can bleed, providing an entry portal for irritants and bacteria that can lead to infections. To prevent dry skin, customers should be advised to maintain skin hydration through adequate fluid intake, avoid hygiene products that dry out the skin, reduce fullbody bathing to every other day, and avoid long, hot showers. To treat dry skin, there are several suggestions pharmacists can offer. Patients can apply oil-based emollients (eg, petrolatum and mineral oil) after bathing, or they may use colloidal oatmeal or bath oil while bathing to enhance skin
IRISHPHARMACYNEWS.IE
hydration. Humectants, such as glycerin, draw water into the skin. More serious cases of dry skin may require a urea- or lactic acid containing product. Managing Eczema The words eczema (which comes from the Greek word meaning ‘to boil’) and dermatitis (meaning inflammation of the skin) are often used interchangeably to describe several conditions that cause the skin to become dry, itchy, inflamed or irritated. There are a number of different types of eczema but the term is most often used to refer to atopic eczema (also called atopic dermatitis). The word atopic refers to hypersensitivity reactions to something in the environment. Atopic eczema is a very common, non-contagious, chronic (long-term) inflammatory skin condition. While the exact cause is not known, certain factors are thought to be important in its development, these include an inherited (genetic) predisposition to have a weakened skin barrier, as well as altered inflammatory and allergy responses. Atopic eczema most frequently begins in infancy but may also develop for the first time in adulthood. It affects approximately 1 in 5 children and 1 in 12 adults in Ireland. For most children affected, the disease is mild. However, often those who have seemingly outgrown the condition will continue to have life-long sensitive skin and may have recurrences of eczema following long symptomfree spells.
Scratching is a behaviour used to relieve itching, but sometimes it can also be prompted by emotion, or it can become habitual. Some people scratch when they are stressed or anxious. Some people scratch through subconscious repeated behaviour, and can get stuck in the itch scratch cycle. When they feel itchy they scratch – when they scratch chemicals are released that causes more itch. Alongside conventional management and treatments for atopic eczema some simple techniques may help to relieve the itch. Habit reversal is a behaviour modification technique that can be beneficial in helping to replace an old habit with a new one.
Itching stimulates more scratching
Stimulates nerve ending to trigger itch
Pain, swelling and redness
To stop scratching, the person first needs to become aware of the desire to scratch and the action of scratching. However, people living with eczema can get fed up of family saying “stop scratching!”, so it may help by developing a code word to provide encouragement instead. Maybe gently ‘pinch’ or ‘tap’ or count the number of times scratching is observed to create awareness of the action. Some people choose to use a tally counter. The main aim is to improve symptoms and achieve longterm control. In atopic eczema, the skin’s protective barrier is weakened which allows moisture to be lost, and irritants and allergens to pass through the skin more easily. Some common everyday substances e.g. soap, contribute to the weakening of the skin’s barrier and should be avoided. The Irish Skin Foundation’s ‘Living with Atopic Eczema’ survey, which over 450 people living with eczema or caring for someone with eczema responded to between September 2018 – April 2019 showed that the cost of eczema treatments and doctor’s appointments needed to manage the condition can be a significant financial burden. The survey revealed that 42% of carers of children and 49% of adults reported cutting back on household expenses due to the cost of managing atopic eczema. The figures suggest that one quarter of you spend at least ¤2,300 annually on doctor’s fees, over-thecounter management products and prescription treatments.
Itching
Scratching
Release inflammatory chemicals
Wegovy® delivers quality weight loss1,2,5 and provides cardiovascular risk reduction1,3ɬ
~21% mean weight loss1,2*Ŧ
~25%
weight loss in 1 in 31,2*¥
Safety and tolerability profile comparable to the GLP-1 RA class in general1
Wegovy® is recommended in the ESC CCS guidelines for cardiovascular risk reduction4 tThis product is subject to additional monitoring. ESC = European Society of Cardiology. CCS = Chronic Coronary Syndrome. GLP-1 RA = Glucagon Like Peptide 1 Receptor Agonist. Wegovy®t(semaglutide). Please refer to the full Summary of Product Characteristics (SmPC) before prescribing. Wegovy® 0.25 mg FlexTouch® solution for injection in pre-filled pen. Wegovy® 0.5 mg FlexTouch® solution for injection in pre-filled pen. Wegovy® 1 mg FlexTouch® solution for injection in pre-filled pen. Wegovy® 1.7 mg FlexTouch® solution for injection in pre-filled pen. Wegovy® 2.4 mg FlexTouch® solution for injection in pre-filled pen. Indication(s): Adults: Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (Obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. For trial results with respect to cardiovascular risk reduction, obesity-related heart failure, and populations studied, see section 5.1. of the Wegovy® SmPC. Adolescents: Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with obesity* and body weight above 60 kg. Treatment with Wegovy® should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose. *See table 1 in the Wegovy® SmPC for BMI cut-off points for obesity by sex and age. Posology and administration: Administered once weekly at any time of the day, with or without meals. Injected subcutaneously in the abdomen, in the thigh or in the upper arm. The injection site can be changed. It should not be administered intravenously or intramuscularly. For the 7.2 mg dose, inject three doses of 2.4 mg one after each other. The injections can be administered in the same body area but should be at least 5 cm apart. Injection sites should always be rotated to reduce the risk of injection site amyloid deposits. The day of weekly administration can be changed if necessary, as long as the time between doses is at least 3 days (>72 hours). After selecting a new dosing day, once-weekly dosing should be continued. Adults: The maintenance dose of semaglutide 2.4 mg once-weekly is reached by starting with a dose of 0.25 mg. To reduce the likelihood of gastrointestinal symptoms, the dose should be escalated over a 16-week period to the maintenance dose. If needed, the dose can be increased to 7.2 mg once weekly after a minimum of 4 weeks on the 2.4 mg dose in adults with BMI ≥ 30 kg/m2 at treatment initiation. If no additional clinical improvement in body weight is observed with 7.2 mg, lower the dose to 2.4 mg once weekly. In case of significant gastrointestinal symptoms, consider delaying dose escalation or lowering to the previous dose until symptoms have improved. Adolescents: For adolescents ages 12 years and above, the same dose escalation schedule as for adults should be applied. The dose should be increased until 2.4 mg (maintenance dose) or maximum tolerated dose has been reached. Weekly doses higher than 2.4 mg are not recommended in the adolescent population. Patients with type 2 diabetes: When initiating Wegovy®, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (such as sulfonylureas) to reduce the risk of hypoglycaemia. Missed dose: If a dose is missed, it should be administered as soon as possible and within 5 days after the missed dose. If more than 5 days have passed, the missed dose should be skipped, and the next dose should be administered on the regularly scheduled day. If more doses are missed, reducing the starting dose for re-initiation should be considered. Elderly: No dose adjustment is required based on age. Renal impairment: No dose adjustment is required for patients with mild or moderate renal impairment. Experience in patients with severe renal impairment is limited. Semaglutide is not recommended for use in patients with severe renal impairment (eGFR <30 mL/min/1.73m2) including patients with end-stage renal disease. Hepatic impairment: No dose adjustment is required for patients with mild or moderate hepatic impairment. Experience in patients with severe hepatic impairment is limited. Semaglutide is not recommended for use in patients with severe hepatic impairment and should be used cautiously in patients with mild or moderate hepatic impairment. Paediatrics: The safety and efficacy of semaglutide in children below 12 years of age have not been established. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Special warnings and precautions for use: Cases of pulmonary aspiration have been reported in patients receiving GLP-1 receptor agonists undergoing general anaesthesia or deep sedation. Therefore, the increased risk of residual gastric content due to delayed gastric emptying should be considered prior to performing procedures with general anaesthesia or deep sedation. Use of GLP-1 receptor agonists may be associated with gastrointestinal adverse reactions. This should be considered when treating patients with impaired renal function, as nausea, vomiting, and diarrhoea may cause dehydration, which in rare cases can lead to a deterioration of renal function. Patients treated with semaglutide should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion. Acute pancreatitis has been observed with the use
of GLP-1 receptor agonists. Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, Wegovy® should be discontinued; if confirmed, Wegovy® should not be restarted. Caution should be exercised in patients with a history of pancreatitis. In the absence of other signs and symptoms of acute pancreatitis, elevations in pancreatic enzymes alone are not predictive of acute pancreatitis. Data from epidemiological studies indicates an increased risk for nonarteritic anterior ischaemic optic neuropathy (NAION) during treatment with semaglutide. There is no identified time interval for when NAION may develop following treatment start. A sudden loss of vision should lead to ophthalmological examination and treatment with semaglutide should be discontinued if NAION is confirmed. Wegovy® should not be used as a substitute for insulin in patients with type 2 diabetes. Wegovy® should not be used in combination with other GLP-1 receptor agonist products. Patients treated with Wegovy® in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia. The risk of hypoglycaemia can be lowered by reducing the dose of sulfonylurea or insulin when initiating treatment with a GLP-1 receptor agonist. In patients with diabetic retinopathy treated with semaglutide, an increased risk of developing diabetic retinopathy complications has been observed. Patients with diabetic retinopathy using semaglutide should be monitored closely and treated according to clinical guidelines. There is no experience with Wegovy® in patients with type 2 diabetes with uncontrolled or potentially unstable diabetic retinopathy. In these patients, treatment with Wegovy® is not recommended. Semaglutide treated patients with gastroparesis may experience more serious or severe gastrointestinal adverse events. Semaglutide should be used with caution in these patients, and semaglutide is not recommended if gastroparesis is severe. The safety and efficacy of Wegovy® has not been investigated in patients treated with other products for weight management, with type 1 diabetes, with severe renal or hepatic impairment or with congestive heart failure New York Heart Association (NYHA) class IV. Use in these patients is not recommended. There is limited experience with Wegovy® in patients aged 85 years or more, with mild or moderate hepatic impairment, with inflammatory bowel disease. Use with caution in these patients. If semaglutide is used in combination with a sulfonylurea or insulin, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines. Fertility, pregnancy and lactation: Women of childbearing potential are recommended to use contraception when treated with semaglutide. There are limited data from the use of semaglutide in pregnant women. Therefore, semaglutide should not be used during pregnancy. If a patient wishes to become pregnant, or pregnancy occurs, semaglutide should be discontinued. Semaglutide should be discontinued at least 2 months before a planned pregnancy due to the long half-life. In lactating rats, semaglutide was excreted in milk. A risk to a breast-fed child cannot be excluded. Semaglutide should not be used during breast-feeding. Effect on fertility unknown. Undesirable effects: Very common (≥1/10): Headache, vomiting, diarrhoea, constipation, nausea, abdominal pain, fatigue. Common (≥1/100 to <1/10): Hypoglycaemia in patients with type 2 diabetes, dizziness, dysgeusia, dysaesthesia, diabetic retinopathy in patients with type 2 diabetes, gastritis, gastrooesophageal reflux disease, dyspepsia, eructation, flatulence, abdominal distension, cholelithiasis, hair loss, injection site reactions. Uncommon (≥1/1,000 to <1/100): Hypotension, orthostatic hypotension, increased heart rate, acute pancreatitis, delayed gastric emptying, increased amylase, increased lipase. Rare (≥1/10,000 to <1/1,000): Anaphylactic reaction, angioedema. Very rare (<1/10 000): Non-arteritic anterior ischaemic optic neuropathy (NAION). Not known (cannot be estimated from the available data): Intestinal obstruction. The SmPC should be consulted for a full list of side effects. MA number(s): Wegovy® 0.25 mg FlexTouch® EU/1/21/1608/006. Wegovy® 0.5 mg FlexTouch® (1.5 ml cartridge) EU/1/21/1608/007. Wegovy® 0.5 mg FlexTouch® (3 ml cartridge) EU/1/21/1608/012. Wegovy® 1 mg FlexTouch® EU/1/21/1608/008. Wegovy® 1.7 mg FlexTouch® EU/1/21/1608/009. Wegovy® 2.4 mg FlexTouch® EU/1/21/1608/010. Legal category: Product subject to prescription which may not be renewed. For complete prescribing information please refer to the SmPC which is available on www.medicines.ie or by email from infoireland@novonordisk.com or from the Clinical, Medical and Regulatory Department, Novo Nordisk Limited, 1st Floor, Block A, The Crescent Building, Northwood Business Park, Santry, Dublin 9, Ireland. Date last revised: February 2026. IE26SEMO00055. tThis medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported to the Health Products Regulatory Authority. Information about adverse event reporting is available at www.hpra.ie. Adverse events should also be reported to Novo Nordisk on Tel: 01 8629700 or complaintireland@novonordisk.com.
*From baseline to week 72. Data presented here from the STEP UP trial are based on the trial product estimand, which describes the treatment effect if all people adhered to treatment, whereas the primary treatment policy estimand describes the treatment effect regardless of treatment adherence. When applying the treatment policy estimand, people treated with Wegovy® 7.2 mg achieved a superior weight loss of 18.7% vs placebo of 3.9%. The proportion of patients with a body weight reduction of ≥25% was greater with Wegovy® 7.2 mg (31.2%), vs placebo (0%).1 ɬ People living with overweight or obesity and established cardiovascular disease without diabetes. Ŧ The co-primary endpoints were percentage change in body weight and the proportion of patients with a body weight reduction of 5% or greater for Wegovy® 7.2 mg vs placebo.1 Applying the trial product estimand, the proportion of patients with a body weight reduction of ≥5% was greater with Wegovy® 7.2 mg (93.2%), vs placebo (35.7%).1 ¥Confirmatory secondary endpoint. References: 1. Wegovy® Summary of Product Characteristics www.medicines.ie 2. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025; S2213-8587(25)00226-8. 3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232 4. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537. 5. Hjelmesæth J, Bhat S, Garvey WT, et al. Effect of semaglutide on body composition and proximal muscle strength: the STEP UP trial. Presented at: The 61st European Association for the Study of Diabetes (EASD) Annual Meeting; September 15-19, 2025; Vienna, Austria. Wegovy® and FlexTouch® are registered trademarks of Novo Nordisk A/S. Live LighterTM is a trademark owned by Novo Nordisk A/S. March 2026; IE26SEMO00057. Novo Nordisk Limited, First Floor, Block A, The Crescent Building, Northwood Business Park, Santry, Dublin 9. D09 X8W3, Ireland. Tel: 01 8629 700, infoireland@novonordisk.com www.novonordisk.ie
32
Winter Skin
Rosacea
3: Cleansing
Gusty winds during the winter and the dry air in overheated rooms cause the skin of patients with rosacea to become more sensitive. Rosacea is defined as a chronic, relapsing, inflammatory condition that affects the central portion of facial skin. More frequently seen in fair-skinned individuals of Celtic or Northern European heritage, rosacea occurs more commonly in women (although men tend to experience more severe disease) and in those between 30 and 50 years of age.
Avoid vigorous washing and scrubbing as this can irritate the skin. Wash the skin with a gentle skin cleanser or a soap substitute, use lukewarm water and pat skin dry.
Self-Care Tips for Rosacea These are some of the most important things sufferers need to know about rosacea and how they can best manage it themselves. 1: Identify the triggers If possible, identify and avoid any lifestyle or environmental factors which trigger or exacerbate symptoms. Examples of common triggers can include alcohol, hot beverages, spicy foods, and extremes in temperatures. Sometimes it may help to keep a written record of flare-ups to identify any trigger. 2: Choosing products Individuals with rosacea, often have sensitive, easily irritated skin. Therefore it is important to select mild, non-irritating, fragrance-free, alcohol-free, skin care products. Advise on the use a moisturiser which is fragrance free and “noncomedogenic” or “oil free”, on a regular basis to improve skin hydration and skin barrier function.
4: Shave carefully Electric shavers may be more comfortable for men with rosacea. Avoid any shaving creams or lotions that burn or sting. 5: Use medications as directed Use prescribed topical preparations and oral rosacea medications as directed; e.g. take them at the correct time of day, as often as prescribed, at the right dose. 6: Be patient! Unfortunately, patience is necessary; rosacea treatment may take time to take effect. Depending on the individual and type of treatment (topical or oral), some studies have suggested it may take 6 – 12 weeks before any particular therapy is changed for another. 7: Are the eyes affected? If a sufferers eyes are affected, they should consult with their doctor. For mild eye symptoms (which may include dryness or a gritty feeling in the eyes) washing the eyes twice daily with warm water and using artificial tears may be beneficial. Chapped Lips Chapped lips can occur in any season of the year, although they are particularly common during the winter months. Chapped lips
can be painful, embarrassing, and uncomfortable. They may sometimes cause difficulty in talking, eating, and drinking. Understanding the causes, treatments, and prevention can help pharmacy teams advise sufferers on how to reduce or avoid the occurrence of chapped lips. The skin on the lips is much thinner and more delicate than that on other parts of the body. The lips are also exposed to the elements, including the sun and cold, dry air, making them prone to dryness, cracking, flaking, and peeling. The lips lack oil glands and so cannot produce their own moisture, but natural moisturisers can help. Whilst the winter conditions most often cause chapped lips, there are other causes such as: Smoking Dehydration Repeatedly licking the lips Skin disorders such as eczema Allergic reactions to certain skin care products or cosmetics Use of certain medications such as anti-acne products Those with chapped lips may experience dryness, redness, tenderness and sensitivity, cracking, splitting, or peeling and pain. A variety of OTC products are available for treating or preventing chapped lips. These products typically contain ingredients that assist in healing, such as skin protectants, moisturisers, pain relievers, and sunscreens.
Use of Emollients Emollient (moisturiser) therapy is often used to manage a number of skin conditions, such as eczema and psoriasis. However, with such a wide variety of emollients available on the market today, it is important you and your team are aware about which products are the best fit for people who need to use emollients regularly. Emollients are moisturisers that come in the form of lotions, creams and ointments. They repair and protect the skin barrier. They hydrate and trap moisture in the skin. Emollient therapy improves symptoms resulting in decreased dryness, flaking, cracking, scaling, resulting in reduced itch and inflammation. Emollients are used in two ways: Leave on emollient or wash emollient. A leave-on emollient is applied directly to the skin to moisturise and trap moisture. Wash emollient comes in the form of a soap substitute as an alternative to soap, emollient body wash in place of shower gel, or emollient bath additive or bath oil instead of bubble bath. Soaps, shower gels and bubble-bath should be avoided as they contain detergents, which strip away the natural oils and dries out the skin. Finding the right emollient is often a matter of trial and error, but the best emollients are ones customers prefer to use and will continue to use every day. Practical tips for emollient therapy Establish a good daily skin care routine and try to stick to it. Don’t stop moisturising when the skin is clear. Apply emollients in a smooth, downward motion, in the direction of the hair growth. Never stick fingers into a tub of emollient – Remember to use a CLEAN spatula, spoon or a pump dispenser to apply so it does not become contaminated. A child with inflamed skin often requires a minimum of 250g of ‘leave-on’ emollient per week, while an adult may need approximately 500g – 1000g per week. Bathwater should be a lukewarm temperature. 5 minutes with an emollient bath additive is sufficient. Remember – avoid soap, bubble bath and shower gel After bathing or showering, gently pat skin dry and apply emollient all over when the skin is still slightly damp.
IRISHPHARMACYNEWS.IE
34
Party Feet
Winter Party Feet: A Seasonal Opportunity for Community Pharmacy From festive footwear and party preparations to fungal nail concerns and winter skin problems, the colder months present community pharmacies with valuable opportunities to promote foot health, provide practical advice and maximise seasonal retail sales. As the festive season approaches, consumers are turning their attention to party outfits, footwear and personal grooming. While skincare, cosmetics and fragrance traditionally dominate seasonal retail displays, footcare represents an often-overlooked category with considerable potential for community pharmacies. Winter brings its own foot health challenges. Prolonged periods in enclosed shoes and boots, changes in footwear, increased social activity and the return of high heels can contribute to discomfort, dry skin, blisters and nail concerns. For pharmacists and their teams, the seasonal focus on appearance provides a natural opportunity to initiate conversations about common foot conditions, particularly fungal nail infections, while encouraging appropriate treatment and preventative care. Fungal Nail Health: Beyond Cosmetic Concerns Fungal nail infections, or onychomycosis, are a common concern encountered in community pharmacy. Although often regarded as primarily cosmetic, affected nails may become discoloured, thickened, brittle or crumbly, sometimes causing discomfort or embarrassment. The condition commonly affects toenails and can develop gradually, meaning patients may delay seeking advice until the appearance of the nail becomes more noticeable. The festive season can bring these concerns into sharper focus, particularly when consumers are planning to wear open-toed shoes or attend social occasions. Pharmacy teams are well placed to identify potential symptoms and explain the importance of early assessment and appropriate treatment. However, not every discoloured or damaged nail is caused by a fungal infection. Trauma from poorly fitting footwear, psoriasis and other nail disorders can produce similar changes. Pharmacists should therefore assess symptoms carefully, considering the number of nails
IRISHPHARMACYNEWS.IE
affected, duration of symptoms, associated skin conditions and any relevant medical history before recommending treatment. Supporting Effective Treatment For suitable patients with mild fungal nail infections, topical antifungal treatments may provide an appropriate pharmacybased option. Products are available in different formulations, including nail lacquers, solutions and applicators, with application instructions varying between products. An important counselling message is that treatment requires patience and consistency. Toenails grow slowly, and visible improvement may take several months. Even where treatment is effective, the affected portion of the nail must grow out before a healthier appearance is restored. Pharmacy teams should explain that treatment duration depends on the product and severity of infection, and that patients should follow the relevant instructions rather than expecting an immediate cosmetic improvement. Patients with extensive infection, significant pain, treatment failure or underlying conditions such as diabetes or immunosuppression may require medical assessment. The festive season also provides an opportunity to remind patients that cosmetic nail polish should not be used to conceal a suspected infection without checking its compatibility with any treatment being used. Winter Footwear and Prevention Enclosed footwear can create warm, moist conditions that favour fungal growth, particularly when boots or shoes are worn for extended periods. Pharmacists and pharmacy assistants can reinforce straightforward preventative measures, including keeping feet clean and dry, changing socks regularly and allowing footwear to dry thoroughly between uses. Athlete's foot is another important consideration. This common fungal skin infection may cause itching, scaling, cracking or whitening
between the toes and can spread to toenails if left untreated.
who would not ordinarily browse the footcare category.
Recognising and treating athlete's foot promptly can therefore form part of a broader approach to maintaining healthy nails.
However, merchandising should remain clinically responsible. Customers should not be encouraged to purchase antifungal products solely for cosmetic nail changes without appropriate assessment.
Other seasonal concerns include cracked heels, calluses, corns and friction-related blisters caused by unsuitable or unfamiliar footwear. Advice on well-fitting shoes, appropriate foot moisturisers, cushioning products and protective dressings can help customers manage discomfort while supporting additional footcare sales. Making Footcare a Seasonal Retail Destination From a merchandising perspective, the winter party season offers pharmacies an opportunity to give footcare greater visibility beyond its traditional location within the healthcare aisle. A dedicated “Winter Party Feet” display could bring together complementary categories, creating a convenient destination for customers preparing for festive events. Antifungal nail treatments, athlete's foot products, heel balms, foot moisturisers, blister plasters, cushioning pads and footcare accessories can be presented alongside simple educational messaging. Displays positioned near seasonal beauty, skincare or personal care ranges may help attract customers
Staff awareness is equally important. Pharmacy assistants should feel confident recognising when a customer needs pharmacist advice and understanding the key differences between cosmetic footcare products and treatments for suspected fungal conditions. Encouraging Conversations at the Counter The strongest seasonal merchandising campaigns combine attractive displays with informed, approachable staff. Simple questions about nail changes, itching, footwear discomfort or previous treatments can help identify unmet needs and create opportunities for appropriate recommendations. For patients seeking fungal nail treatments, staff should reinforce realistic expectations, treatment adherence and the importance of preventing reinfection. Meanwhile, customers purchasing party footwear accessories or blister protection may benefit from wider advice on keeping feet comfortable throughout the winter months.
Nail fun gus? Tr y Nailn er.
Available in selected pharmacies nationwide. *
Nailner 2-IN-1 Pen & Brush are anti-fungal treatments and classified as medical devices. Always read the individual product leaflets and follow instructions before use. There is no age limit for using Nailner products but consult a doctor if the individual is under the age of 16 years. Available in pharmacy only.
|
Ocean Healthcare Email: orders@oceanhealthcare.ie
| Tel: 01 296 8080
36
Pharmacy Profile
Vital Pharmacies Marks Major Rebrand Milestone Across 130+ Pharmacies Vital Pharmacies Celebrates Completion of Ireland's Largest Independent Pharmacy Rebranding Programme With the vast majority of pharmacies now successfully transitioned to the Vital Pharmacies brand, Ireland's largest network of independently owned community pharmacies is celebrating a significant milestone in its continued growth and development.
Over the past 18 months, pharmacies across the former Haven and totalhealth pharmacy networks have progressively adopted the Vital Pharmacies brand, creating a unified identity for more than 130 independently owned pharmacies throughout Ireland. The project represents one of the largest pharmacy rebranding programmes ever undertaken in Ireland. However, unlike traditional corporate rebrands, the focus has been on strengthening the collective identity of independent pharmacies while preserving the local names, heritage, and community connections that patients know and trust. Across the country, customers are now seeing the Vital Pharmacies brand appearing alongside the established family and community pharmacy names that have served their local areas for generations. The approach reflects the group's belief that independent pharmacy is strongest when local ownership is supported by the scale, resources, and expertise of a wider network.
IRISHPHARMACYNEWS.IE
The rebranding programme has also coincided with significant growth for the group. While the transition was underway, additional independent pharmacies continued to join the network, recognising the benefits of belonging to a cooperative organisation that is owned and managed by its members. Today, Vital Pharmacies is the largest pharmacy group in Ireland, supporting more than 130 independently owned pharmacies serving communities across the country. John Arnold, Chief Executive, Vital Pharmacies comments, “This milestone is about much more than new signs and logos. It represents hard work to create a unified identity for independent pharmacy while retaining the local names, local teams, and community connections that make each pharmacy unique. "What has been particularly encouraging is that throughout the rebranding programme we have continued to grow. More independent pharmacy owners are recognising the benefits
37 initiatives, healthcare campaigns, digital services, and patientfocused supports designed to strengthen the role of community pharmacy throughout Ireland. While the rebranding programme is now nearing completion, Vital Pharmacies sees this milestone as the beginning of the next phase of development for the network. With more than 130 pharmacies, continued membership growth, and a clear focus on supporting independent community pharmacy, Vital Pharmacies is now firmly established as Ireland's largest pharmacy group and the country's leading community pharmacy network.
of working together, sharing expertise, improving procurement, strengthening operational supports, and accessing services that help them compete in an increasingly challenging environment. "The completion of the rebranding programme marks the beginning of the next phase for Vital Pharmacies. Our focus now is on continuing to build the brand, strengthen member supports, enhance patient services, and ensure independent pharmacies remain at the heart of healthcare delivery in communities across Ireland." Rory O'Donnell, Chairman, Vital Pharmacies added, "Vital Pharmacies is unique because it is owned by its members and operated for the benefit of its members. Every pharmacy within the network remains independently owned, and every member has an equal voice in the future direction of the group.
"The transition from the previous Haven and totalhealth brands to Vital Pharmacies was never simply about creating a new brand. It was about creating a stronger future for independent pharmacy while preserving the local ownership, entrepreneurial spirit, and community focus that patients value so highly.
marketing programmes, operational guidance, training initiatives, and access to a nationwide network of fellow independent pharmacy owners. The group has also invested significantly in local community engagement, sponsorship
Most importantly, patients can continue to expect the same trusted advice, familiar faces, and personal service they have always received from their local pharmacy—now backed by the strength of a nationwide network working together for the benefit of independent pharmacy and the communities it serves. If you’re interested in joining Vital Pharmacies or learning more about how we can support you and your pharmacy, please get in touch at info@vitalpharmacies.ie .
"Independent pharmacies continue to play a critical role in communities throughout Ireland. By working together through a cooperative model, our members gain the scale and strength of a national network while retaining complete control of their own businesses. That combination is what makes Vital Pharmacies different and is why we continue to attract new members from across the country." As the network has grown, members have benefited from enhanced procurement support, professional services assistance,
IRISHPHARMACYNEWS.IE
38 | IRISHPHARMACYNEWS.IE
IRISHPHARMACYNEWS.IE | 39
40
News
The PMI Impact Awards 2026 The inaugural PMI Impact Awards are now open for nominations! Whether it's a colleague who consistently goes the extra mile to support and develop others, or an organisation delivering an outstanding community or patient initiative, the PMI are inviting their members to submit nominations in either or both award categories. The winners will be announced and celebrated at the PMI’s Annual Charity Lunch on Thursday, 10th December, in front of more than 400 industry colleagues. 🏆 People Champion Award Recognising individuals who go the extra mile to mentor colleagues, develop future talent and give back to the wider healthcare and pharmaceutical community. 🏆Community Contribution Award Celebrating organisations making a meaningful difference to patients, local communities and wider society through outstanding initiatives. Members can nominate deserving individuals and organisations in either or both categories, with winners selected by an independent panel of six senior industry representatives. You must be a PMI member to nominate, but nominations can be anyone in the industry, at any stage in their career. We know there are inspiring people and initiatives across our industry whose contributions deserve greater recognition. This is your opportunity make sure their efforts don't go unnoticed! Submit your nominations through the PMI website: https://thepmi.com/pmi-awards/
Trust in Irish Pharmacists almost doubles as public demands repeat prescription powers New research by Clonmel Healthcare has revealed a cultural shift in how Irish people access healthcare, with trust in local pharmacy teams nearly doubling in the last 12 months. Data from the STADA Health Report 2026, which surveyed 501 Irish adults, shows that 65% of Irish adults now rely on pharmacists to guide their personal health decisions, a significant surge from just 34% in 2025. The findings underline a growing reliance on community pharmacists as frontline health partners amid ongoing health system pressures and long GP waiting times. • #1 in Europe for repeat prescription demand: Over half of Irish adults (51%) want pharmacists granted the authority to issue repeat prescriptions, making Ireland the highest-ranking country in Europe to push for this service (compared to a 39% European average). • Rejecting digital-only pharmacies: Despite the rise of digital health platforms, 70% of Irish people insist on in-person pharmacist consultations (well
IRISHPHARMACYNEWS.IE
above the 61% EU average), while 59% actively prefer buying OTC health products from their local physical pharmacy, compared to just 10% who would choose an online pharmacy. • Support for expanded services: Beyond repeat prescriptions, 42% of Irish adults want access to 24/7 pharmacy opening hours with consultation services, ranking Ireland #3 in Europe for this future service (vs. a 34% European average). This surge in public trust closely follows recent primary care evolutions, such as the expansion of pharmacy services like the Common Conditions Scheme, demonstrating that patients increasingly view the local pharmacy as a vital, highly accessible first port of call rather than just a dispensary. Donagh O’Leary, Managing Director of Clonmel Healthcare, commented: “This year’s STADA
Health Report clearly demonstrates that Irish patients view their community pharmacist as a cornerstone of primary healthcare. Trust in pharmacy teams has nearly doubled in a single year, reflecting the incredible dedication of pharmacists right across the country. "The message from the public is clear: as our health system faces mounting pressure, people don't want impersonal, digital workarounds but instead prefer accessible, human-first care in their communities. Empowering pharmacists with expanded clinical authorities, such as issuing repeat prescriptions, is a sensible, practical solution that has the potential to ease GP workloads, reduce waiting times, and deliver better outcomes for patients nationwide." Established in 1970, Clonmel Healthcare Ltd has been supplying pharmaceutical products for 56 years both internationally and in Ireland. Today, the company is the
Irish affiliate of STADA AG, based in Frankfurt, Germany. Celebrating 56 years in business this year, Clonmel Healthcare is the number one generic supplier of medicines by value and volume in the Irish market*. It is committed to providing access to essential medicines, empowering individuals to live healthier, fuller lives. With two locations and over 70 employees in Ireland, Clonmel Healthcare distributes 28** million packs of medicine annually. It is accredited by Guaranteed Irish. The STADA Health Report 2026 is an established annual benchmark on the state of health in Europe. This year's 12th edition of the report is based on a representative online study of 19,773 respondents across 20 countries globally, conducted by the market research institute Human8 on behalf of STADA. The survey in Ireland was conducted among a representative sample of 501 participants (49% male, 51% female).
CPD: Cancer Pain
41
Author: Wen Yan Low, Thomas Cahill and Nessa Keane
Continuing Professional Development
CPD
Dr Wen Yan Low, Dr Thomas Cahill, and Dr Nessa Keane are specialist registrars working within the St. Francis Hospice Dublin group across its hospices and hospital consult services. They are clinically immersed in community palliative care work alongside other healthcare professions to ensure patient comfort and symptom control are met as much as possible at home.
Dr Wen Yan Low
Dr Thomas Cahill
Dr Nessa Keane
60 Second Summary Cancer pain is a common experience. Nearly half of patients with a malignant diagnosis experience cancer-related pain during the course of their illness, and the burden of pain is even greater among patients known to specialist palliative care services, where advanced metastatic disease predominates and approximately two thirds experience cancer pain (Snijders et al., 2023). Specialist Palliative Care (SPC) is a healthcare service that is available to available to people with complex needs related to a life-limiting illness. Through different illnesses and disease trajectories, we deliver expert symptom management and end-of-life care. SPC may be involved at any stage where there is complexity, and less involved when conditions are stable. SPC works closely with general practitioners, hospital doctors, and community services to deliver safe, timely, and effective care to patients in the community. For the assessment of pain, the most well-known structure is the mnemonic SOCRATES. Asking about Site, Onset, Character, Radiation, Associated symptoms, Timing of pain, Exacerbating/ relieving factors, and Severity of pain provides an excellent starting point to our pain assessment. Every consultation should also establish urgency as it guides the urgency of treatment. The pain may be new, rapidly worsening or associated with weakness, altered sensation, falls or bladder or bowel changes, in which case pharmacological management are not sufficient, and further evaluation in the hospital may be necessary. The WHO analgesic ladder remains a useful framework, but it is not a strict protocol, as a patient with moderate or severe cancer pain should not be required to fail every weaker treatment before receiving an appropriate strong opioid (WHO, 2018). Awareness of common SPC practices will hopefully shed light to some unfamiliar practices you might have come across in community practice. We greatly appreciate the help from all community pharmacists in delivering high standard care in dispensing medications to all our patients.
1. REFLECT - Before reading this module, consider the following: Will this clinical area be relevant to my practice?
knowledge gap - will this article satisfy those needs - or will more reading be required?
2. IDENTIFY - If the answer is no, I may still be interested in the area but the article may not contribute towards my continuing professional development (CPD). If the answer is yes, I should identify any knowledge gaps in the clinical area.
4. EVALUATE - Did this article meet my learning needs - and how has my practise changed as a result? Have I identified further learning needs?
3. PLAN - If I have identified a
5. WHAT NEXT - At this time you may like to record your learning for future use or assessment. Follow the
4 previous steps, log and record your findings. Published by IPN. Copies can be downloaded from www.irishpharmacytraining.ie Disclaimer: All material published is copyright, no part of this can be used in any other publication without permission of the publishers and author. Panadol has no editorial oversight of the CPD programmes included in these modules.
Cancer Pain Management in the Community Specialist palliative medicine perspective Introduction Cancer pain is a common experience. Nearly half of patients with a malignant diagnosis experience cancer-related pain during the course of their illness, and the burden of pain is even greater among patients known to specialist palliative care services where advanced metastatic disease predominates (Snijders et al., 2023). Cancer pain, like any other pain, has an immense impact on a person’s quality of life, disrupting sleep, mobility, relationships, and independence. Pain is known to evoke both physical and emotional responses with probable bidirectional association with depression (Vadivelu et. al, 2017). It is therefore important to consider pain not just in the physical sense, but also the psychological, social, and spiritual aspects, in the concept known as Total Pain, to achieve effective pain management (Saunders, 1967; Wood, 2022). In 2024, SPC teams in Ireland cared for 15,253 patients in their own homes or nursing homes (Irish Hospice Foundation, 2026). Many factors such as frailty and co-morbidities necessitate close follow up and titration of medications. Community pharmacists play an important role in ensuring these changes are
paracetamol, caffeine
made in the safest manner. The community pharmacist may be the first healthcare professional to notice an early rescue prescription, a new opioid strength or an increasingly worried carer. These encounters offer an opportunity to improve symptom relief and identify deterioration. In this article, we will discuss how specialist palliative care services manage complex cancer pain in the community with a focus on comprehensive assessment, treating the different mechanisms of pain, managing side effects, and managin g complications in the community. We hope this article will be helpful in informing your practice. Learning objectives The learning objectives for this article are aligned with the Palliative Care Competence Framework (2014). On completion of this article, pharmacists should be able to: • Explain the role of specialist palliative care services in supporting pharmacists provide a palliative approach to care for people with life-limiting illness. • Apply principles of safe and effective analgesic use in the management of cancer pain in the community.
• Recognise changing pharmacological and pharmaceutical care needs across the illness trajectory. • Identify medication-related risks, provide education on medicine use to patients and families, and collaborate with the multidisciplinary team to optimise care. How Specialist Palliative Care Operate Specialist Palliative Care (SPC) is a healthcare service that is available to people with complex needs related to a life-limiting illness. Through different illnesses and disease trajectories (Figure 1), we deliver expert symptom management and end-of-life care. SPC may be involved at any stage where there is complexity, and less involved when conditions are stable. SPC works closely with general practitioners, hospital doctors, and community services to deliver safe, timely, and effective care to patients in the community. Our guiding principle is highlighted in the National Adult Palliative Care policy, and that is to deliver the “Right Care” at the “Right Place and Right Time”, by the “Right People”, and overseen by “Good Governance” (Department of Health, 2024). Every person with a life-limiting or life-threatening condition should receive care that respects their dignity and
Panadol Extra Film-Coated Tablets Paracetamol 500mg Caffeine 65mg. Legal Classification: 24s: Pharmacy Only. MAH: Haleon Ireland Limited, Clocherane, Youghal Road, Dungarvan, Co. Waterford, X35 Y983, Ireland. Further information is available upon request to the MAH or in the Summary of Product Characteristics. PM-IE-PAN-26-00014
professionals are of the utmost importance avoidneeds. patients being supplied with the same medicat meets their physical, psychosocial, and spiritual palliativetocare multiple times.
42
CPD: Cancer Pain Choosing the appropriate treatment
Figure 1 Source: Barker PC and Scherer JS. Illness Trajectories: Description and Clinical Use (Fast Fact #326). Palliative Care Network of Wisconsin, 2024. Licensed under CC BY-NC 4.0.
The WHO analgesic ladder remains a useful framework, but it is not a strict protocol, as a patient with moderate or severe cancer pain should not be required to fail every weaker treatment before receiving an appropriate strong opioid (WHO, 2018). ASCO recommends offering opioids for moderate-to-severe pain related to cancer or its treatment unless contraindicated, with individual titration and early reassessment (Paice et. al, 2023). Treatment should reflect the types of pain as discussed above, as patients may need a different combination of analgesics, adjuvants, and non-pharmacological treatments. Patients with a history of substance use disorder require coordinated care, rather than the abandonment of analgesia.
Figure 2: Overview of the Specialist Palliative Care Pathway.
Source: Health Service Executive (2019), National Clinical Programme for Palliative Care Model o
Source: Barker PC and Scherer JS. Illness Trajectories: Description and Clinical Use (Fast Fact #326). P Paracetamol and NSAIDs
autonomy and meets their physical, psychosocial, and spiritual palliative care needs.
types of pain to analgaesia in cancer-related mixed4.0. Network ofguide Wisconsin, 2024. Licensed under pain, CC BY-NC choice. Pain may be classified pain occurs when two or more as nociceptive, neuropathic, pain mechanisms coexist, most or nociplastic (Bennett et al., commonly a combination of 2019). Nociceptive pain results nociceptive and neuropathic pain. from tissue injury and may be Therefore, frequent reassessment somatic or visceral in origin. is needed to decide on Neuropathic pain arises from appropriateness of therapy, dose damage or disease affecting the titration, medication rotation, and somatosensory nervous system. more (NICE, 2012; Department of Nociplastic pain reflects altered Health, 2015; Fallon et al., 2018; nociceptive processing in the Bennett et al., 2019; Paice et al., absence of clear tissue injury or 2023; Healthcare Improvement nerve damage. Frequently seen Scotland, n.d.).
Assessment of Pain
Assessment of Pain
For the assessment of pain, the most well-known structure is the mnemonic SOCRATES. Asking about Site, Onset, Character, Radiation, Associated symptoms, Timing of pain, Exacerbating/ relieving factors, and Severity of pain provides an excellent starting point to our pain assessment. This is followed by a clinical examination to complete the assessment. Other important questions include mood, impact on daily life, prior analgesic response, and patient beliefs and fears about opioids. A numerical pain score helps track change and response to treatment in most patients. For patients who are unable to verbalise their pain experience, an observational tool like the Abbey Pain Scale for dementia tracks vocalisation, facial expression, body language, behavioural change, physiological change and physical change to monitor pain.
Paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) may help selected patients, but continued use requires demonstrable benefit. A Cochrane review found no good quality evidence that adding paracetamol to an opioid improves cancer pain (Wiffen et. al, 2017). NSAIDs are best reserved for a defined indication, such as bone or inflammatory pain, and given as a short defined course with a planned review. Before supplying,
For the comprehensive assessment of pain, the most well-known structure is the mnemonic SOCRA Ca about Site, Onset, Character, Radiation, Associated symptoms, Timing of pain, Exacerbating/relievin Severity of pain provides an excellent starting point to our pain assessment. A numerical pain score change in most patients, and patients with less abilities to communicate may require a faces pain ra (Figure 3).
Each pain should be evaluated separately. The aim is to distinguish between different
Figure 2: Visual Analogue Scale (VAS) used to assess children's pain perception Source: Ghaderi, Banakar and Rostami (2013), Dental Research Journal, 10(6), pp. 790-794, licensed under CC BY 4.0.
Figure 3: Visual Analogue Scale (VAS) used to assess children's pain perception.
paracetamol
Panadol 500 mg Film Coated Tablets. Legal Classification: 24s: Pharmacy Only. MAH: Haleon Ireland Limited, Clocherane, Youghal Road, Dungarvan, Co. Waterford, X35 Y983, Ireland. Further information is available upon request to the MAH or in the Summary of Product Characteristics. PM-IE-PAN-26-00014
43 Figure 3: Summary of Nociceptive and Neuropathic pain
consider renal, gastrointestinal and cardiovascular risk, along with hydration, anticoagulation and any other nephrotoxic medicines. (Fallon et al., 2018) NSAIDs increase the risk of bleeding, especially when there is concomitant corticosteroids or anticoagulants. It would be prudent to check for interactions before dispensing. Weak Opioids The role of weak opioids such as codeine and tramadol in cancer pain is increasingly questioned. Evidence suggests that low-dose strong opioids may provide superior analgaesia over weak opioids, with acceptable tolerability. Codeine’s effect varies with CYP2D6 activity, whilst tramadol is associated with many adverse effects including serotonergic and seizure risks. Therefore, the ESMO Clinical Practice Guideline supports the consideration of strong opioids rather than mandating progression through a weak-opioid step (Fallon et al., 2018). Where a weak opioid is used, it needs the same regular review, laxative, and escalation plan as any opioid, and a check for over-the counter codeine products to avoid duplication and overdose. Adjuvants Neuropathic Agents Neuropathic pain often responds only partly to opioids, and an adjuvant such as gabapentin, pregabalin, duloxetine or a tricyclic antidepressant may be added. Duloxetine showed modest benefits in the management of established chemotherapyinduced peripheral neuropathy (Loprinzi et al.,2020). There is limited evidence supporting the use of pregabalin in neuropathic cancer pain (Derry et al., 2019) Choice of neuropathic agent depends on comorbidity, interactions and tolerability. Gabapentinoids cause dizziness, sedation and require renal
Nociceptive pain
Neuropathic pain
•InfiItration or pressure unto organs, skin, or bone, and/or medical procedures/surgery •Aching/squeezing/throbbing/pressure •Peripheral or central nerve damage as a result of tumour and/or cancer treatment •Sharp/stabbing/shooting/burning
Figure 3: Summary of Nociceptive andoral Neuropathic pain dose adjustment. Although indicate candidiasis. Every
in different formulations to suit course needs a planned review gabapentinoids are not classified clinical need. Extended-release or reduction. If treatment is likely as a controlled drug in the Misuse medicines provide background to continue for months, consider of Drugs Regulation 2017.1, treatment and should not be used bone protection, balanced against pregabalin particularly is subject to as an improvised rescue dose as Every consultation should also tablet establish urgency as it guides the urgency treatment. burden. abuse (Guiney, 2025). Amitriptyline it is more likely of to result in opioidThe pain has anti-cholinergic side effects toxicity. Breakthrough cancer rapidly worsening or associatedOthers with–weakness, altered sensation, falls or bladder or bowel cha Antiresorptives, and is dangerous in overdose, pain is a transient flare despite Antispasmodics, Muscle pharmacological management is not sufficient, and further evaluation in the hospital may be ne while duloxetine adds serotonergic otherwise adequately controlled Relaxants, Laxatives risk alongside tramadol. In a frail, background pain, and it requires interpret a reassuring pain score, after the use of rescue analgaesia, as a way to exclude a serio multimorbid population, specialist a rescue dose of immediateThere are other causes of pain palliative care teams often start at their release patient is absent, establish location and whether canopioid. describe alertness and brea which may respond better to the carer very low doses and titrate slowly. targeted treatment, such as NICE recommends initiating oral may itself justify direct clinical assessment. After starting, ask about dizziness, antiresorptive agents for malignant morphine for cancer pain using falls and drowsiness. Each bone pain, antispasmodics for either regular modified-release adjuvant should have a review plan colicky abdominal pain, and morphine or immediate-release rather than continuing indefinitely muscle relaxants such as Baclofen morphine according to patient without evidence of benefit. in managing voluntary muscle As goals of care change and patients enter their terminal phase, meaningful goals for pain contr preference, with immediateGabapentinoids should be tapered spasticity in multiple sclerosis release morphine available for rather than stopped abruptly. sleeping, reaching the bathroom sitting comfortably andor stroke for example. Opioid-with family. It is carefully balanced with breakthrough pain. During dose induced constipation can also Corticosteroids effects like sedation which could restrict a patient’s titration, immediate-release undesirable ability to achieve personal goal lead to pain, and as such, ensure morphine is commonly used to on opioids have a supply Corticosteroids,vomiting, usually swallowing, mobility patients and who administers medicines. Ask about the actual establish the effective opioid regimen th of laxatives. dexamethasone, are dose while monitoring efficacy at home against the prescription, including over-the-counter products, old supplies and recent recommended as adjuvants (WHO, and tolerability. Once pain Use of strong Opioids 2018) and can be particularly Establish what benefit follows each dose and what adverse effects patient control the is achieved andfinds opioidunacceptab helpful for pain from nerve Oral morphine is the usual firstrequirements are stable, patients compression, liver capsule stretch line strong opioid when clinically may be converted to an equivalent or raised intracranial pressure suitable. Seek specialist advice modified-release preparation. The (Wilcock et. al, 2025). Counsel in moderate-to-severe renal or Department of Health recommends patients to take doses in the hepatic impairment (Department that the breakthrough dose of morning to reduce insomnia, check of Health, 2015). We would immediate-release opioid should that blood glucose monitoring commonly use oxycodone, generally be calculated as oneis in place, and advise them to hydromorphone, fentanyl, sixth of the total 24-hour opioid buprenorphine, and alfentanil report a sore mouth, which may dose (NICE, 2012; Department of
Choosing the appropriate treatment
The WHO analgesic ladder remains a useful framework, but Health, it is not a strict protocol, as a pat 2015). Pharmacists should that prescribed background or severe cancer pain should not be required to fail everyverify weaker treatment before receiv and breakthrough opioid doses Case are clinically appropriate and strong opioid (WHO, 2018). ASCO recommends offering opioids for moderate-to-severe pain r Michael is a 79-year-old gentleman living with metastatic colorectal consistent with national guidance, itscancer treatment contraindicated, with individual titration and timely earlyreview reassessment (P and facilitate where with liver unless metastases. He is experiencing generalised pain remains uncontrolled or abdominal pain from his cancer. Histypes renal and function are Treatment should reflect the ofliver pain as discussed above, as patients may need a differ adverse effects occur. normal. He is taking regular laxatives and is moving his bowels analgesics, adjuvants, and non-pharmacological treatments.Patient Patients with a history of subs regularly. Initial trial of Oramorph 2.5mg was successful in reducing and family education his pain. Over the course of 24 hours, Michael took a total of 15mg is a key component of opioid require coordinated care, rather than the abandonment of analgesia. of Oramorph with good pain control. He did not experience any
stewardship. Pharmacists should provide counselling on the rationale for opioid therapy, expected benefits, Paracetamol and NSAIDs and common adverse effects, For the following week, Michael required between 5-7.5mg of including constipation, nausea, Oramorph to maintain good pain control per day. He did not and drowsiness. Misconceptions Paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) may help selected patients, experience any side effects through close follow-up. The decision regarding addiction, tolerance, was made to increase his MST to 10mg twice daily. This was met requires demonstrable benefit. A Cochrane review found no and good quality evidence that adding physical dependence should with good effect, without side-effects. Michael’s oramorph use bebest addressed, distinguishing opioid improves cancer pain (Wiffen et. al, 2017). NSAIDs are reserved for a defined indic decreased to none or once a day. these from appropriate opioid useafor cancer pain. Patients and supply or inflammatory pain, and given as a short defined course with planned review. Before opioid side effects. His analgaesia was converted to MST 5mg twice daily, rounding down to reduce the risk of toxicity, with Oramorph 2.5-5mg as needed every 4 hours.
gastrointestinal and cardiovascular risk, along with hydration, anticoagulation and any
paracetamol
Panadol Actifast Tablets 500mg. Legal Classification: GSL MAH: Haleon Ireland Limited, Clocherane, Youghal Road, Dungarvan, Co. Waterford, X35 Y983, Ireland. Further information is available upon request to the MAH or in the Summary of Product Characteristics. PM-IE-PAN-26-00014
44
CPD: Cancer Pain
caregivers should be advised on adherence to prescribed regimens, the appropriate use of breakthrough analgesia, recognition of adverse effects, and the importance of not abruptly discontinuing therapy. Education should also include safe storage, avoidance of sharing opioid medicines, and appropriate disposal of unused supplies to minimise the risks of accidental ingestion, diversion, and misuse (Department of Health, 2015; World Health Organization, 2018; Guiney, 2025). Opioid Side-effects Nausea following opioid initiation is often transient; however, persistent vomiting warrants reassessment for alternative causes such as constipation, bowel obstruction, metabolic disturbance, treatmentrelated toxicity, or intracranial disease. Antiemetic choice should be guided by the underlying cause, such as metoclopramide for delayed gastric emptying, haloperidol for drug or toxininduced nausea, and cyclizine for vestibular disturbances or raised intracranial pressure. Pharmacists should assess for potential drug interactions and additive sedative effects. If oral medicines or fluids cannot be tolerated, specialist review is required to consider an alternative route of administration (Healthcare Improvement Scotland, n.d.). Opioid-induced constipation usually persists. NICE recommends regular laxatives when strong opioids are started; the Irish constipation guideline supports assessment and individual management (NICE, 2012; Department of Health, 2015). A combination of stimulant and osmotic laxatives may be needed according to the bowel assessment and the treating team’s plan (Department of Health, 2015). Colicky abdominal pain, distension, vomiting or failure to pass flatus warrants urgent assessment for obstruction. Do not respond by automatically increasing laxatives. Overflow diarrhoea can coexist with faecal loading and needs clinical assessment rather than reflex treatment with an antidiarrhoeal. The signs of opioid neurotoxicity include visual hallucinations, myoclonic jerks, increased drowsiness, and paradoxically worsening pain (Healthcare
Improvement Scotland, n.d.). Review co-prescribed benzodiazepines, gabapentinoids, sedating antihistamines and alcohol exposure, alongside interacting medicines. Their presence may be clinically justified but demands an explicit benefit–risk assessment and monitoring. Advice against driving or hazardous activity when drowsy, dizzy or cognitively impaired. New impairment should prompt review, including a check for dosing errors and recent additions. Opioid rotation Differences in opioid pharmacokinetics, metabolism, and receptor-binding profiles provide alternative therapeutic options when treatment complexity arises. Opioid rotation may be considered in patients who develop intolerable adverse effects (e.g. pruritus, neurotoxicity), renal or hepatic impairment, or inadequate analgesia despite dose optimisation (Paice et al., 2025). Opioid rotation involves switching from one opioid to another using conversion ratios to maintain analgesia while minimising toxicity. Due to incomplete cross-tolerance between opioids, the calculated equianalgesic dose is typically reduced by 25-50% before titration according to clinical response and tolerability. Careful monitoring is required following opioid rotation, as analgesic efficacy and adverse effect profiles may differ between opioids. Challenges in the Community Patients receiving palliative care at home may require medicines that are not routinely stocked in all community pharmacies. For example, subcutaneous fentanyl or alfentanil may be required for patients with severe renal impairment, while transmucosal fentanyl formulations may be prescribed for selected opioidtolerant patients with breakthrough pain. Early communication between specialist palliative care services, prescribers, and community pharmacists can facilitate timely access to these medicines and reduce delays in symptom control. Community pharmacists also have an important role in supporting anticipatory prescribing and solution for injection for use in continuous subcutaneous infusions, ensuring the availability of medicines required for symptom
paracetamol, diphenhydramine hydrochloride
management at the end of life, and facilitating access to controlled drugs in accordance with Irish regulatory requirements. Coordination between specialist palliative care services, general practitioners, out-of-hours services, and community pharmacies is essential to support patients who wish to remain at home. Opioid-related medication errors remain a significant safety concern in the community. Particular attention should be paid to oral morphine formulations, as concentration differences may increase the risk of dosing errors. For example, Oramorph 10 mg/5 mL contains 2 mg/ mL. Prescriptions should clearly specify both the dose in milligrams and the corresponding volume in millilitres. Pharmacists should provide counselling on dose measurement using oral syringes, confirm understanding using teach-back techniques, and reinforce education regarding safe storage and disposal of controlled medicines to minimise the risks of accidental ingestion, diversion, and misuse. Conclusion Opioids do not address all types of pain. Careful selection of drugs tailored to individual patients is required, with close follow up to titrate to effect, anticipate and treat side-effects, and refer to hospital when indicated. Awareness of common SPC practices will hopefully shed light to some unfamiliar practices you might have come across in community practice. We greatly appreciate the help from all community pharmacists in delivering high standard care in dispensing medications to all our patients. Questions 1. A patient has persistent pain for most of the day despite regular opioid treatment. Which interpretation is most appropriate? a. This necessarily represents opioid use disorder b. It is always breakthrough pain c. Background control and the pain mechanism need reassessment d. A fentanyl rescue product can be added without assessment 2. A recent discharge prescription unexpectedly has a patient commenced on a fentanyl
patch with no previous opioid exposure. What should the pharmacist do? a. Assume the lowest patch strength is safe b. Clarify the indication, prior exposure and specialist monitoring with the prescriber c. Replace it with buprenorphine independently d. Dispense and advise the patient to halve the patch 3. A patient on morphine develops dehydration, new hallucinations and myoclonus but remains responsive with normal breathing. What is the best action? a. Arrange same-day clinical assessment for possible toxicity and other causes b. Reassure that this is normal tolerance c. Increase rescue morphine d. Administer naloxone solely for hallucinations 4. A patient with cancer has progressive new back pain but no weakness or bladder symptoms. What is most appropriate? a. Routine review next month b. Same-day clinical contact to arrange urgent spinal assessment advice c. Rule out spinal disease because there is no weakness d. Recommend heat and wait for rescue analgesia to work 5. A new oral morphine liquid has a different concentration from the previous supply. What is essential? a. Continue the same volume without checking b. Reconcile dose in milligrams, concentration and volume, then use teach-back c. Measure doses with a kitchen spoon d. Use the liquid only as background treatment regardless of prescription Answers: C–B–A–B–B References available on request
Panadol Night Coated Tablets Paracetamol 500mg Diphenhydramine Hydrochloride 25mg. Legal Classification: Pharmacy Only MAH: Haleon Ireland Limited, Clocherane, Youghal Road, Dungarvan, Co. Waterford, X35 Y983, Ireland. Further information is available upon request to the MAH or in the Summary of Product Characteristics. PM-IE-PAN-26-00014
Scan to learn more
46
Movember
Beyond the Moustache: Why Ireland Must Rethink Men's Health As Movember returns for another November of fundraising and awareness, the organisation is calling for something far more enduring: a fundamental shift in how Ireland approaches men's health. Walter Jayawardene, Director of Policy & Advocacy (Ireland) at Movember, speaks to Irish Pharmacy News about persistent health inequalities, the importance of community-based prevention and why pharmacists could be among the most valuable allies in reaching men who are reluctant to seek help. The two approaches, he believes, are complementary. Awareness opens conversations, while policy and advocacy create opportunities for lasting change. Understanding the real face of men's health In September 2025, Movember published The Real Face of Men's Health in Ireland, a comprehensive examination of the country's men's health landscape.
Walter Jayawardene, Director, Policy & Advocacy (Ireland) Every November, moustaches appear across Ireland as thousands of people participate in one of the world's most recognisable men's health campaigns. What began as a light-hearted fundraising initiative in Australia has developed into an international movement addressing some of the most serious challenges facing men's health, from prostate and testicular cancer to mental health and suicide prevention. But behind Movember's distinctive branding lies an increasingly ambitious policy agenda, one that aims to transform awareness into meaningful, lasting improvements in health outcomes. For Walter Jayawardene, Director of Policy & Advocacy (Ireland), the challenge is ensuring that men's health remains a priority long after November ends. Movember has always understood the importance of meeting men where they are. Walter believes its approachable, sometimes humorous campaigns provide a starting point for conversations that might otherwise never happen. He explains that the organisation has a long track record of engaging men on their own terms, combining the lighter side of Movember with the more serious business of influencing policymakers and securing investment.
IRISHPHARMACYNEWS.IE
Developed in collaboration with the Men's Health Forum and researchers at South East Technological University, the report examined physical and mental health, healthcare infrastructure, attitudes, behaviours and demographic trends. Its findings now underpin Movember's policy and advocacy activities, and have been updated with fresher public data in this year's followup 'Where Ireland Stands' report. While improvements in population health are encouraging, the underlying inequalities affecting men remain stubbornly persistent. Premature mortality has declined overall, but the benefits have not been experienced equally by men and women. Understanding why requires looking beyond individual lifestyle choices to the social expectations and healthcare structures that shape men's behaviour. Why men are still reluctant to seek help One of the most persistent challenges is men's tendency to delay seeking medical advice. "Men tend to be slower to seek help. And when they do, they tend to do it later in the process," Walter explains. He describes a combination of factors, including traditional expectations of masculinity, discomfort discussing personal concerns and healthcare services that are not always designed around men's needs. “There are several interconnected factors contributing to the stigma
surrounding health, including deeply ingrained cultural attitudes that emphasise stoicism and emotional restraint.”
Walter believes this makes improving men's health a broader social priority, rather than an issue affecting men in isolation.
These expectations can encourage men to minimise symptoms or delay seeking professional support.
He describes the objective as building "stronger families, stronger communities" and helping men contribute positively to the lives of those around them.
Walter also points to the influence of gender norms, which continue to shape attitudes towards health and emotional vulnerability. However, he emphasises that responsibility cannot rest entirely with individual men. Healthcare systems must also consider how effectively they engage different populations. The original Movember research identified concerns among some GPs about their preparedness to address men's health issues, particularly mental health. For Walter, this reinforces the need for gender-responsive healthcare: services that recognise how social expectations, communication styles and personal circumstances influence whether someone feels comfortable seeking help. The objective is not to create an entirely separate healthcare system for men, but to ensure that existing services are accessible, responsive and effective. The economic and social cost of poor health Movember estimates that men's ill health costs the Irish Exchequer approximately ¤1 billion annually, with around 70% of that cost potentially avoidable through earlier, community-based preventative interventions. These estimates illustrate the potential economic benefits of shifting healthcare investment towards prevention. When men experience serious or prolonged ill health, the consequences frequently extend to partners, children and wider families. Women often assume additional caring responsibilities, while households may experience financial pressures, emotional strain and disruption to everyday life.
This perspective is central to Movember's argument that investment in men's health should not be regarded as competing with other healthcare priorities. Rural isolation and the farming community Among the populations facing particular challenges are men working in agriculture. Farming is recognised as a priority group within Ireland's National Men's Health Action Plan, reflecting concerns about occupational pressures, social isolation and mental wellbeing. Walter points to HSE research indicating that almost 24% of farmers surveyed were at risk of suicide, while more than half reported symptoms of moderate to severe depression. These figures relate to the surveyed population and highlight the importance of targeted interventions. Walter describes farming as an occupation in which individuals can find themselves working "in isolation, literally in isolation, out in the field all day on your own". Financial pressures, unpredictable working conditions and the demands of running a farm can compound these difficulties. Movember has supported research with the University of Adelaide examining mental health interventions for farming communities across several countries, including Ireland. A central finding was that effective interventions already exist, but their availability remains limited. “Peer-led community settings are particularly effective. While this approach is highly relevant to farmers, its underlying principles have much broader applicability
47 Irish Grammy-winning musician and Movember ambassador Cian Ducrot; Sarah Ouellette, Movember Country Manager; Minister for Health Jennifer Carroll MacNeill; and sporting legend, and Movember Ambassador, Barry McGuigan. Pic: Julien Behal
The concept would involve collaboration between government, Movember and potentially other philanthropic organisations.
across communities throughout Ireland,” Walter explains.
these conversations represent important progress.
Trusted individuals within farming communities can provide important opportunities for conversations about mental health, particularly where formal healthcare settings may feel unfamiliar or intimidating.
Reflecting on public discussions about mental health, he says, "These difficult conversations have to happen. And sometimes opinions are aired that you disagree with. It’s about engaging with them in good faith and in a loving and empathetic way."
However, Walter stresses that encouraging someone to ask for help is only the beginning. Appropriate services must also be available when that person is ready to access support. Changing the conversation around mental health Despite the challenges, Walter sees encouraging signs that attitudes towards men's mental health are changing. Public discussion of emotional wellbeing has become more visible, supported by individuals who are willing to speak openly about their own experiences. He points to sporting ambassadors who have spoken candidly about their mental health, including rugby player Andrew Porter. Younger generations, in particular, may be increasingly comfortable recognising mental health concerns and seeking support. At the National Ploughing Championships, Movember has experimented with informal approaches to engagement, including conversations facilitated in familiar social settings such as a barber's chair. The intention is to create an environment in which discussions about health feel natural rather than intimidating. Movember also works with the GAA and Gaelic Players Association through its Movember Ahead of the Game programme, engaging young people in settings where they already feel comfortable. Walter acknowledges that longstanding attitudes towards masculinity will not disappear overnight, but believes
For Walter, challenging stigma is not simply about confronting negative attitudes. It is also about creating an environment in which people feel understood and supported. Moving from awareness to prevention For Movember, improving men's health requires sustained investment rather than a succession of short-term campaigns. The organisation is advocating for greater investment in relatively inexpensive community-level initiatives that encourage earlier engagement with healthcare. Men's Sheds is one example of an approach that can provide social connection, companionship and opportunities for conversations about wellbeing. Walter believes there is considerable value in supporting initiatives that have already demonstrated their effectiveness. Such programmes may appear modest compared with major healthcare investments, but their preventative value can be considerable. A Community Men's Health Fund One proposal being explored by Movember is the establishment of a dedicated Community Men's Health Fund. Walter explains the ambition saying, "We aim to collaborate with government and philanthropic partners to establish a sustained, multi-year grant programme supporting community health interventions, with built-in evaluation to identify what works.”
Rather than prescribing one universal solution, the fund could support different approaches tailored to the needs of particular groups. These might include mental health awareness initiatives, programmes encouraging men to visit their GP or activities designed to reduce isolation. Walter points to a similar initiative already operating in England, where Movember has partnered with government and philanthropic organisations to support community men's health projects.
who may be less accessible to other healthcare professionals.” Walter believes the value lies not in expecting pharmacists to diagnose or manage every concern, but in recognising opportunities to encourage appropriate help-seeking. This includes encouraging conversations about cardiovascular risk, smoking cessation, screening awareness and modifiable lifestyle factors. Their established role in medicines management and regular patient contact places pharmacists in a strong position to reinforce preventative health messages. Importantly, Walter sees community pharmacy as complementary to general practice and other healthcare services. By working collaboratively and using the trust they have developed within their communities, pharmacists can help men take the first step towards accessing appropriate care. Making men's health a national priority
The response has been encouraging, with significant interest from organisations seeking funding.
Looking ahead, Movember wants to see a more comprehensive, cross-government approach to men's health in Ireland.
He believes a similar approach could help recognise and strengthen the contribution already being made by community organisations throughout Ireland.
The country has an important history in this area, having become the first in the world to introduce a national men's health policy.
Community pharmacy: a trusted point of contact For Ireland's community pharmacists, the discussion has particular relevance. Pharmacies are among the most accessible healthcare settings in the country, with many patients maintaining longstanding relationships with their local pharmacist. That familiarity can be especially valuable when engaging men who may be reluctant to make an appointment with their GP.
However, Walter believes there is an opportunity to build on that foundation through stronger coordination across government departments and community organisations. He points to the progress achieved through Ireland's approach to women's health as an example of what comprehensive, coordinated policy can deliver. Men's health is influenced by far more than healthcare provision alone.
Walter believes pharmacists should not underestimate their potential influence.
Employment, education, housing, social connection and economic circumstances all contribute to health outcomes, making collaboration essential.
“The focus is not necessarily on the nature of the conversation, but on recognising the pharmacist’s role in initiating it, drawing on their understanding of the local community.”
Movember hopes to play a coordinating role, bringing together policymakers, researchers, healthcare professionals and community organisations while contributing funding and expertise.
He believes that continuity of care and familiarity with patients can create opportunities to recognise concerns that might otherwise go unnoticed.
And if Movember's ambitions are realised, the lasting legacy of the campaign will be measured not simply in funds raised or conversations started, but in healthier men, stronger families and communities better equipped to support them.
“Pharmacists are often uniquely positioned to initiate discreet, supportive conversations with individuals
Find out more at movember.com
IRISHPHARMACYNEWS.IE
48
Prostate Cancer
Beyond Survival: The Hidden Impact of Prostate Cancer As new Irish research reveals significant gaps in the support available to prostate cancer patients and their partners, Martin Sweeney, PRO-ACT Co-Chief Investigator and prostate cancer survivor, speaks to Irish Pharmacy News about his own experience, the lasting consequences of treatment and why healthcare professionals must look beyond survival to quality of life. Martin Sweeney, Co-chief Investigator of the PRO-ACT Survey
in 2015, when I was 49. There was a family history: my father had prostate cancer, and my grandfather died from it. Despite that, I had no symptoms and wasn't expecting a diagnosis at that age. After being referred by my GP to a urologist, I was told I had prostate cancer. It was extremely difficult to process, and looking back, I probably rushed into treatment. I underwent radical surgery, which treated the cancer, but I was left with significant quality-of-life issues. For many men, a prostate cancer diagnosis brings an overwhelming focus on one thing: survival. Yet, as treatment outcomes improve and more men live longer following diagnosis, attention is increasingly turning to what happens afterwards. An Irish Cancer Society-funded study, PRO-ACT (Patient-led Research On sexual experience After Cancer Treatment), has highlighted substantial gaps in how patients and their partners are prepared for the physical, emotional and sexual consequences of prostate cancer treatment. The findings are striking. Some 66% of patients surveyed reported being underprepared or completely unprepared for the impact of treatment on their sexual function, while 60% said the effects were worse or much worse than anticipated. Furthermore, 80% believed a longer or clearer discussion with their medical team would have helped them prepare.
I eventually sought support through ARC Cancer Support Services in Dublin and began volunteering there. In 2016, I established a prostate cancerspecific peer-support group. What became apparent was that many men were struggling with issues that weren't necessarily about the immediate threat to their lives. They were dealing with the longer-term consequences of treatment, often without adequate support. Over approximately a decade, I collected around 2,200 anonymous patient accounts and pieces of information. Recurring themes emerged around sexual health, relationships, urinary problems and mental wellbeing. Through my work as a patient consultant with Cancer Trials Ireland, I was paired with Professor Paul Kelly, and together we developed PRO-ACT.
For Martin Sweeney, who co-led the research alongside Professor Paul Kelly, radiation oncologist at Cork University Hospital, these findings are deeply personal.
Understanding the Patient Experience
A Diagnosis that Changed Everything
Martin: We established a steering committee involving urologists, radiation oncologists, advanced nurse practitioners, patients and a partner representative.
Irish Pharmacy News: Your own experience of prostate cancer was instrumental in developing PRO-ACT. Can you tell us about that journey? Martin Sweeney: I was diagnosed with localised prostate cancer
IRISHPHARMACYNEWS.IE
IPN: What did the PRO-ACT research involve, and what were its most significant findings?
Jacqueline Daly, who runs the East Galway and Midlands Cancer Support Centre, developed the partner questionnaire.
We created two parallel surveys, containing more than 170 questions between them, examining intimacy, sexual function, mental health, urinary and bowel issues, and overall quality of life. We received approximately 1,150 responses, more than double our original target. The results highlighted a significant deficit in information and support at critical stages of diagnosis and after treatment. Patients frequently felt unprepared for changes to their sexual function, while partners were often excluded from important conversations. The partner findings were particularly concerning. Only 65% reported being present when their partner's sexual function was discussed, while 78% said their own sexual wellbeing had not been discussed with them at all.
The decisions made at diagnosis can affect a person for many years. The Impact Beyond Treatment IPN: What concerns you most about the long-term consequences of prostate cancer treatment? Martin: The mental health consequences can be among the most difficult. Patients often go through diagnosis and treatment focused entirely on the immediate clinical process. Then, a year or two later, they're expected to return to normal life. But their reality may be very different from what they anticipated. Urinary difficulties can affect confidence and everyday activities. Sexual function may change significantly and, following radical treatment, may not return to what it was before.
These are not minor concerns. They affect people's relationships, confidence, identity and ability to live well following cancer.
And this isn't simply about erectile function. Sexual wellbeing involves identity, intimacy, confidence and relationships.
IPN: You have spoken about feeling that you rushed into surgery. Why do you think this happens?
There is also the impact on partners, who may be experiencing profound changes to their intimate lives without having been properly included in treatment discussions.
Martin: A cancer diagnosis is frightening. Surgery can seem like the most direct solution: remove the cancer and get on with your life. Often, the urologist is the specialist who makes the diagnosis, and patients may not have an opportunity to explore other potentially appropriate treatments with a different specialist. There can also be limited understanding of active surveillance, which may be suitable for selected men with lower-risk, localised prostate cancer. It's important to distinguish localised disease from metastatic prostate cancer, because the circumstances and treatment decisions are very different. What matters is that patients understand their options and the potential consequences before making a decision. Keeping someone alive is obviously essential, but we must also consider what their life will look like afterwards.
We need to recognise that prostate cancer affects couples and families, not just the individual receiving treatment. IPN: Why are conversations about sexual health still so difficult? Martin: There is a longstanding reluctance to talk openly about sex, particularly as people get older. We make assumptions about whether people in their 50s, 60s or 70s are sexually active and what their relationships should look like. Those assumptions don't reflect real life. Patients may have spent their entire lives regarding these subjects as private. We cannot expect them suddenly to raise intimate concerns during a medical consultation. Healthcare professionals need to open that conversation respectfully and make it easier for patients and partners to discuss their experiences.
49 where appropriate and making specialist support more accessible. These issues are not unique to Ireland. Through my involvement with the International Society for Sexual Medicine, I've seen that reluctance to discuss sexual health and the lack of support after cancer treatment are international challenges. The implications also extend beyond prostate cancer. Changes to body image, appearance, confidence and intimate relationships can affect people living with many different cancers. If PRO-ACT helps open these conversations and improve how we support patients and their partners, it could have benefits across cancer care. (Left to right): Claire Hopkins (head of marketing at Cancer Trials Ireland), Martin Sweeney (co-chief investigator of PRO-ACT and prostate cancer patient), Dr Claire Kilty (head of research at the Irish Cancer Society) and Niki Warner (programme manager of Research Partnerships at the Irish Cancer Society at the launch of the study of people affected by prostate cancer A Gap in the Patient Pathway IPN: What support is currently available to patients after treatment? Martin: There is some excellent work being done by individual healthcare professionals, including clinicians and advanced nurse practitioners who go beyond their formal responsibilities to support patients. PRO-ACT is not intended as a criticism of those professionals. The problem is that specialist quality-of-life support is not consistently embedded within the treatment pathway. Patients may need psychological support, sexual therapy or physical rehabilitation, but these services are not always readily available. The HSE and Irish Cancer Society provide useful information, but information alone isn't enough. We need properly resourced, structured services that patients and their partners can access before and after treatment, rather than depending on individual clinicians recognising a need and finding ways to help. The research demonstrates the importance of wraparound care that addresses the whole person. Prostate Cancer Awareness and Early Conversations IPN: What should men understand about prostate cancer risk and PSA testing? Martin: Family history is an important consideration, and ethnicity can also influence risk.
There are misconceptions about screening. Some men assume it necessarily involves a physical examination, whereas a PSA test is a blood test.
Pharmacists can also be alert to medicines that may contribute to sexual difficulties and encourage patients to discuss concerns with their prescriber where appropriate.
A raised PSA level does not automatically mean someone has prostate cancer. Other conditions can also affect the result.
Signposting is particularly important. Pharmacies could keep information about local cancer support centres available, including services for partners.
I would encourage men, particularly as they reach their mid-40s and beyond, to speak with their GP about their individual risk and whether PSA testing is appropriate. It's about having an informed conversation rather than assuming that testing is either necessary or unnecessary for everyone. Community pharmacists could play a valuable role in encouraging those discussions. The Role of Community Pharmacy IPN: How can community pharmacists support men affected by prostate cancer and their partners? Martin: One of the greatest strengths of community pharmacy is the relationship pharmacists build with patients over many years. People often see the same pharmacist regularly. That continuity and familiarity can create opportunities for conversations that might not happen elsewhere. A pharmacist doesn't need to solve every problem. Sometimes a quiet word, asking how someone is managing or pointing them towards an appropriate support service can make a considerable difference.
The National Cancer Control Programme has a directory of recognised cancer support centres, and building relationships with local services could help pharmacists guide patients towards appropriate assistance. Even simple awareness materials explaining PSA testing or encouraging men to discuss their risk with their GP could be useful. It's about helping people recognise that these conversations are possible and that support exists. Turning Research into Change IPN: What happens next for PRO-ACT, and what changes would you like to see? Martin: PRO-ACT is feeding into the review of clinical guidance on prostate cancer, and I hope the findings will also help inform the next National Cancer Strategy. We have an opportunity to develop a more comprehensive approach to care, one that recognises the importance of quality of life alongside successful cancer treatment. That means improving information at diagnosis, involving partners
Ultimately, we need to move beyond measuring success solely in terms of survival. People deserve the opportunity not only to live longer after cancer, but to live well. PRO-ACT: Key Findings • 66% of prostate cancer patients felt underprepared or completely unprepared for treatment-related changes to sexual function. • 60% said the impact on sexual function was worse or much worse than expected. • 80% believed a longer or clearer discussion with their medical team would have helped. • 78% of partners reported that their own sexual wellbeing had not been discussed with them. • Approximately 1,150 responses were received across the patient and partner surveys. PRO-ACT was funded by the Irish Cancer Society and led by Martin Sweeney and Professor Paul Kelly under the guidance of Cancer Trials Ireland. Support and Information Community pharmacists can direct patients and partners towards recognised cancer support centres, including those listed through the National Cancer Control Programme. ARC Cancer Support Services also provides a prostate cancer peer-support group. Patients should contact ARC directly to confirm current meeting arrangements and how to join.
IRISHPHARMACYNEWS.IE
Regus City Gate Building 1000, Units 1201 & 1202 Mahon, Cork T12 W7CV
087 3895577
087 3895577
Adverse events should be reported. Reporting forms and information can be found on the HPRA website (www.hpra.ie) or by emailing at adverse.event.ireland@sandoz.com. MLR ID:MLR-0247-IE Date of prepation: (09/2026)
52
Male Hair Loss
Male Hair Loss: Why Earlier Assessment Can Lead to Better Long-Term Outcomes Male hair loss is now discussed far more openly. Improved transplant techniques, established medical therapies and social media have transformed the conversation, particularly among younger men. Surgery may appear to offer an obvious solution, but managing hair loss is rarely as simple as choosing between medication and transplantation. They are different, often complementary tools. The starting point should be an accurate diagnosis and a plan that makes sense not just today, but in the decades ahead. Written by Dr Dmitri Wall, Medical Director, Hair Restoration Blackrock (HRBR) www.hrbr.ie
An effective strategy therefore combines science, surgical judgement and an appreciation of how the appearance of hair loss may evolve over time. Start with a diagnosis, not a treatment Pharmacists, often among the first healthcare professionals approached, have an important role in guiding men towards informed choices and timely assessment. How the conversation has changed Greater openness about transplantation is welcome, but online coverage can foster the impression that surgery is the first, or only, effective response. This is especially relevant to younger men, whose hair loss may have many years to progress. The commonest cause is androgenetic alopecia (AGA), driven by genetically determined sensitivity to dihydrotestosterone (DHT). Susceptible follicles progressively miniaturise, typically affecting the temples, crown and top of the scalp. A transplant redistributes hair from relatively resistant donor areas, usually at the back of the head, but does not stop non-transplanted hair from continuing to thin. Even donor hair may not be entirely immune to future change.
IRISHPHARMACYNEWS.IE
Not every man with thinning hair has uncomplicated AGA. The distribution and pace of hair loss, family history, scalp health, symptoms and personal expectations all matter. Other disorders may mimic or coexist with male pattern hair loss, altering both treatment and transplant suitability. Of particular concern are inflammatory scarring alopecias, which can permanently destroy follicles. They may cause redness, itching, burning or pain, but can also be surprisingly asymptomatic. Surgery undertaken in the presence of active disease risks exacerbating inflammation and compromising both native and transplanted hair. Suspected cases require specialist dermatological assessment and disease control before any surgical decision; medical treatment may not fully halt progression. For pharmacists, unusual patterns of loss, persistent or sudden shedding, scalp symptoms, or doubt about the diagnosis are reasons to recommend medical review rather than simply another hair-growth product.
Where do minoxidil and finasteride fit? For appropriately selected men with AGA, medical treatment remains central. Minoxidil can improve growth and density, while finasteride reduces the conversion of testosterone to DHT, slowing the underlying miniaturisation process in many patients. Used together, they can provide meaningful cosmetic benefit, although the degree and location of improvement cannot be precisely predicted. The aim is not necessarily dramatic regrowth, stabilising hair loss can be especially valuable in a younger man. Both treatments generally require continued use to maintain their benefits. Suitability, adverse effects and expectations deserve proper discussion with an experienced prescriber. Patients should also be advised about relevant individual circumstances, including family planning. Topical minoxidil requires careful handling because accidental exposure can be dangerous to household pets, particularly cats. The fact that a product is applied to the scalp does not mean it is without risks. Where does transplant surgery fit? Medication can improve coverage, but it cannot reliably determine where additional density will appear. By contrast, a skilled transplant team can deliberately position grafts to create a naturallooking result. Follicular unit transplantation (FUT) and follicular unit excision (FUE) are established techniques, both involve surgery and both leave scars. Crucially, transplantation redistributes a finite donor supply, it does not create new hair. An ambitious hairline may look appealing at 25 but become difficult to support if substantial hair loss develops behind it. Donor characteristics, likely progression and long-term scalp health therefore matter as much as the immediate cosmetic goal. Medical
treatment may be appropriate before and after a procedure to protect existing hair. A successful result depends not only on surgical technique, but on patient selection, careful planning and a realistic understanding of future change. Expectations have changed too Before and after photographs, advertising and social media can help demystify treatment, but may also distort expectations. Images may be selectively chosen, captured under different conditions or digitally altered, including with AI and their publication online is not a guarantee of independently assessed quality. Another person's result may not be achievable with a patient's own hair characteristics, donor reserve or pattern of loss. The consequences of poorly planned surgery can be particularly difficult for younger patients. Revision may consume precious donor grafts, sacrifice transplanted follicles or expose permanent scarring. A conservative, sustainable result is often preferable to an impressive shortterm hairline. No transplant is better than a bad transplant. The pharmacist's role A brief, practical conversation can make a real difference, when did the loss begin, has it been gradual or sudden, what treatments have been tried, and are there scalp symptoms? Pharmacists can explain that established therapies take time, ongoing treatment may be necessary, and unexpected patterns or symptoms warrant medical assessment. Perhaps the most important message is that seeking help earlier need not mean having surgery earlier. It means establishing the diagnosis, discussing appropriate options and, where possible, preserving existing hair. Hair loss can affect confidence and wellbeing, but no patient should feel pressured into a rapid decision. The best outcome is one that remains appropriate many years from now.
54
Male Diabetes
Diabetes and Sexual Health: The Impact of Diabetes on Male Sexual Function Written by Amy Doyle Education & Support Co-ordinator Diabetes Ireland
The aetiology of sexual dysfunction is frequently multifactorial. Alongside vascular and neurological complications, psychological and relationship factors can influence sexual function. Anxiety, depression, diabetes-related distress, concerns about body image and relationship difficulties may contribute to reduced libido or sexual performance. It is therefore important that assessment does not focus exclusively on erectile function but considers the patient's wider physical, psychological and social circumstances. Risk Factors and Clinical Assessment
Clinical Considerations for Healthcare Professionals Diabetes mellitus is a chronic metabolic condition associated with a range of microvascular, macrovascular and psychosocial complications. Although many people living with diabetes can maintain a normal and fulfilling sex life, diabetes is associated with an increased risk of sexual dysfunction in both men and women. Sexual health is an important component of overall health, wellbeing and quality of life, yet it may be overlooked during routine diabetes consultations. Healthcare professionals therefore have an important role in recognising sexual dysfunction, identifying potentially modifiable risk factors and ensuring that patients have access to appropriate assessment and treatment. Diabetes and Male Sexual Function In men living with diabetes, erectile dysfunction (ED) is one of the most common sexual complications. ED is characterised by difficulty achieving or maintaining an erection sufficient for satisfactory sexual activity. Although occasional erectile difficulties are common, persistent ED warrants clinical assessment, particularly in the context of diabetes. Normal erectile function requires the coordinated interaction of vascular, neurological, hormonal and psychological systems. Sexual stimulation results in neurological signalling and the release of
IRISHPHARMACYNEWS.IE
mediators that promote relaxation of smooth muscle and increased penile blood flow. Diabetes can disrupt this process through several mechanisms. Chronic hyperglycaemia (high blood glucose levels), contributes to endothelial dysfunction, vascular damage and impaired circulation, reducing the blood flow required to achieve and maintain an erection. Diabetes can also result in diabetic neuropathy, affecting the peripheral nerves and neural pathways involved in sexual stimulation and erectile response. Over time, these vascular and neurological effects can significantly compromise erectile function. ED is therefore considerably more prevalent among men with diabetes than among men without diabetes. More than 50% of men with diabetes experience erectile dysfunction, and ED may develop 10–15 years earlier than in men without diabetes. This earlier onset is clinically significant and reinforces the importance of considering sexual health as part of comprehensive diabetes care rather than attributing erectile difficulties solely to ageing. While ED is the most widely recognised sexual complication, diabetes can affect several other aspects of male sexual function. Patients may report reduced libido, delayed ejaculation, difficulty achieving orgasm or reduced sexual satisfaction. In some individuals, lower testosterone levels may also contribute to reduced sexual desire and other symptoms.
Several factors increase the risk of sexual dysfunction in men with diabetes. These include sub optimal glycaemic control, longer duration of diabetes, smoking, obesity, hypertension, diabetic neuropathy and cardiovascular disease. Sub optimal glycaemic control is particularly relevant because prolonged exposure to elevated blood glucose contributes to progressive vascular and neurological damage. The duration of diabetes is also important, reflecting cumulative exposure to these pathological processes. Cardiovascular risk factors require particular attention. Hypertension, dyslipidaemia, obesity and smoking can contribute to endothelial dysfunction and impaired vascular health. ED may therefore represent more than a sexual health problem; in some patients, it can be an early clinical manifestation of underlying vascular disease. The presence of ED should consequently prompt consideration of the patient's overall cardiovascular risk profile. Supporting Sexual Health through Diabetes Management Optimising diabetes management remains an important component of protecting sexual health. Maintaining blood glucose within an individual's recommended target range can help reduce the risk of diabetes-related microvascular and macrovascular complications. Regular physical activity can support cardiovascular health, improve metabolic control and assist with weight management. Smoking cessation should be actively encouraged, given the negative effects of smoking on
vascular health and blood flow. Similarly, effective management of blood pressure and cholesterol is important in reducing cardiovascular risk and may contribute to improved sexual function. Healthcare professionals should recognise that sexual dysfunction may persist despite appropriate diabetes management and may require specific treatment. Management should therefore be individualised according to the underlying cause, comorbidities, patient preferences and potential contraindications. Where appropriate, referral to a relevant specialist or multidisciplinary service should be considered. Communication and PatientCentred Care One of the greatest barriers to addressing sexual health in
55 diabetes is communication. Patients may feel embarrassed or uncomfortable discussing sexual difficulties, while healthcare professionals may be reluctant to initiate the conversation because of time constraints or uncertainty about how the subject will be received. A proactive, confidential and non-judgemental approach can help normalise sexual health discussions. Rather than waiting for a patient to raise the issue, healthcare professionals can incorporate a brief enquiry into appropriate diabetes reviews, particularly where risk factors or symptoms are present. For example, asking whether diabetes has had any impact on sexual function can provide an opportunity for patients to disclose concerns that they may otherwise not mention. Normalising the discussion can reduce stigma and reinforce that sexual health is a legitimate component of diabetes care.
When Further assessment is Required Healthcare professionals should encourage patients to seek further assessment when sexual difficulties persist for several weeks or months, cause significant distress, affect relationships or occur alongside other symptoms, such as numbness, pain, fatigue or low mood. Persistent ED should not simply be regarded as an inevitable consequence of diabetes or ageing. A comprehensive assessment may identify potentially reversible or treatable contributing factors, including sub optimal glycaemic control, cardiovascular disease, medication effects, hormonal abnormalities, psychological factors or diabetic neuropathy. Medication management should be an integral part of assessing sexual dysfunction in men with diabetes. Review prescribed and over-the-counter medicines, particularly antihypertensives and antidepressants, while recognising that underlying cardiovascular and
mental health conditions may also contribute. Medicines should never be stopped or changed without clinical review. Where medicationrelated effects are suspected, consider appropriate alternatives or adjustments. Particular attention should be given to patients presenting with ED alongside cardiovascular risk factors or symptoms. Identification of sexual dysfunction may provide an opportunity to review wider cardiovascular and metabolic health and reinforce preventive interventions. Conclusion Sexual health should be recognised as an integral component of holistic diabetes care. Diabetes can affect male sexual function through vascular, neurological, hormonal and psychological mechanisms, with erectile dysfunction being particularly common. More than half of men with diabetes may experience ED, often at an earlier age than men without diabetes.
For healthcare professionals, effective management requires more than simply identifying erectile difficulties. Assessment should consider glycaemic control, cardiovascular and metabolic risk factors, diabetic neuropathy, medication, hormonal factors and psychological wellbeing. Lifestyle interventions, including regular physical activity, smoking cessation and effective management of blood pressure, cholesterol and blood glucose, remain important components of risk reduction. Most importantly, healthcare professionals should create opportunities for open and sensitive discussion of sexual health. Early recognition and appropriate assessment can identify treatable causes, improve quality of life and, potentially, highlight wider cardiovascular or diabetes-related complications. Sexual dysfunction should therefore be approached not as an inevitable consequence of diabetes, but as an important and treatable clinical issue that deserves routine consideration within personcentred diabetes care.
IRISHPHARMACYNEWS.IE
56
Male Mental Health
The Experience of Mental Health - Recognising and Signposting In this year's Aware Mental Health Week Survey, responses indicated that nearly two thirds of men surveyed reported some experience of depression (similar to women in the survey), with the concurrent finding (that aligns to existing research) that women tend to have a diagnosis of depression at slightly higher rates than men. Our survey found that 40% of men who experienced anxiety, said it was so bad that they can’t function. Written by Dr Susan Brannick, Aware Clinical Director and Senior Clinical Psychologist people who hadn’t sought help for depression or anxiety said they believed they could deal with it themselves.
We might understand this finding in different ways. For instance, is it a case that men experience broadly equivalent levels of distress but are less likely to seek help than women? The first step of help seeking is to recognise and acknowledge that there is a problem. Some research says that men may be less likely to acknowledge signs of depression or if they do recognise them, they may judge them as not severe enough to need help. This aligns somewhat to our survey findings this year, which indicates that nearly half of
Additional training can be useful to develop confidence in responding to concerns about suicide, e.g Let’s Talk about Suicide is a free online, suicide prevention training programme provided through the HSE, that is designed to keep others safe from suicide.
Also, self-stigma around mental health (including shame and embarrassment) can act as an obstacle to speaking out, some studies report that social and cultural ideas around gender and gender stereotypes may influence how people perceive their own personal experiences. Equally according to some research, men are less often asked about potential psychological distress in part because of gender norms.
When thinking about conversations about mental health, it is important to remember it is not necessary to have all the answers or to have to give advice, rather listen with empathy and refer appropriately to a GP or relevant service. Often beginning to speak about a problem can be the first important part of a recovery journey for a person experiencing mental health difficulties. There is an up to date listing of specialised mental health services in Ireland listed for review on hse.ie/mental-health
Starting conversations about mental health and wellbeing can be important.
Recognising depression its symptoms
Healthcare professionals including community pharmacists are often part of the wider network of support in mental healthcare and may be at the frontline of noticing changes in the community as people access medications or advice in this setting. Good links within the community to additional services both in primary care and onward mental healthcare can be helpful to build for when needed.
Depression is a common mood condition, and any one of us, irrespective of age, gender, or background, can be affected. It is characterised by persistent low mood that can last a long time or keep returning, affecting a person's day-to-day life. It can impact their thinking, energy, feelings and behaviour - varying from mild to severe symptoms which can have a profound effect on every aspect of a person's relationships, family and work life. A useful acronym we use in Aware to remember the eight main symptoms of depression is F.E.S.T.I.V.A.L.; FEELING - sad, anxious, guilty ENERGY - low energy, tired or fatigued SLEEPING - under or over sleeping, any change to normal sleep pattern THINKING – poor concentration, thoughts slowed down INTEREST – loss of interest in hobbies, family or social life VALUE - low self esteem ACHES - physical aches and pains with no physical basis, and LIFE - loss of interest in living, thinking about death, suicidal thoughts.
IRISHPHARMACYNEWS.IE
If a person is experiencing five or more of these symptoms, lasting for a period of two weeks or more, as a next step Aware recommends they speak to their GP or a mental health professional. If a person is in need of urgent help and expresses their intention to attempt suicide, or may have seriously harmed themselves, or another is at risk instead inform the emergency services through 999 or 112, refer to crisis mental health services such as Samaritans or Pieta House – or direct them straight to A&E if appropriate. It is important to note that everyone's mental health journey is unique. Aware's range of free Mental Health Services offer a range of supports for adults impacted by depression, bipolar or anxiety including Support & Self Care peer to peer Groups online and in-person, Counselling, a Support Line and Support Mail, a monthly Educational Webinar on series on related topics with professionals and lived experience experts, as well as a range of evidence based Adult Education Programmes, designed to build resilience and empower people with the tools to manage their mental health, including services for relatives and friends supporting a loved one. For more information visit aware.ie or call 1800 80 48 48. Learn more about the Aware 2026 National Mental Health Survey at aware.ie/national-survey-2026/ Dr. Susan Brannick's Biography Aware Clinical Director Dr Susan Brannick is a Senior Clinical Psychologist with several years’ experience of service development and innovation as well as offering psychological consultation and training to health and community organisations. She is passionate about tackling stigma in mental health and understanding how the socio-political context that people live within may impact on psychological difficulties including depression and bipolar disorder. Susan holds a Doctorate in Clinical Psychology from the University of Surrey, an MSc in Neuroscience from Kings College London, and is also an Adjunct Associate Professor at UCD.
TIRED OF OF TIRED FEELING TIRED? TIRED? FEELING
Meet Pharma Pharma Plus Plus Meet Magnesium+ Bisglycinate Bisglycinate Magnesium+
Magnesium contributes contributesto toaareduction reductionof oftiredness tirednessand and Magnesium fatigue and and to to normal normalenergy-yielding energy-yieldingmetabolism. metabolism. fatigue
58
Male Smoking
The Unique Role of Pharmacists in Helping Men to Quit Smoking Written by Elaine Buckley, Edward Murphy & Aishling Sheridan, HSE Tobacco Free Ireland Programme and Shane O’Donnell, HSE Men’s Health - Health & Wellbeing
The Unique Role of Pharmacists in Helping Men to Quit Smoking Written by Elaine Buckley, Edward Murphy & Aishling Sheridan, HSE Tobacco Free Ireland Programme and Shane O’Donnell, HSE Men’s Health - Health & Wellbeing Background
Elaine Buckley
Background In Ireland, despite much success in tobacco control, the population is still experiencing an epidemic of smoking-related harm. And like many other developed countries, this smoking-related harm is progressing differently for men and women in Ireland. Males have higher rates of smoking, higher incidences of smoking related hospital admissions, disabilityadjusted life years and deaths compared to females. Behind these statistics are real people; our fathers, husbands, brothers, friends and colleagues who experience disease, disability and sadly die prematurely because of smoking. Even more heart breaking is the fact that the suffering caused by smoking is completely avoidable. Smoking Prevalence:
In Ireland, despite much success in tobacco control, the population is still experiencing an epidemic of smoking-related harm. And like many other developed countries, this smoking-related harm is progressing differently for men and women in Ireland. Males have higher rates of smoking, higher incidences of Edward Murphy Aishling Sheridan Shane O’Donnell smoking related hospital admissions, disability-adjusted life years and deaths compared to females. Behind these statistics are real people; our fathers, husbands, brothers, friends and colleagues who experience disease, disability and sadly die prematurely because of smoking. more heart breaking is • Among both men and women, equates to approximately 15% of • 4% Even of all hospital-admissions thethose fact that smoking completely avoidable. agedthe 25suffering to 34 havecaused by all for men are estimated to deaths,isfrom all causes. the highest rate of smoking. However, rates of smoking among this age group have declined by 10 points since 2015 Smoking Prevalence: (22%, down from 32% in 2015).
• Almost 60% (57%, n=2,564) of these deaths are among men, with 43% (n=1,948) among women.
In addition to hospitalisation, those who smoke require support from In• 2025, of the population with 13% smoking daily and 4%and occasional. • 16%smokers, of all deaths among Within17% the youngest age groupare current our primary communitySmoking care men2019. were Smoking related to prevalence smoking, (15have to 24), smoking broadly rates have services to every for for ill-health rates remained static since continues be day, higher men than compared to 13% of all deaths declined for women (from 19% caused by smoking. women and while recent trends in decline are similar, over a longer period it appears that there has been in 2015, to 13% in 2025), while among women; therefore, the Men's increased prevalence a greater relative decline in smoking among women than men. for men they have risen slightly burden of smoking-related of smoking and reticence for (2015: 19%, 2025: 21%). deaths among men is 25% help-seeking do of not4 occur 2 • Overall, 20% of men and 14% of women or occasionally – declines pointsinfor men higher thansmoke amongdaily women. • A similar trend can be seen isolation. They can be influenced and forolds women 2015. among 35 7topoints 44 year with since by social relationships, working Each week in Ireland, there are smoking ratesboth declining • Among menfaster and women, those aged 25 to 34 have the highest rate of financial smoking. However, environments, pressures approximately 1,000 hospital for women (from 25% in 2015, and expectations about down from forhave smoking-related rates of smoking among thisadmission age group declined by 10 points since 2015 (22%, to 13% in 2025) than men (from ‘what it means to be a man.’ conditions, this equates 32% in 2015). 28% in 2015, to 24% in 2025).1 Research has highlighted how to approximately 3% of all masculinefor norms and identities • Within the youngest age group (15 to 24), smoking rates have declined women (from 19% in hospitalisations, for all causes. Smoking-related Deaths & can19%, influence men's smoking 2015, to 13% in 2025), while for men they have risen slightly (2015: 2025: 21%). Hospitalisations • Almost 60% (58%) of these behaviours and engagement 3,4 faster for • year A similar trend 35 to year men, olds with smoking rates support. declining admissions are44 among with cessation For Each in Ireland, over can 4,500be seen among 1 people die due to(from smoking, with 42% among women. men, around women 25%this in 2015, to 13% in 2025) than men (from 28%some in 2015, toexpectations 24% in 2025).
In 2025, 17% of the population Prevalence of of smoking smoking by (%) are current smokers, with 13% Prevalence bysex sexby byyear, year,2015-2025 2015-2025 (%) smoking daily and 4% occasional. Smoking rates have remained broadly static since 2019. Smoking prevalence continues to be higher for men than women and while recent trends in decline are similar, over a longer period it appears that there has been a greater relative decline in smoking among women than men. • Overall, 20% of men and 14% of women smoke daily or occasionally – declines of 4 points for men and 7 points for women since 2015.
IRISHPHARMACYNEWS.IE
be attributable to smoking, compared to 3% of all admissions for women. 2
Source: Healthy Ireland Survey (2025). IPSOS B&A. Source Healthy Ireland Survey (2025). IPSOS B&A.
59 independence, self-reliance and personal control may influence how they approach quitting, including preferences for unaided cessation rather than using professional support or nicotine replacement therapy.5 However, masculine identities can also provide important motivations for quitting, particularly in relation to fatherhood, physical health, financial responsibilities and social connections. Recognising these influences can help pharmacists adopt a gender-sensitive, strengths-based approach that respects men's autonomy while actively promoting the benefits of evidence-based cessation support. There is nothing unmanly about getting support to quit smoking. These numbers are a stark reminder that Ireland is still experiencing an epidemic of smoking-related harm. However, the good news is that smoking in Ireland is now less common than it was in the past. We have all worked hard collectively to build a society where smoking is no longer a social norm. The benefits of this are visible in the fewer numbers of younger people who now smoke. Trying to Quit Half (46%) of current smokers have attempted to quit in the past 12 months. During their last attempt to quit, 67% of smokers did so without using any quitting aids. Of the 33% of people who used at least one quitting aid during their last attempt to quit, 18% used nicotine patches, gum, lozenges or spray, 11% used an e-cigarette and 2% used a nicotine pouch/pod. Only 1% used www.quit.ie to help them quit during their last attempt.6 In 2025, approximately 14% of current smokers reported that they were actively trying to quit smoking. Male smokers (18%) were twice as likely to say they are trying to quit, compared with 9% of female smokers.6
This data may suggest that men Pharmacists can further support The unique and influential role of pharmacists in helping people the client on their quit journey by may not be choosing the most to quit providing additional information on effective ways to quit smoking, a range of NRT including patches, and where they do engage Pharmacists have a unique gums, lozenges and sprays. in recommended supports, expertise and opportunity to The HSE Tobacco Free Ireland for example, with the HSE promote recommended stop Programme has funding to provide Stop Smoking Service, they smoking care and the benefits of clients who are accessing the HSE successfully engage and commit role The unique and influential of pharmacists in helping to quit quitting smoking, in particular, the people QUIT service behavioural support to quitting and are equally likely to correct and sustained use of stop programme with FREE medication quit as female participants. smoking medications. Pharmacists have a unique expertise and opportunity to promote recommended stop smoking c (regardless of medical card status). Allin stop smoking medicines the benefits of quitting smoking, particular, the correct and sustained use of stop smoking med How can you support people to Currently this medication can work best when combined with stop smoking? be accessed through a defined behavioural support. HSE Stop number of Allcare pharmacies Effective stop smoking care is now Smoking Advisors deliver a quality All stop smoking medicines work best when combined with behavioural support. This HSE Stop and their partner pharmacies. well established and the World assured and evidence based service was commissioned through Advisors deliver a quality assured and evidence based standard treatment programme to clients w Health Organisation has described standard treatment programme to EU tender; however work is Ireland’s efforts to support people clients who wish to quit smoking, to quit smoking, recommend stop smoking medicines/nicotine replacement (NRT) base underway to developtherapy a new FREE recommend stop smoking to quit smoking as the ’Gold NRT scheme through the PCRS , client’s innicotine and client replacement choice. medicines/nicotine standard’ this area.dependence score which will enable any pharmacist therapy (NRT) based on the client’s In January 2022, the Department to provide free medication to those nicotine dependence score and of Health published Ireland’s first Clinical This new development client choice. line treatment: The National Stop Smoking Guideline recommends aswho 1st smoke. National Stop Smoking Clinical will be very much welcomed by The National Stop Smoking Clinical the HSE Tobacco Free Ireland Varenicline NRT, or where Varenicline is unsuitable, 8 Guideline. The +/Pharmaceutical Guideline recommends as 1st line st Programme Pharmacists alike. Society of Ireland NRT was represented patch and used in combination wit Combination should be used as 1 line i.e. a slow-release treatment: It will remove further barriers and on the Guideline Development acting product,thesuch as gum, lozenge or+/mouth spray. provide easier and quicker access Group throughout guideline Varenicline NRT, or where Varenicline is unsuitable, to this ‘lifesaving’ medication. development process.
Combination NRT should be used It is generally recommended that For theproduce Allhealthcare the NRT professionals, formulations relatively low levels of nicotine that contrast with the spikes of as 1st line i.e. a slow-release NRT products are used by the guideline recommendations can be produced by cigarette smoking. Combining a nicotine patch with a rapid delivery form of NRT suc patch used in combination with a client for up to 12 weeks. With summarised in 3 simple steps: fast-acting product, such asthan gum, using combination mouth spray has been reported to be more effective a single NRT, typethe of initial NRT.patch Aishling She Routinely ASK people about lozenge or mouth spray. strength is determined by the the HSE Tobacco Free Ireland Programme said, “The single biggest mistake with use of NRT i their smoking, amount smoked per day, lighter All the NRT formulations produce smokers can start on step 2 for dosing as under-treated cravings increase the risk of smoking relapse.” relatively low levels of nicotine that ADVISE them of the benefits of example (14mg/24 hr patch or contrast with the spikes of nicotine quitting and the advise them of Pharmacists can further support the client on their quit journey by providing additional informat 15mg/16 hr patch). The 24-hour the supports that are available to produced by cigarette smoking. is helpful if the Free Ireland Pro Combining nicotine patch range of NRT including patches, gums, alozenges andwith sprays.patch The HSE Tobacco help them to quit client struggles with early a rapid delivery form of NRT such has funding to provide clients who are accessing the HSE QUIT service behavioural support pro ACT by 1) Recommending as the mouth spray has been morning cravings and the 16-hour reported be more card effective than or prescribing stop smoking(regardless patch is helpful patients withcan be a with FREE medication of to medical status). Currently thisfor medication using a single type of NRT. Aishling medication and 2) Referring to sleep disturbances. through a defined number ofSheridan Allcare pharmacies of the HSE Tobaccoand Free their partner pharmacies. This serv QUIT Services For pregnant women, who Ireland Programme said, “The commissioned through EU tender; however work is underway to develop a new FREE NRT scheme These 3 steps when delivered currently smoke NRT can be single biggest mistake with use the PCRS , which will enable any pharmacist to provide freerecommended medication following to those who smoke. T routinely in care can increase the a shared of NRT is under-dosing as underchance that someone will quit and decision-making process and cravings increase the development will be very muchtreated welcomed by the HSE Tobacco Free Ireland Programme and Pha risk of smoking relapse.” following discussion of the benefits remain smoke-free by 2 to 3-fold.
alike. It will remove further barriers and provide easier and quicker access to this ‘lifesaving’ med
Nicotine plasma concentration time profiles following smoking and NRT
Nicotine plasma concentration time profiles following smoking and NRT
In 2025, the HSE Stop Smoking Services engaged with over 20,000 clients for behavioural support to stop smoking. • More women than men attended the service - 53% female: 47% male. • Men who engaged with the service were significantly more likely to set a quit date than women engaging with the service (men: 61% set a quit date, women: 57% set a quit date), • Men were equally likely as women to remain quit at 4-week, 12-week and 26-week followups post quit date.7
It is generally recommended that NRT products are used by the client for up to 12 weeks. With com IRISHPHARMACYNEWS.IE NRT, the initial patch strength is determined by the amount smoked per day, lighter smokers can
60
Male Smoking
of cessation versus the risks of continued smoking to mother and developing foetus.
without requiring men to initiate a separate appointment with another healthcare service.
• Within 1 year, the risk of sudden death from a heart attack falls by half.
By asking just a few quick questions about your client’s smoking habits and lifestyle, you can help them choose the product and strength best suited to their needs. Some clients may express concern that using NRT is just like swapping one addiction for another, but this is not true. NRT is a safe and effective treatment that helps manage nicotine withdrawal and cravings, enabling individuals to focus on breaking the behavioural, psychological and social aspects of smoking dependence.
• Pharmacists can maintain contact during NRT use and support ongoing engagement.
• Within 5 years the risk of smoking-related cancers will be greatly reduced
“Community pharmacies are particularly well placed to engage men who may not otherwise seek smoking cessation support. Through routine interactions, pharmacists can initiate conversations about smoking, provide practical advice and offer a straightforward pathway to evidence-based treatment. These everyday encounters can help make smoking cessation support a normal part of healthcare, rather than something that individuals must actively seek out themselves”
What the HSE offer: Evidence based Stop Smoking Support & Free NRT/Stop Smoking Medicines
Smoking is highly addictive. As a drug delivery system, no other drug doses at such a high frequency therefore managing withdrawals and use of NRT is highly successful when titrated down over a 12 week period. Some additional notes: • Pharmacies are familiar community settings where men may already be visiting for other reasons. Men tend to favour engagement and discussions on their health in familiar environments. • Pharmacists offer opportunities for brief, opportunistic conversations. They can provide a route into professional support
Remind your clients of both the immediate and long-term health benefits of stopping smoking • After 8 hours, oxygen levels rise in the blood, and nicotine and carbon monoxide levels reduce • After 48 hours sense of smell and taste improve • After 3 days breathing gets easier and lung capacity increases • Within 2-3 months lung capacity may increase by up to 30%. Blood flows more easily to the arms and legs
A Standard Treatment Programme within the HSE Stop Smoking Service includes: • Intensive behavioural support, an assessment of nicotine dependence ± advice on recommended pharmacological support • A number of stop smoking consultations - pre quit consultation X 2, Quit date consultation, follow-up consultation at week 1, week 2, week 3, week 4, 12-week, and 52-week follow up • FREE confidential, non-judgemental, professional support • Access to FREE NRT through a network of local community pharmacy regardless of medical card status
• Online supports on QUIT.ie A number of stop QUIT smoking consultati (a•personalised online follow-up consultation plan, regular email and text at week 1, we message • FREEsupport) confidential, non-judgemental, • Access to FREE NRT through a netwo Contact your local stop status smoking services • Face-to-Face, individual or group sup The HSE provides local stop • on QUIT.ie smokingOnline clinicssupports nationwide. The (a person locationssupport) and contact details for individual clinics can be found here: https://www2.hse.ie/services/ stop-smoking-services/
Alternatively, can call services Contact your your localclients stop smoking the QUIT team on Freephone 1800HSE 201provides 203. local stop smoking clinics n The
clinics can be found here: https://www2.hse. The HSE-supported ENGAGE Men's Health Training programme is also a useful resource for pharmacists. This is a one-day Alternatively, your clients can call the QUIT te training programme providing practical, evidence-informed approaches to engaging men more effectively around theirMen's Health Tr The HSE-supported ENGAGE health. nottraining specificprogramme to This is aWhile one-day providin smoking principles men morecessation, effectivelythe around their health. Wh are directly relevant to how directly relevant to how pharmacists initiate c pharmacists initiate conversations supports - https://engagetraining.ie/ with men and encourage uptake of cessation supports - https:// engagetraining.ie/
References available on request
• Face-to-Face, individual or group support, virtually or in local communities & hospitals
NEWS - Think F.A.S.T this World Stroke Day To mark World Stroke Day (Thursday, 29 October) HSE West and North West has urged Roscommon and Galway people to know the signs of stroke and the importance of seeking treatment as soon as symptoms appear. Over 90,000 people live with the effects of stroke in Ireland, and it is estimated that there will be a 58% increase in incidents of stroke over the next 10 years. An easy way to be aware of the signs of stroke is to remember the established acronym, F.A.S.T: • Face – Has the face droope d or become weak on one side? • Arm – Has an arm become suddenly weak or clumsy on one side? • Speech – Has speech suddenly become slurred or confused in nature? • Time – Time to act FAST: phone 999 or 112 for an ambulance immediately. F.A.S.T. is a well-known worldwide acronym, and yet, there is still some hesitancy when calling an ambulance for stroke symptoms. You only need one of these symptoms for it to be a stroke. Currently, fewer than 50% of stroke patients arrive at the hospital within three hours of symptoms starting a critical window for lifesaving and disability-reducing treatments. Dr Tom Walsh, Consultant Physician in Geriatrics/Stroke at Galway University Hospital (GUH) said, “Stroke is a medical emergency and getting to hospital as quickly as possible is vital. There are two main treatments that have radically improved survival and recovery from stroke by getting the blood flowing back to the brain: Thrombolysis (clot dissolving) and thrombectomy (clot retrieval by transfer to Beaumont hospital). “However, not everyone will be suitable for these treatments, and timing is critical. Thrombolysis for example must be given within 4.5 hours of symptoms starting. The earlier that treatment begins, the greater the chance of saving brain tissue and reducing the risk of long-term disability or death.”
IRISHPHARMACYNEWS.IE
3 STEPS TO CLEARER SKIN:
1
CLEANSE DAILY
S • E XC E S S O I
L
2
TREAT SPOTS
RE TER
PO
B
AC
I A • C LO G G E
D
MOISTURISE DAILY
SKIN RESTORE STORE FOR
WHITE HEADS HEA E DS EA
OT ABSORBS SPOT SPOTS SP OTS RESTORES ORES SKIN AIDS RECOVERY COVERY VERY
FAST F FIX FOR
EMERGING SPOTS EMER
SHRINKS SP SPOTS SOOTHES SKIN SOO FFADES MARKS
Acnecide 5% w/w Gel and Acnecide Wash 5% w/w Gel contain Benzoyl peroxide. Indications: Gel: For the topical treatment of acne vulgaris. Wash: For the cutaneous treatment of acne vulgaris of the face, chest and back, where comedones and papules predominate. Legal category: P. Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at: Gel: Acnecide 5% w/w Gel (hpra.ie). Wash: Acnecide Wash 5 % w/w Gel (hpra.ie). Marketing authorisation number: Gel: PA 22743/001/001; Wash: PA 22743/001/002. Further information is available from Licence Holder: Galderma (UK) Limited, Evergreen House North, Euston, London, NW1 2DX. IE-ACPU-2600002 September 2026. Adverse Event Reporting: Suspected adverse events can be reported via HPRA Pharmacovigilance, Website: www.hpra.ie. Adverse events should also be reported to Galderma (U.K.) Limited. E-mail: medinfo.uk@galderma.com Tel: +44 (0)300 3035674
62
Sports Health
The Pharmacist on the Sidelines: Supporting Performance, Recovery and Everyday Athletes Written by Tiernan McCann, Pharmacist, Alchemist Omagh As both a community pharmacist and a Gaelic footballer, I appreciate the relationship between health, performance and recovery. My sporting experience shapes my approach to training, while my professional background helps me understand how pharmacists can support active individuals. pharmacist can give an athlete is to seek a proper assessment rather than attempting to push through an injury. Another obscure one in my bag is Insect repellent spray, usually Jungle Formula as our pitch is alongside a river and we can really struggle with midges again during the warm summer evenings. Hydration and supplements: what actually matters?
Whether preparing for a championship match, managing a niggling injury during a busy training schedule or simply trying to recover properly between sessions, good advice and appropriate pharmacy products can make a real difference. Match-day essentials Anyone involved in competitive sport will know that preparation goes well beyond the warm-up. Having a few essentials on match day helps manage minor problems and prepare for the unexpected. An unusual one to start: zinc-oxide tape over my Whoop wrist-strap to ensure it doesn’t come off during a game. Strapping or braces can also support certain injuries, but should not replace proper assessment or rehabilitation. Pain relief is another consideration for ongoing niggles, with paracetamol and ibuprofen being staples. Importantly, pain relief should not simply mask an injury to allow someone to keep playing. Significant pain, inability to bear weight, suspected fractures or serious head injuries require assessment rather than a quick fix. I also use rubefacients such as Deep Heat or Biofreeze to add a numbing sensation to the area before games.
Pharmacists can help people distinguish minor problems from injuries requiring further assessment. For a minor sprain or muscle injury, protecting the affected area, modifying activity and gradually returning to normal movement may be appropriate. Ice can provide short-term pain relief for some injuries, although it is not essential for every injury and should not be applied directly to the skin. More significant injuries, persistent symptoms or recurrent pain should be assessed by an appropriate healthcare professional. Pharmacists can help patients select suitable pain relief, explain how to use it safely and identify circumstances where selftreatment is not appropriate. They can also reinforce the importance of following a physiotherapist's rehabilitation plan and avoiding an early return to sport simply because the pain has settled.
Injury management and recovery
There are several warning signs that should never be ignored. These include a suspected fracture, severe or worsening pain, significant swelling, deformity, an inability to use or bear weight on a limb, and symptoms following a head injury. New neurological symptoms, or severe back pain accompanied by bladder or bowel dysfunction or numbness around the groin, require emergency assessment.
Sport inevitably comes with injuries. I have experienced the frustration of balancing rehabilitation with the desire to return to training, and the temptation to come back too early.
Recovery is not just about managing pain. Sleep, adequate nutrition, appropriate hydration and a sensible progression of training all contribute to the process. Sometimes the best advice a
IRISHPHARMACYNEWS.IE
Sports nutrition is an area where athletes can easily become overwhelmed by products promising improved performance, faster recovery or greater strength. In my experience, it is worth getting the basics right before spending money on supplements. Adequate calories, sufficient protein, carbohydrate to fuel training, good-quality sleep and appropriate hydration should form the foundation. Hydration needs vary with the person, exercise intensity, duration and conditions. Start well hydrated, drink according to thirst and replace fluids after particularly sweaty sessions. Electrolyte drinks may help during prolonged or intense exercise, especially in heat. Avoid overdrinking, which can dangerously lower blood sodium. I favour an electrolyte drink 30–60 minutes before summer training or games, and sometimes caffeine in an energy drink such as Nocco. My approach is to ask what someone is trying to achieve, whether there is a genuine need and whether the product is safe and evidence-based before recommending it.
product being requested and consider the bigger picture. That means asking the right questions, checking for contraindications and interactions, helping patients understand appropriate dosing, and recognising when a referral is needed. It also means offering practical advice on hydration, sleep, nutrition and the safe use of over-the-counter medicines. For athletes, medication checks can be particularly important. Some medicines may be restricted under anti-doping regulations, depending on the substance, route of administration and circumstances. Athletes should check current rules and seek appropriate advice rather than assuming a medicine is permitted because it is available in a pharmacy. Pharmacists can also support people managing long-term conditions who want to remain physically active, helping them understand their medicines and encouraging them to discuss exercise-related concerns with their wider healthcare team. Ultimately, the role is not to replace a doctor, physiotherapist or sports dietitian. It is to provide accessible, evidence-based advice, identify potential problems early and help people make informed decisions about their health. A final thought Sport teaches you plenty about discipline, resilience and the importance of preparation. It also teaches you that looking after yourself properly is just as important as the work you put into training.
Community pharmacists are often one of the most accessible healthcare professionals, making them well placed to support people who are active at every level, from recreational runners to competitive athletes.
As pharmacists, we have an opportunity to bring that same practical approach into everyday healthcare. By combining clinical knowledge with an understanding of the demands athletes face, we can help people manage minor problems safely, recognise when they need further support and stay active for longer.
A patient might come in looking for pain relief after a match, advice about a blister before a race, or something to help with recovery after a demanding training block. These conversations provide an opportunity to look beyond the
Sometimes, the most valuable intervention is a suitable product or a straightforward piece of advice. Other times, it is recognising when someone needs to stop, get assessed and give their body the time it needs to recover.
The community pharmacist's role in supporting active patients
FAST, PROVEN HYDRATION
Formulated by Pharmacists, to follow World Health Organisation oral rehydration solution guidelines O.R.S Hydration tablets contain a scientific blend of electrolytes, glucose, salts and minerals for fast and effective hydration that tastes great.
Tel: +353 44 939 6188 Email: info@pharmed.ie
NEW FORMAT VIAGRA CONNECT® (sildenafil)
MELTS ON YOUR TONGUE1 Viagra Connect® 50 mg orodispersible films ABBREVIATED PRESCRIBING INFORMATION Viagra Connect (sildenafil) 50 mg Film-Coated Tablet Viagra Connect (sildenafil) 50 mg orodispersible films Please refer to Summary of Product Characteristics (SmPC) before prescribing Indications, Dosage and Administration: Indications: Viagra Connect is indicated in adult men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for Viagra Connect to be effective, sexual stimulation is required. Dosage and Method of use: For oral use. Film-Coated Tablets: Adults: one 50 mg tablet taken with water approx. one hour before sexual activity. Orodispersible films: 50 mg taken on an empty stomach approx. one hour before sexual activity. Orodispersible films can be taken with or without water. The maximum dosing frequency is once per day. The onset of activity may be delayed if taken with food (see SmPC Section 5.2). Patients should be advised that they may need to take Viagra Connect a number of times on different occasions (max of one 50 mg tablet/film per day), before they can achieve a penile erection satisfactory for sexual activity. If after several attempts on different dosing occasions patients are still not able to achieve a penile erection sufficient for satisfactory sexual activity, they should be advised to consult a doctor. Elderly: no dosage adjustments required (≥ 65 years old). Renal Impairment: No dosage adjustments for patients with mild to moderate renal impairment. Dosage adjustments required for those with severe renal impairment, individuals must be advised to consult their doctor before taking Viagra Connect, since a 25 mg tablet may be more suitable for them (see SmPC Section 4.4). Hepatic Impairment: Dosage adjustments required for those with mild-moderate hepatic impairment, individuals must be advised to consult their doctor before taking Viagra Connect, since a 25 mg tablet may be more suitable for them (see SmPC Section 4.4). Viagra Connect is contraindicated for patients with severe hepatic impairment (see contraindications). Presentation: Film-Coated Tablets: each tablet contains sildenafil citrate equivalent to 50 mg of sildenafil. Orodispersible films: orodispersible film contains sildenafil citrate equivalent to 50 mg of sildenafil. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Co-administration with nitric oxide donors (such as amyl nitrite), nitrates, ritonavir, guanylate cyclase stimulators (such as riociguat) is contraindicated. Agents for the treatment of erectile dysfunction, including sildenafil, should not be used by those men for whom sexual activity may be inadvisable, and these patients should be referred to their doctor. This includes patients with severe cardiovascular disorders such as a recent (6 months) acute myocardial infarction (AMI) or stroke, unstable angina or severe cardiac failure. Sildenafil should not be used in patients with severe hepatic impairment, hypotension (blood pressure < 90/50 mmHg) and known hereditary degenerative retinal disorders such as retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases). Sildenafil is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see SmPC Section 4.4). Viagra Connect should not be used in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease). Viagra Connect is not indicated for use by women. The product is not intended for men without erectile dysfunction. This product is not intended for men under 18 years of age. Warnings and precautions: Erectile dysfunction can be associated with a number of contributing conditions, e.g. hypertension, diabetes mellitus, hypercholesterolaemia or cardiovascular disease. As a result, all men with erectile dysfunction should be advised to consult their doctor within 6 months for a clinical review of potential underlying conditions and risk factors associated with erectile dysfunction (ED). If symptoms of ED have not improved after taking Viagra Connect on several consecutive occasions, or if their erectile dysfunction worsens, the patient should be advised to consult their doctor. Cardiovascular risk factors: Since there is a degree of cardiac risk associated with sexual activity, the cardiovascular status of men should be considered prior to initiation of therapy. Agents for the treatment of erectile dysfunction, including sildenafil, are not recommended to be used by those men who with light or moderate physical activity, such as walking briskly for 20 minutes or climbing 2 flights of stairs, feel very breathless or experience chest pain. For a list of patients who are considered at low cardiovascular risk from sexual activity (see SmPC Section 4.4). Patients previously diagnosed with the following must be advised to consult with their doctor before resuming sexual activity: uncontrolled hypertension, moderate to severe valvular disease, left ventricular dysfunction, hypertrophic obstructive and other cardiomyopathies, or significant arrhythmias. Sildenafil has vasodilator properties, resulting in mild and transient decreases in blood pressure. Patients with increased susceptibility to vasodilators include those with left ventricular outflow obstruction (e.g. aortic stenosis), or those with the rare syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure. Men with these conditions must not use the product without consulting a doctor. Sildenafil potentiates the hypotensive effect of nitrates (see SmPC section 4.3). Priapism: Patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia), should consult a doctor before using agents for the treatment of erectile dysfunction, including sildenafil. Prolonged erections and priapism have been occasionally reported with sildenafil in post-marketing experience. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result. Concomitant use with other treatments for erectile dysfunction is not recommended. Effects on vision: Patients should be advised that in the event of any sudden visual defect, they should stop taking Viagra Connect and consult a physician immediately. Concomitant use with CYP3A4 inhibitors: patients should be advised to consult a doctor before taking Viagra Connect as a 25 mg tablet may be more suitable for them. Concomitant use with alpha-blockers: Caution is advised when sildenafil is administered to patients taking an alpha-blocker, as the co-administration may lead to symptomatic hypotension in a few susceptible individuals. Thus, patients taking alpha blockers should be advised to consult their doctor before taking Viagra Connect as a 25 mg tablet may be more suitable for them (see SmPC Section 4.2 & 5.2). Treatment should be stopped if symptoms of postural hypotension occur, and patients should seek advice from their doctor on what to do. Effect on bleeding: the use of sildenafil is not recommended in those patients with history of bleeding disorders or active peptic ulceration, and should only be administered after consultation with a doctor. Renal and Hepatic impairment: Patients with hepatic or severe renal impairment (creatinine clearance < 30 mL/min), must be advised to consult their doctor before taking Viagra Connect, since a 25 mg tablet may be more suitable for them (see SmPC Section 4.2 & 5.2). Use with alcohol: Drinking excessive alcohol can temporarily reduce a man's ability to get an erection. Men should be advised not to drink large amounts of alcohol before sexual activity. Film-Coated Tablets: Lactose: The film coating of the tablet contains lactose. Viagra Connect should not be administered to men with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Sodium: This medicinal product contains less than 1 mmol sodium (23 mg) per tablet. Patients on low sodium diets can be informed that this medicinal product is essentially ‘sodium-free’. Interaction with other medicinal products and other forms of interaction: Effects of other medicinal products on sildenafil In vitro studies Sildenafil metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance. In vivo studies Pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance when co-administered with CYP3A4 inhibitors (such as ritonavir, ketoconazole, itraconazole, erythromycin, cimetidine). Although no increased incidence of adverse events was observed in these patients, with the exception of individuals taking ritonavir for which co-administration with sildenafil is contraindicated, individuals must be advised to consult their doctor before taking Viagra Connect, since a 25 mg tablet may be more suitable for them. Co-administration of the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg twice daily) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1,000% (11-fold) increase in sildenafil plasma AUC. At 24 hours, the
plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was administered alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. Sildenafil had no effect on ritonavir pharmacokinetics. Based on these pharmacokinetic results sildenafil should not be co-administered with ritonavir (see SmPC Section 4.3). Co-administration of the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at steady state (1200 mg three times a day) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC. Sildenafil had no effect on saquinavir pharmacokinetics (see SmPC Section 4.2). Stronger CYP3A4 inhibitors such as ketoconazole and itraconazole would be expected to have greater effects. When a single 100 mg dose of sildenafil was administered with erythromycin, a specific CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC). In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite. Cimetidine (800 mg), a cytochrome P450 inhibitor and non-specific CYP3A4 inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers. Grapefruit juice is a weak inhibitor of CYP3A4 gut wall metabolism and may give rise to modest increases in plasma levels of sildenafil. Single doses of antacid (magnesium hydroxide/aluminium hydroxide) did not affect the bioavailability of sildenafil. Although specific interaction studies were not conducted for all medicinal products, pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, barbiturates). In a study of healthy male volunteers, co-administration of the endothelin antagonist, bosentan (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of CYP2C19) at steady state (125 mg twice a day) with sildenafil at steady state (80 mg three times a day) resulted in 62.6% and 55.4% decrease in sildenafil AUC and Cmax, respectively. Therefore, concomitant administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in plasma concentrations of sildenafil. Nicorandil is a hybrid of potassium channel activator and nitrate. Due to the nitrate component it has the potential to result in a serious interaction with sildenafil. Effects of sildenafil on other medicinal products In vitro studies Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 > 150 μM). Given sildenafil peak plasma concentrations of approximately 1 μM after 100 mg of sildenafil, it is unlikely that Viagra Connect will alter the clearance of substrates of these isoenzymes. There are no data on the interaction of sildenafil and non-specific phosphodiesterase inhibitors such as theophylline or dipyridamole. In vivo studies Consistent with its known effects on the nitric oxide/cGMP pathway (see SmPC Section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors or nitrates in any form is therefore contraindicated (see SmPC Section 4.3). Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including sildenafil, is contraindicated (see SmPC Section 4.3). Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours post sildenafil dosing (see SmPC Sections 4.2 and 4.4). In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were observed. When sildenafil and doxazosin were administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports of patients who experienced symptomatic postural hypotension. These reports included dizziness and light-headedness, but not syncope. No significant interactions were shown when sildenafil (50 mg) was co-administered with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolised by CYP2C9. Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by acetyl salicylic acid (150 mg). Sildenafil (50 mg) did not potentiate the hypotensive effects of alcohol in healthy volunteers with mean maximum blood alcohol levels of 80 mg/dl. Pooling of the following classes of antihypertensive medication; diuretics, beta-blockers, ACE inhibitors, angiotensin II antagonists, antihypertensive medicinal products (vasodilator and centrally-acting), adrenergic neurone blockers, calcium channel blockers and alpha-adrenoceptor blockers, showed no difference in the side effect profile in patients taking sildenafil compared to placebo treatment. In a specific interaction study, where sildenafil (100 mg) was co-administered with amlodipine in hypertensive patients, there was an additional reduction on supine systolic blood pressure of 8 mmHg. The corresponding additional reduction in supine diastolic blood pressure was 7 mmHg. These additional blood pressure reductions were of a similar magnitude to those seen when sildenafil was administered alone to healthy volunteers (see SmPC Section 5.1). Sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates. In healthy male volunteers sildenafil at steady state (80 mg three times a day) resulted in a 49.8% increase in bosentan AUC and a 42% increase in bosentan Cmax (125 mg two times a day). Addition of a single dose of sildenafil to sacubitril/valsartan at steady state in patients with hypertension was associated with a significantly greater blood pressure reduction compared to administration of sacubitril/valsartan alone. Therefore, caution should be exercised when sildenafil is initiated in patients treated with sacubitril/valsartan. Fertility, pregnancy and lactation: There was no effect on sperm motility or morphology after single 100 mg oral doses of sildenafil in healthy volunteers. Viagra Connect is not indicated for use by women. There are no adequate and well-controlled studies in pregnant or breast-feeding women. No relevant adverse effects were found in reproduction studies in rats and rabbits following oral administration of sildenafil. Undesirable effects: Very common (≥1/10): headache. Common (>1/100, <1/10): dizziness, visual colour distortions, visual disturbance, vison blurred, flushing, hot flush, nasal congestion, nausea, dyspepsia. For details of uncommon, rare and very rarely reported adverse events and those of unknown frequency, see SmPC. Reporting of adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Website: www.hpra.ie. Adverse reactions/events should also be reported to the marketing autorisation holder at the email address: pv.ireland@viatris.com or phone 0044(0)8001218267. Legal Category: Not subject to medical prescription. Supply through pharmacies only. Marketing Authorisation Numbers: PA23355/063/001-002 Marketing Authorisation Holder: Viatris Healthcare Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland Full prescribing information available on request from: Viatris, Dublin 17. Email : info.ie@viatris.com Date of Revision of Abbreviated Prescribing Information: 06 July 2026 Reference Number: IE-AbPI-ViagraConnect-FCT+ODF-v001
References: 1. Viagra Connect 50 mg orodispersible films Summary of Product Characteristics Feb 2026 IE-VIAC-2026-00055 DOP: July 2026
66
Masculinity
Engaging Young Men in Conversations about Masculinity and Respect Recent findings from Dublin Rape Crisis Centre have renewed discussion about young men’s attitudes towards sexual violence. With this in mind, how do we help young men recognise harm, question expectations and develop more respectful relationships? Written by Dr Jordan Kirwan
confidence or belonging can reinforce expectations around gender and demonstrating disagreement can be difficult when a young man fears losing his place within a group.
At Men’s Development Network, our forthcoming White Ribbon research examines gender expectations, relationships and the support young men need, as well as the implications in employing said supports. These questions have relevance for pharmacists and other health professionals whose everyday work can provide opportunities to listen, recognise and signpost support. Understanding the expectations placed on young men Masculinity, in straightforward terms, refers to the expectations, which can vary between communities and indeed generations, attached to being a boy or a man. Some, especially more contemporary expectations, encourage some element of care and responsibility. Others suggest that men should hide distress, prove themselves through aggression or exercise control within relationships. Questioning these expectations gives young men the room to consider the kind of men they want to become. Young men did not wake up on their eighteenth birthday with fully formed ideas about women, relationships and what it means to be a man – positive or otherwise. Those ideas develop through everyday experiences, including what is accepted among friends or modelled at home. Engagement with online content is part of this process. Messages offering
IRISHPHARMACYNEWS.IE
Content offering confidence or belonging could also introduce claims about women or relationships that need to be questioned. Asking what a clip is trying to ‘sell’, whose experience it leaves out and how it might influence behaviour gives young people a way to examine it. Our current research responds to these influences by exploring how young men can be supported to question the expectations these messages promote. This creates questions such as: what does being a caring partner involve and does taking responsibility mean taking charge? Bringing these questions into everyday situations gives young men opportunities to examine contradictions without being treated as a problem. Understanding what supports those who already reject harmful views should form part of that work. Recognising when care becomes control More to the previous point, one area that deserves attention is the way controlling behaviour can be understood or presented as care for young people. A young man might recognise the importance of respecting his partner’s independence, yet view jealousy or repeatedly checking their whereabouts under the guises of concern. This creates a need to discuss what those behaviours mean for the person experiencing them. Mutually agreed contact differs from demanding constant updates
or becoming angry when a partner does not respond. Concern does not give someone the right to check private messages without permission, restrict friendships or decide what their partner wears. The point is to help young men recognise that care must leave room for another person’s choices, privacy and independence. That respect for another person’s choices extends to sexual consent, too. Being in a relationship does not create an entitlement to sexual activity. Rather, consent must be freely given, ongoing and capable of being withdrawn at any time. Discussing these situations openly gives young men concrete opportunities to consider whether their behaviour reflects the respect and level of equality they support in principle. The role of pharmacists and other health professionals For pharmacists and other health professionals, understanding pressures to appear strong, hide uncertainty or manage difficulties alone can help explain why young men may struggle to discuss personal problems. Offering privacy, listening carefully and responding without judgement can provide space for a conversation they have struggled to have elsewhere. When sexual violence is disclosed, listening, believing the person and avoiding blame are essential, alongside respecting their choices and explaining relevant safeguarding responsibilities. Knowing where to refer someone is valuable, but that referral begins with recognising an issue correctly and responding appropriately when it is raised. Supporting change over time While it is unfortunate to say, the reality is that there is no straightforward answer to what will work in engaging young men and addressing concerning attitudes. Different experiences and influences require due consideration, but no single approach can be expected to reach everyone in the same way.
Meeting young men where they are matters – this is often the rallying cry that comes in response to addressing these attitudes, but we must consider how they got there in the first place. Earlier, ageappropriate and accessible primary prevention education should help children question and understand gender expectations, as well as learning about the importance of respect and basic decency. In the meantime, equipping those in regular contact with young people remains crucial to challenging the beliefs that normalise disrespect and excuse abusive behaviour. Teachers, youth workers and health professionals alike who are motivated to help reduce the impact of this behaviour are encouraged to arm themselves with the growing body of evidence and research in this area, however, there is a need to accommodate specific training and clear ways to discuss these topics, alongside continued support to do so. The same work requires time and regular backing for the people delivering it. What comes about from this current discourse is that men are responsible for their behaviour and for considering how their actions affect others, but schools, community organisations and health services have a responsibility to create opportunities for young men to question the expectations placed upon them, understand what respectful relationships involve and find support when they need it. This requires attention to the everyday environments in which ideas about gender are learned and reinforced, which ought to include what adults themselves model and accept. To this end, expecting men to take greater responsibility must be accompanied by a collective commitment to making that learning possible and sustaining it over time. The panic generated by research needs to translate into opportunities for learning and support that remain available after the headlines, and the attention generated by them, have subsided.
68
Men’s Grooming
Unlocking a High-Growth Category for Community Pharmacy Once considered a niche market, male grooming has evolved into one of the most dynamic and profitable sectors within personal care. From skincare and beard maintenance to men’s wellness supplements and fragrances, male grooming now represents a diverse, fast-moving category that continues to attract new customers and product innovation. Understanding the Male Grooming Market The modern male grooming market has shifted far beyond traditional shaving products. Men of all ages are investing more in their personal appearance, health, and hygiene — and expect easy access to high-quality, credible products. According to industry analysts, the global men’s grooming market is projected to exceed $115 billion by 2028, with skincare, beard care, and hair styling products among the fastest-growing segments. In Ireland and the UK, the growth has been driven by lifestyle changes, social media influence, and the increasing normalisation of male self-care. Where once male grooming was confined to aftershave and razor blades, today’s consumer is exploring moisturisers, anti-ageing serums, exfoliating cleansers, beard oils, hair styling clays, and wellness supplements. The lines between health and beauty are blurring, placing pharmacies in a prime position to serve this evolving demand. Who Is the Male Grooming Customer? Understanding customer motivation is the first step in designing an effective merchandising and service strategy. Broadly, the male grooming shopper falls into three main groups: 1. Traditionalists - often 40+, these men focus on shaving, deodorant, and basic skincare. They value trusted brands, practicality, and ease of use. 2. Modern Groomers - typically 20–40 years old, they’re interested in skincare, hair styling, and beard maintenance. They’re more brand-conscious and influenced by social media and professional appearance. 3. Gift Buyers - partners, family, and friends buying male grooming sets, fragrances, or luxury shaving kits, particularly around Father’s Day, Christmas, and Valentine’s Day. Pharmacies can tailor promotions and merchandising to appeal
IRISHPHARMACYNEWS.IE
to each group. For instance, Father’s Day displays can combine premium shaving sets and skincare gift boxes, while a year-round shelf can emphasise affordable everyday essentials for men. Product Segmentation: Building the Right Range Successful male grooming merchandising starts with smart range selection. The category can be divided into five clear segments: 1. Shaving and Beard Care razors, blades, shaving foams and gels, beard oils, trimmers, and aftershave balms. 2. Skincare - facial cleansers, moisturisers, exfoliators, serums, and anti-ageing products formulated for men. 3. Haircare and Styling shampoos, conditioners, styling gels, clays, pomades, and scalp treatments. 4. Fragrance and Body Care deodorants, body washes, and signature scents. 5. Men’s Wellness and Supplements - hair loss prevention, vitamins for skin and nails, energy boosters, and testosterone support.
Display products vertically by category (e.g. shave → skincare → hair → fragrance), and ensure pricing and product information are clear. Keep the section uncluttered — men shop differently from women and are often goal-oriented, preferring clarity over variety. 3. Seasonal Focus: Plan seasonal refreshes around key male gifting times: • Father’s Day - gift sets, premium grooming kits, and fragrance bundles. • Christmas - pre-wrapped gift options and limited editions. • Summer - travel-size grooming kits and SPF skincare. Seasonal displays help maintain freshness and encourage repeat visits. 4. Cross-Merchandising Opportunities: Strategic crossmerchandising can boost average basket size. Pair related categories, such as: • Beard oil beside beard trimmers. • Moisturiser beside razor blades or shaving gel. • Shampoo beside hair supplements.
Merchandising Strategies: Making the Category Stand Out
• Aftershave beside men’s fragrance testers.
1. Location and Layout: Visibility is crucial. Many pharmacies still position male grooming in lowtraffic corners or near women’s beauty aisles, where male shoppers may feel out of place.
Front-of-Store Engagement: Turning Browsers into Buyers
Instead, consider creating a distinct male grooming zone — ideally near the entrance, men’s health products, or fragrance displays. A dedicated end bay or branded gondola signals that this is a space for men, encouraging browsing. Clear signage such as “Men’s Grooming – Shave, Style, Skincare” works well. 2. Visual Appeal: Use darker tones like charcoal, navy, or metallic accents for shelf headers and signage — these convey a masculine aesthetic that contrasts well with brighter cosmetics sections.
Pharmacy teams play a vital role in converting casual interest into sales. Here are some practical, achievable tips:
1. Use the Counter Space Wisely: Counter displays can feature highmargin impulse products such as beard oils, small travel grooming kits, or moisturisers. Compact point-of-sale (POS) units with bold visuals work well. 2. Empower the Team: Many pharmacy teams are more familiar with female skincare, so training is key. Encourage staff to test male grooming products themselves or use brand training materials to learn about key ingredients (e.g., charcoal, hyaluronic acid, caffeine). Confidence in discussing these products helps overcome the barrier many male customers feel when asking for advice. 3. Sampling and Mini Sizes: Small testers or sachets of shaving gels, moisturisers, and beard oils allow men to try products risk-free. Sampling drives brand trust and repeat purchase. Digital and Cross-Channel Opportunities While pharmacies excel in physical engagement, integrating digital touchpoints enhances visibility. • Use the pharmacy’s social media to post product highlights, seasonal promotions, or skincare tips for men. • Offer click-and-collect for male grooming gift sets. • Include QR codes on displays linking to online advice from pharmacists on skincare or shaving tips. This hybrid approach builds brand consistency and helps pharmacies compete with online retailers.
Erectile Dysfunction
69
Erectile Dysfunction: Assessment, Management and the Role of the Community Pharmacist Erectile dysfunction (ED) is a common yet frequently underreported condition that can have a significant impact on men's physical health, emotional wellbeing and relationships. Although prevalence increases with age, ED can affect men at any stage of adulthood. Embarrassment, stigma and reluctance to discuss sexual health often prevent individuals from seeking timely advice, making community pharmacists particularly well placed to provide accessible, confidential support. ED is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual activity. Occasional difficulties are common and do not necessarily indicate an underlying medical condition. However, persistent or worsening symptoms warrant further assessment, particularly as ED may be an early manifestation of cardiovascular or metabolic disease. Understanding the Causes Erectile dysfunction is often multifactorial, with physical, psychological and lifestyle factors contributing to its development. Common physical causes include cardiovascular disease, diabetes mellitus, hypertension, dyslipidaemia, obesity, neurological disorders and hormonal abnormalities, including testosterone deficiency. Men with diabetes are at particularly increased risk because of vascular and neurological complications. ED and cardiovascular disease share several risk factors, including endothelial dysfunction and atherosclerosis. Importantly, erectile difficulties may precede more obvious cardiovascular symptoms, providing an opportunity to identify previously unrecognised risk factors. Lifestyle influences, including smoking, excessive alcohol consumption, physical inactivity, poor diet and recreational drug use, can also contribute to erectile difficulties. Psychological factors such as anxiety, depression, relationship difficulties and performance anxiety may be particularly relevant in younger men, although they can occur at any age. Sudden symptom onset, preserved morning erections or difficulties occurring only in particular situations may suggest a psychological component, but these features do not exclude an underlying physical cause.
Medication-Related Erectile Dysfunction A comprehensive medication review is an important component of ED assessment. Several commonly prescribed medicines may contribute to erectile difficulties, including selective serotonin reuptake inhibitors (SSRIs), thiazide diuretics, certain beta-blockers and spironolactone. Other medicines may affect libido or sexual performance through hormonal, neurological or vascular mechanisms. Pharmacists should explore whether symptoms developed following the initiation of a new medicine or a dosage adjustment. Where a medicine-related cause is suspected, discussion with the patient's prescriber may identify suitable alternatives.
risk evaluation and referral for investigations such as blood glucose or HbA1c and lipid testing.
Patients should be advised not to discontinue prescribed medication without medical guidance.
Patients with persistent ED should be encouraged to attend their GP for appropriate assessment, even where symptomatic treatment is suitable.
Assessment in Community Pharmacy
Treatment and Management Options
Community pharmacy offers an accessible and confidential environment for patients who may be reluctant to discuss sexual health concerns with their GP.
Phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil and tadalafil, are established pharmacological treatments for ED.
An empathetic, non-judgemental approach is essential. Offering a private consultation room and using straightforward, sensitive language can help patients feel more comfortable. Assessment should consider the duration, severity and pattern of symptoms, including whether difficulties developed gradually or suddenly. Relevant medical conditions, current medicines, lifestyle factors and psychological wellbeing should also be explored. Because ED may indicate underlying cardiovascular disease, pharmacists should consider the need for blood pressure assessment, cardiovascular
These medicines enhance the erectile response to sexual stimulation by increasing blood flow to penile tissue. They do not independently produce an erection and require sexual stimulation to be effective. Treatment selection should consider onset and duration of action, patient preference, existing medical conditions, concurrent medicines and potential adverse effects. PDE5 inhibitors must not be used alongside nitrates or recreational nitrites, because of the risk of potentially severe hypotension. Particular caution is also required in patients with significant cardiovascular disease or those
taking medicines that may interact with ED treatments. In Ireland, pharmacists must ensure that any supply complies with the applicable prescription requirements, product authorisation and professional guidance. Where appropriate, other management approaches may include psychological support, psychosexual therapy, vacuum erection devices or specialist referral. Recognising Red Flags Pharmacists should recognise situations requiring prompt medical assessment, including new or worsening ED associated with cardiovascular symptoms, significant penile pain or deformity, neurological symptoms, or symptoms following pelvic trauma. Chest pain or other symptoms suggesting an acute cardiovascular event require emergency assessment. A prolonged painful erection lasting four hours or more is also a medical emergency. Patients with suspected hormonal abnormalities, significant urinary symptoms or persistent unexplained ED should be referred for appropriate investigation.
IRISHPHARMACYNEWS.IE
70
Surfers Ear
Management of Surfer’s Ear Written by Noof Albannai, Medical Intern at Al-Amiri Hospital in Kuwait, Trinity College Dublin graduate, and Professor Naishadh Patil, Consultant ENT Surgeon, Sligo University Hospital Mention "surfer’s ear" to most people and they picture someone who spends their winters chasing ocean waves. Historically, that wasn't far off. External auditory canal (EAC) exostoses were traditionally seen in hardcore surfers, divers, and cold-water mariners. However, over the last decade, ENT clinics have seen a clear demographic shift. With the recent boom in wild swimming, open water triathlons, and cold water endurance sports, we are regularly seeing advanced exostoses in patients who have never stepped foot on a surfboard.
typically surface only when the ear canal becomes heavily obstructed. When patients do present, they usually complain of: Persistent "Water Trapping, Recurrent Otitis Externa, Conductive Hearing Loss, Tinnitus or Fullness.
Conservative Management
Otoscopy
Recognizing these lesions early and understanding when to manage them conservatively versus when to refer for surgery can save patients from unnecessary complications, chronic pain, and hearing loss.
On examination, exostoses present as smooth, firm, skin covered mounds arising from the canal walls. They are usually multiple, broad based, and bilateral (though often asymmetrical depending on dominant wind or wave directions).
1. Keep Cold Water Out: Custom silicone earplugs are frequently used to reduce cold water turnover in the canal.
patients with Grade III or IV obstruction who suffer from intractable ear infections, persistent conductive hearing loss, or severe, unmanageable wax impactions.
If a patient has Grade I or II When patients do present, they usually complain of: Persistent "Water Trappi exostoses, surgery is rarely indicated. The priority is Recurrent Otitis Externa, Conductive Hearing stopping progression and Loss, Tinnitus or Fullness.
Staging & Clinical Management Otoscopy
Pathophysiology: Why Cold Water Triggers Bone Growth?
Exostoses are benign, slow growing, broad based bone formations arising from the tympanic portion of the temporal bone. It is important to distinguish them from canal osteomas: osteomas are true benign tumours, whereas exostoses are a reactive, hyperostotic response to repetitive thermal stress.
We generally grade canal narrowing into four stages:
preventing infection:
2. Post-Swim Drops: Using acidifying or alcohol-based drying drops (like a simple 2% acetic acid spray or diluted rubbing alcohol) right after getting out of the water helps dry the canal and prevent bacterial growth.
Modern otology offers a few surgical options: - Micro Drill Canaloplasty: The traditional technique using high speed burs to shave down bone. Effective, but requires meticulous care to avoid thermal injury to surrounding tissues, acoustic trauma from drill noise, or damage to the facial nerve. - Micro Osteotome Chisel Technique: Shaving the exostoses at their base using tiny hand held chisels. This preserves the overlying canal skin intact, reduces recovery time, and eliminates the risk of drill induced acoustic trauma.
3. Avoid Cotton Swabs: Patients On examination, exostoses Grade I <50 % occlusion: Usually present as smooth, firm, skin covered mounds ar must be instructed to stop using asymptomatic. Found incidentally. cotton buds. Pushing wax pastbased, a the canal walls. They are usually multiple, broad and bilateral (though narrow exostosis packs it tightly Grade II 50 – 75 % occlusion: Mild against the eardrum, making water trapping, minor wax buildup. asymmetrical depending on dominant wave directions). manual micro wind suction inor clinic
The mechanism is straightforward. Cold water or cold wind draft entering the ear canal causes local cooling. Because the skin overlying the deep bony canal is extremely thin and lacks subcutaneous fat, this cold exposure triggers localized hyperaemia and periosteal inflammation. Over years of repeated exposure, osteoblasts in the subperiosteal layer are activated, depositing thin layers of lamellar bone directly into the canal. Wind chill plays a major role here. Even in moderate water temperatures, evaporative cooling from wind blowing across a wet ear canal can drop local tissue temperatures significantly, accelerating bone deposition. Clinical Presentation & Diagnosis Because exostoses grow so slowly, patients rarely notice them in the early stages. Symptoms
Figure 1. High definition otoscopic view of an external auditory canal showing severe exostoses. Multiple broad based bony nodules arise from the canal walls, narrowing the lumen and partially obscuring the tympanic membrane
Grade III 75 – 90 % occlusion : Frequent ear infections, noticeable hearing loss. Grade IV >90% occlusion: Near total blockage, severe recurrent infections.
much harder and increasing the risk of acute otitis externa.
When to Consider Surgery Surgical intervention (canaloplasty) is reserved for
- Trans canal Endoscopic Ear Surgery (TEES): Using wide angle endoscopes directly through the ear canal gives surgeons an exceptional view around bony corners, often avoiding the need for an incision behind the ear. - Piezoelectric (Ultrasonic) Surgery: A newer development where ultrasonic vibration cuts bone while leaving soft skin and mucosal flaps completely intact, significantly lowering the risk of canal trauma. Key Takeaways for Primary and Hospital Clinicians
1- Inspect the Deep Canal: When a patient presents with recurrent swimmer's ear or unexplained hearing loss after water sports, look deep into the bony canal for smooth, firm nodules. 2- Focus on Prevention: Educate active outdoor swimmers early. Wearing ear protection today can prevent the need for surgical canaloplasty. 3- Refer Appropriately: If a patient is dealing with >75% closure or repeated bouts of severe otitis externa despite using preventive drops and plugs, an ENT referral for microsection or surgical evaluation is the next best step. References available on request
IRISHPHARMACYNEWS.IE
Figure 1. High definition otoscopic view of an external auditory canal showing
MAGNESIUM (GLYCINATE) Bioavailable magnesium chelate for sensitive individuals Why Try Magnesium (Glycinate)? Well tolerated and highly bioavailable magnesium glycinate Provides 240 mg of magnesium per 2 capsule serving Helps replenish low magnesium levels Contributes to normal functioning of the nervous system and psychological function Contributes to normal energy-yielding metabolism and the reduction of tiredness and fatigue Contributes to normal muscle function and the maintenance of normal bones and teeth Contributes to electrolyte balance
Voted three-time Best Product1 1 In the U.K. and Ireland., as voted by health professionals and their patients, IHCAN Magazine © 2019, Nutrition I-Mag© 2019, True Health Magazine© 2019
Gold winner in ‘Better Sleep’ category2 Voted in the Wellness From Within Awards 2026 by a panel of highly regarded qualified judges who closely assess the products 2
Stock the Brand Healthcare Professionals Trust - Contact Us to Find Out More. Food supplements should not be used instead of a varied and balanced diet and a healthy lifestyle.
Topic Team Training – Cough, Cold and Flu: Supporting Customers with Confidence Following on from the October issue Continuing Professional Development article on managing cough, cold and flu in community pharmacy, this 5-Minute Learning Module is designed to enhance the community pharmacy team's understanding of common winter respiratory illnesses and how to support customers seeking advice and treatment. After completing this module, you should be able to recognise common respiratory symptoms, understand the appropriate use of OTC treatments, identify important medicine safety considerations and recognise when referral to the pharmacist is necessary.
Understand Common Symptoms
A community pharmacy environment that fosters teamwork ensures high levels of patient satisfaction. This series of articles is designed to help you identify training needs, support ongoing professional development and keep your team's knowledge and skills up to date.
Chesty cough: Involves mucus that the body is attempting to clear. Treatment suitability should be assessed by the pharmacist, particularly for patients with respiratory conditions.
As winter approaches, pharmacies experience increased demand for cough, cold and flu remedies. Many customers, particularly busy working adults, seek rapid symptom relief. However, effective advice requires more than simply recommending a familiar brand. Ask the Right Questions The WWHAM framework provides a structured approach to consultations: • Who is the medicine for? • What symptoms are being experienced? • How long have symptoms been present? • Action: What treatments have already been tried? • Medication: What other medicines are being taken? These questions help identify customers requiring pharmacist assessment, including pregnant women, older adults and those with asthma, cardiovascular conditions or other significant illnesses.
Dry or tickly cough: Often associated with post-nasal drip following a viral infection. Saline nasal sprays, hydration and sleeping with an additional pillow may help.
Nasal congestion: Decongestants may provide temporary relief, but oral products containing pseudoephedrine are unsuitable for some patients, including those with certain cardiovascular conditions. Fever and muscle aches: Common during influenza and other respiratory infections. Analgesics may help when used appropriately and according to recommended doses. Know What's in the Product Many customers request branded combination remedies without understanding their ingredients. Cold and flu preparations frequently contain paracetamol, decongestants or sedating antihistamines. Taking multiple products containing the same ingredients can result in accidental overdose or adverse effects. Always check whether customers are already taking paracetamolcontaining medicines. Combining decongestants may increase cardiovascular risks, while sedating antihistamines can impair concentration and driving ability.
Consider: Reflect on the following in assessing your own knowledge and your team’s training: Are you confident using WWHAM when customers request cough, cold and flu remedies? Can you recognise the differences between common respiratory symptoms? Do you understand the risks of combining OTC products containing similar ingredients? Can you identify customers requiring immediate pharmacist referral? Are you familiar with the risks of prolonged nasal decongestant use?
72 | IRISHPHARMACYNEWS.IE
Recognise Nasal Spray Overuse Nasal sprays containing xylometazoline can relieve congestion temporarily, but prolonged use may cause rebound congestion, where blockage worsens when treatment wears off. Customers repeatedly purchasing these sprays should be referred to the pharmacist. Saline nasal preparations may provide an alternative without this risk. Explain Antibiotic Use Most uncomplicated colds and acute coughs are caused by viruses, meaning antibiotics are ineffective.
Key Points: Always establish the customer's symptoms, duration and existing medication before recommending treatment. Understand the active ingredients in commonly requested cough, cold and flu products. Recognise that most uncomplicated winter respiratory infections are viral. Be alert to medicine duplication, contraindications and adverse effects. Refer vulnerable patients and those presenting with concerning symptoms to the pharmacist. Reinforce appropriate selfcare, infection prevention and vaccination advice.
Customers may incorrectly associate coloured mucus or persistent coughing with bacterial infection. Explain that a cough can continue for several weeks following a viral illness, although worsening or concerning symptoms require assessment. Know When to Refer Refer customers to the pharmacist when they report breathlessness, wheezing, chest pain, coughing up blood, persistent fever or deteriorating symptoms. Those with significant underlying conditions or symptoms that improve and subsequently worsen also require assessment. Severe breathing difficulties, chest pain or confusion may require emergency care. Actions: Review the pharmacy's range of cough, cold and flu products and their active ingredients. Refresh team knowledge of WWHAM and respiratory symptom assessment. Ensure all staff understand referral triggers and follow pharmacy SOPs. Discuss common risks associated with combination remedies and nasal decongestants. Deliver regular winter respiratory health training and assess team understanding. Encourage consistent, evidence-based advice that supports safe selfcare and appropriate pharmacist intervention.
A SIMPLE WAY TO RELIEVE ANY COUGH * AND SORE THROAT
*Associated with a cold. Broncho 5 in 1 Multi-Symptom Cough Pastilles is a medical device in accordance with Directive 93/42/EEC, used to relieve any cough (dry and chesty) associated with a cold, as well as related sore throat, hoarseness and throat dryness. Adults and adolescents from 12 years of age: 1-2 pastilles up to 4 times daily (maximum daily dose 8 pastilles). Not recommended for children under 12 years of age. Always read the instructions for use. MAT-16745
74
News
Menopause and Heart Disease Risk Heart disease is the leading cause of death in women, and the risk rises during the menopause years. But an international study has revealed that only half of women know this. Many have never talked about their heart with a doctor or a nurse, and the majority are living with multiple symptoms. Dr Sharon O’Donnell, Associate Professor in Critical Care Nursing, and CARAMEL lead at the School of Nursing and Midwifery
much less sure about risks that belong to women. Fewer than half (45%) knew that an early menopause raises the risk of heart disease. 2. Women are waiting to be asked. Nearly half (47%) have not talked about their heart with a professional in the past year. This included three in ten who had already been diagnosed with high blood pressure. The most common reason women gave was that they expected the professional to raise it. The silence goes beyond the heart. Almost one in three women (31%) had not talked about menopause with a professional in the past year, and fewer than one in four did so at most visits. Four in ten used no treatment at all for their symptoms.
This discovery, and many more, came from a survey of 7,470 women aged 40 to 60 in Ireland, Spain, Greece, Croatia, Lithuania and Colombia, whose responses were analysed as part of the Horizon Europe project, CARAMEL (CArdiovascular Risk Assessment in MEnopausaL women). Women and clinicians also took part in interviews and co-design workshops in all six countries, and the data were subsequently analysed by researchers in Trinity’s School of Nursing & Midwifery. Dr Sharon O’Donnell, Associate Professor in Critical Care Nursing, and CARAMEL lead at the School of Nursing and Midwifery, said, “Our research found major gaps in what women know about heart health and menopause. More than half of women who participated in the study were unaware of their risk of heart disease or that menopause can increase that risk. Most of these women were university-educated, so the knowledge gaps we identified
IRISHPHARMACYNEWS.IE
are probably greater within the wider population. We are also very concerned by what we heard from women with intellectual disabilities, most of whom had received no information about menopause before it began. “As part of the CARAMEL project, we have developed a new CVD Prevention Portal to help women learn about their heart health and support healthcare professionals to give better advice and care during menopause.” Key messages from the research 1. Only around half of midlife women (48%) know heart disease is their leading cause of death.
3. Menopause is far more than hot flushes. Seven in ten women had experienced fatigue, and two in three had sleep problems and mood swings. About half reported brain fog and anxiety, and nearly four in ten were unhappy with their sleep. Hot flushes, the bestknown symptom, were less common than fatigue, sleep problems or mood swings. Women want help they can trust. Two in three (67%) said they would like menopause information through an app, yet only 5% had ever used one as a source. They told us why: too many apps feel commercial, carry adverts or seem to collect their data. 4. Women’s heart attack signs are the least known. Almost every woman (95%) knows that chest pain can signal a heart attack. But far fewer know the subtler signs that are common in women: unusual fatigue (57%), nausea (47%), indigestion (38%) or anxiety (34%).
Awareness ranged from two in three women in Ireland (67%) to fewer than one in five in Colombia (19%). About one in three women named a cancer instead.
In women, a heart attack can begin with these less dramatic symptoms. A woman who does not recognise them may not seek help in time, and may be told, or tell herself, that it is nothing.
Women know the classic heart risks, such as high blood pressure and being overweight. They are
5. When the heart sends a warning, many women wait. More than half of women (55%)
have had a moment when they thought something might be wrong with their heart. Waiting to see what happened was as common a response as contacting a doctor, and fewer than one in ten called emergency services. Others stopped to rest or told a partner or a friend. Among the women with intellectual disability who had such a moment, none called emergency services. 6. HRT depends on where a woman lives. Two in three Irish women (65%) have used HRT, compared with between 6% and 19% of women at the other six sites. Across all sites, nutritional supplements (36%) were used more often than any medical treatment. Whether a woman used HRT depended more on whether she had seen a gynaecologist or a private menopause clinic than on her education or income, and the site she lived in mattered most of all. Among women with the heaviest symptoms and poor health, one in four used no treatment at all and one in two no medical treatment. 7. One in four (27%) have have been diagnosed with high blood pressure, a major cause of heart attack and stroke. Yet three in ten of these women had not talked about their heart health with a professional in the past year. Asked why not, almost half with high blood pressure (48%) said they expected the professional to raise it if there was a problem. Diagnosed heart disease was much less common (10%), which makes the menopause years a window for prevention. 8. Women with intellectual disability are left furthest behind. Four in five women with intellectual disability (78%) had not been told anything about menopause before it began, compared with 45% of Irish women in general. Only one in three (36%) knew that heart disease is women’s leading cause of death.
0 0 1 C I M DYNIAN AT E T O DAY NOM
The Dynamic 100 is a network of the most influential professional in the Irish pharmacy industry who act as ambassadors and role models for their peers, colleagues and the rising stars of tomorrow within Community Pharmacy.
Dynamic
How to enter: Please submit 250-800 words, describing how you/they have achieved something special,
gone above and beyond or behaved dynamically.
We also require a high-resolution photograph of the entrant for print publication. Each entry must be within the pharmacy industry.
Pharmacists have continued to provide a first-class service in the face of adversity, with each pharmacy team displaying the highest levels of resilience, determination, and courage. And now the time has come to reward that resilience. That determination. That courage… Nominations are sought from across the pharmacy profession in Ireland. anna@ipn.ie or Kelly-jo@ipn.ie Email nomination(s) to aoife@ipn.ie DEADLINE MONDAY 2nd OCTOBER2026 DEADLINE MONDAY 2ND NOVEMBER,
76
Impetigo
Impetigo in Community Pharmacy: A New Opportunity for Clinical Assessment and Treatment With impetigo now included in Ireland's Common Conditions Service, community pharmacists have an expanded role in assessing and managing this highly contagious bacterial skin infection. Appropriate diagnosis, responsible antibiotic prescribing and effective patient counselling are central to delivering safe, accessible care. Fusidic acid is a topical antibiotic with activity against susceptible organisms, particularly Staphylococcus aureus, and has an established role in treating bacterial skin infections including impetigo. However, antimicrobial stewardship remains a critical consideration. Repeated or prolonged use of topical antibiotics can contribute to bacterial resistance, potentially reducing treatment effectiveness over time. Pharmacists should therefore ensure antibiotics are prescribed only where clinically indicated, for the appropriate duration, and with clear instructions regarding application.
Impetigo is a common superficial bacterial skin infection, particularly affecting young children, although it can occur at any age. Traditionally managed through general practice, selected presentations can now be assessed and treated by appropriately trained community pharmacists under the HSE's Common Conditions Service. The inclusion of impetigo within the service represents another step towards expanding pharmacists' clinical responsibilities and improving access to treatment for common conditions. For pharmacy teams, understanding the clinical presentation, appropriate treatment options and circumstances requiring referral is essential. Recognising Impetigo Impetigo is primarily caused by Staphylococcus aureus and Streptococcus pyogenes. The infection spreads through direct skin contact or contaminated items and can develop where the skin barrier has been compromised by minor cuts, insect bites or existing skin conditions such as eczema. Two principal forms are recognised: non-bullous and bullous impetigo. Non-bullous impetigo is the more common
IRISHPHARMACYNEWS.IE
presentation. It typically begins as small red lesions or blisters that rupture, leaving characteristic golden-yellow or honey-coloured crusts. Lesions frequently occur around the nose and mouth, although other exposed areas may be affected. Bullous impetigo presents with larger, fluid-filled blisters and requires a different management approach. Pharmacists should also consider alternative diagnoses, including herpes simplex, infected eczema, contact dermatitis and other bacterial skin infections. A structured consultation should establish the duration and progression of symptoms, number and location of lesions, previous treatments, relevant medical conditions and whether the patient is systemically unwell. Impetigo and the Common Conditions Service Under the HSE's Common Conditions Service protocol, pharmacists can assess eligible patients presenting with localised non-bullous impetigo. The prescribing pathway is restricted to suitable presentations involving no more than three lesions, with additional eligibility and exclusion criteria determining whether treatment can be provided.
Patients presenting with bullous impetigo, more extensive infection, systemic symptoms or other features outside the protocol require appropriate referral. This distinction is important. While pharmacy-based prescribing can improve timely access to care, it must operate within clearly defined clinical parameters. The service also creates an opportunity for pharmacists to educate patients and parents about the condition, its contagious nature and the importance of appropriate treatment. Treatment and Antimicrobial Stewardship Treatment decisions should reflect the severity and extent of infection, patient-specific factors and current antimicrobial prescribing guidance. For localised non-bullous impetigo, topical treatment may be appropriate. The HSE Common Conditions Service protocol includes fusidic acid 20 mg/g cream or sodium fusidate 20 mg/g ointment for eligible patients with no more than three lesions, generally applied every eight hours for five to seven days in accordance with the protocol.
The HSE protocol also advises against combining topical and oral antibiotics where oral treatment has already been prescribed for the same episode. For patients with more extensive disease, systemic illness or treatment failure, medical assessment may be necessary to determine whether alternative treatment is required. Supporting Treatment Adherence Effective counselling can significantly influence treatment outcomes. Patients and carers should understand how to apply prescribed treatment, the importance of completing the recommended course and the need to avoid unnecessary additional applications. Before applying topical treatment, the HSE protocol advises gently removing crusts after softening them with petroleum jelly and a warm, damp facecloth. Used facecloths should not be shared or reused without thorough washing. Pharmacists should also explain that improvement should be monitored and that worsening symptoms, spreading redness, increasing pain or failure to respond to treatment require reassessment. Where infections recur, further investigation may be needed to identify contributing factors or possible bacterial resistance.
78
News
¤2.1m Wellcome Award for UCC Research A University College Cork (UCC) researcher has received a prestigious €2.1 million Wellcome Trust Award to help uncover why women are up to three times more likely than men to develop multiple sclerosis. Dr. Éanna Fennell, the 10th recipient on the island of Ireland of a Wellcome Trust Career Development Award. Image Credit: Bríd O'Donovan, UCC
Multiple sclerosis (MS) is an autoimmune disease in which the immune system damages the protective coating surrounding nerves in the brain and spinal cord. Approximately 160,000 people across Ireland and the
IRISHPHARMACYNEWS.IE
UK are living with MS, which can significantly affect quality of life and reduce life expectancy. Women are up to three times more likely than men to develop MS, yet the biological mechanisms behind
this striking difference remain poorly understood. Understanding why women are more susceptible to the disease could provide important new insights into its causes and potentially identify new approaches to treatment. UCC researcher Dr. Éanna Fennell has been awarded ¤2.1 million by Wellcome Trust, a global charitable foundation supporting scientific research, to investigate why MS is much more common
in women than in men. His research will examine whether the X chromosome plays a role in this difference by influencing the immune response to Epstein-Barr virus (EBV), which is strongly linked to the development of MS. Dr Fennell, who is based in the Department of Pathology within UCC’s School of Medicine, will together with his team study immune cells from people with MS and use genetic engineering to introduce or correct specific genetic differences in laboratorygrown cells. "By bringing together genetics, immunology and sophisticated models, we hope to better understand the mechanisms driving the disease and identify new opportunities for therapeutic intervention," states Dr. Fennell.
Empower Your Health Journey with
B-COMPLEX PLUS Balanced B Vitamin Formula with Active Folate Why Try B-Complex Plus? Comprehensive blend of B vitamins Provides active forms of B vitamins Features folate as 5-methyltetrahydrofolate (5-MTHF), the universally metabolized and biologically active form of folate Vitamins B1, B2, B3, B5 and B6 contribute to normal energy-yielding metabolism Vitamins B1, B3, and B6 contribute to normal functioning of the nervous system Folate, vitamin B5 and B12 contribute to the reduction of tiredness and fatigue
At Pure Encapsulations®, we know it’s what’s inside that counts. Uniquely formulated products made with high-quality, pure ingredients, backed by verifiable science to complement your healthy lifestyle.
Stock the Brand Healthcare Professionals Trust - Contact Us to Find Out More. Food supplements should not be used instead of a varied and balanced diet and a healthy lifestyle.
80
Clinical Profiles
DR CATHERINE MCGORRIAN APPOINTED AS MEDICAL DIRECTOR OF THE IRISH HEART FOUNDATION The Irish Heart Foundation has announced the appointment of Dr Catherine McGorrian PhD FRCPI, as Medical Director. Dr McGorrian, Consultant Cardiologist and General Physician in the Mater Misericordiae University Hospital, and an Associate Clinical Professor in University College Dublin, will take up the role of Medical Director on 1st November 2026, succeeding Dr Angie Brown. Having graduated from RCSI in 1997, Dr McGorrian has been a doctor for nearly 30 years, with a career still founded on clinical work with patients. She completed her specialty training in Cardiology and General Medicine in Ireland and Canada. Dr McGorrian worked and studied at McMaster University in Ontario and UCD, where she graduated with an MSc in Health Research Methodology and PhD on Cardiovascular Epidemiology, respectively. An author and co-author of more than 60 scientific publications, she has been working in the Mater Inherited Cardiac Conditions Clinic since 2008, along with work on the hospital wards and emergency department. As well as her clinical work, she has worked as a hospital Clinical Director, and the chair of the Clinical Advisory Group in Acute Medicine through the RCPI. The role of Medical Director is to promote the aims and objectives of the Irish Heart Foundation by advising the Chief Executive, Senior Management Team and the Board of Directors on medical
matters in relation to all aspects of cardiovascular disease prevention and cardiology generally.
Commenting on the event, HIQA’s Deputy CEO and Director of HTA, Dr Máirín Ryan, said:
Dr McGorrian said: “I am delighted to take up the role of Medical Director of the Irish Heart Foundation. I am passionate about cardiovascular disease prevention and treatment, and equity in service provision and delivery. I look forward to working with colleagues to achieve our mission to eliminate preventable death and disability from heart disease and stroke and to support and care for those living with these lifechanging conditions.”
“We are delighted to host this HAG meeting as part of Ireland’s Presidency of the Council of the EU along with our colleagues in the National Centre for Pharmacoeconomics. Ireland’s participation in the HAG allows us to collaborate and discuss strategic priorities with our European colleagues and share best practices for managing the common challenges facing our healthcare systems. I would like to thank all of our partners involved in organising this event, including the National Centre for Pharmacoeconomics, the Department of Health, the Office of Public Works, the Department of Foreign Affairs, the Convention Centre Dublin as well as the HAG Secretariat.”
Speaking of the appointment, Irish Heart Foundation CEO, Emma Balmaine, said, “I congratulate Dr McGorrian on her appointment and look forward to welcoming her to the Irish Heart Foundation. Dr McGorrian will play a pivotal role working with myself and Senior Management, our Board of Directors, colleagues, patients and stakeholders to support our strategic agenda, mission and vision.” Dr McGorrian takes up the role of Medical Director in the Irish Heart Foundation alongside her role as Consultant Cardiologist and General Physician in the Mater Misericordiae University Hospital. HIQA AND NCPE HOST A MEETING OF THE EUROPEAN HEADS OF HTA AGENCIES GROUP AS PART OF IRELAND'S PRESIDENCY OF THE COUNCIL OF THE EU The Health Information and Quality Authority (HIQA), and the National Centre for Pharmacoeconomics (NCPE) have jointly hosted a meeting of the Heads of HTA Agencies Group (HAG), supported by the Department of Health, at the Convention Centre Dublin as part of Ireland’s Presidency of the Council of the EU. With Ireland guiding discussions on the upcoming long-term EU budget during its Presidency, this meeting is an important opportunity to highlight the role of health technology assessment (HTA) in supporting governments across Europe to make evidencebased decisions on funding for different health technologies.
Dr Catherine McGorrian
IRISHPHARMACYNEWS.IE
During the meeting, Chief Medical Officer Professor Mary Horgan will speak about the value of HTA in improving the sustainability of healthcare systems. There will also be strategic discussions on how the first Joint Clinical Assessments of the EU HTA Regulation are being used by Member States, the evaluation of the EU HTA Regulation itself, as well as what the future of European HTA collaboration looks like.
NCPE’s Head of Strategy and External Engagement, and Chair of the EU Member State Coordination Group on HTA, Dr Róisín Adams, commented: “The National Centre for Pharmacoeconomics welcomes the opportunity along with HIQA to invite our European colleagues to Ireland for this important meeting. The NCPE has played a central role in the development and implementation of EU HTA and in cross border working via the Beneluxa and the International Horizon Scanning Initiative. Jointly with HIQA we are looking forward to working with the HAG which has an important strategic role in planning the future direction of EU HTA in partnership with the EU Member State Coordination Group.” Further information about this event is available here: https://irishpresidency.consilium.europa.eu/en/ events/meeting-of-the-heads-ofhta-agencies-group-hag/. MU RESEARCH FINDS BARIATRIC SURGERY CAN RESTORE IMMUNE CELL FUNCTION AFFECTED BY OBESITY New Maynooth University (MU)led research has found that obesity impairs key immune cells that help protect the body against infection and cancer, and that bariatric surgery can reverse this damage. The study is published in JCI Insight. More than one billion adults worldwide live with obesity, which is linked to a greater risk of severe outcomes from viral and bacterial infections. During the COVID-19 pandemic, for example, people living with obesity faced a significantly higher risk of serious illness. The study helps explain this heightened vulnerability by
examining gamma delta (γδ) T cells, a specialised group of immune cells, particularly a subset called Vδ2+ T cells. These cells are part of the body’s first line of defence. They respond rapidly to infection and help identify and destroy certain cancer cells. Researchers found that people living with obesity had fewer Vδ2+ T cells in their blood and that the cells were less active when stimulated. The cells also showed abnormalities in the processes that control nutrient uptake and energy production, both of which are essential to an effective immune response. The findings indicate that obesity disrupts the cells’ metabolism, limiting the energy available to respond to infection and disease. The study was led by Dr Ciara Flynn, working within the research group of Prof Andrew Hogan at MU’s Kathleen Lonsdale Institute for Human Health Research. Crucially, the immune cell defects were reversed following Roux-en-Y gastric bypass (RYGB) surgery. Patients showed significant improvements in the metabolic processes that support immune cell function, together with a marked recovery in the cells’ ability to respond. The research was conducted in collaboration with Prof Helen Heneghan and Prof Donal O’Shea at St Vincent’s University Hospital and University College Dublin, and was funded by the Health Research Board. Prof Andrew Hogan, Principle Investigator with the Obesity Immunology Research Group at Maynooth University’s Department of Biology, said: “The findings provide new insight into the relationship between obesity and immune dysfunction, helping to further explain why people living with obesity may be more vulnerable to serious infections, and a range of other conditions. “They also highlight that obesity is limiting immune cells metabolism, essentially leaving it without the energy it needs to protect us.” Professor Paul Moynagh, Director of the Kathleen Lonsdale Institute for Human Health Research at Maynooth University, said: “This study is an excellent example of highly impactful translational research. It has been achieved by Professors Hogan and Heneghan bringing their scientific and clinical expertise together to provide new insights into how obesity and its treatment affect the immune system in fighting infections and cancer.”
81
GALWAY-BASED HEART HEALTH ADVOCATE HONOURED WITH GLOBAL AWARD Neil Johnson has received the 2026 World Heart Federation Advocacy Award in Cardiovascular Health, recognising more than three decades of work to improve cardiovascular health in Ireland and internationally. The award was announced at the World Heart Federation’s World Congress of Cardiology in Brazil on 8 October. It recognises an individual who has made a notable contribution to strengthening advocacy for cardiovascular health at local, regional and global level. It also recognises a career defined by sustained leadership, collaboration and a commitment to strengthening the role of people with lived experience in shaping cardiovascular health. Johnson’s career has taken cardiovascular advocacy from community-based action in the West of Ireland to a global patient movement reaching more than 28 million people worldwide. He has made a lasting contribution to prevention, rehabilitation, health
promotion, patient advocacy and healthcare innovation. Johnson’s work has consistently focused on improving cardiovascular health and ensuring that the voices of people living with or affected by cardiovascular disease are heard. For over 32 years, he served as Chief Executive of Croí, the Heart and Stroke Charity, where his work helped advance cardiovascular prevention, rehabilitation, health promotion and patient advocacy. In 2014, he established the National Institute for Prevention and Cardiovascular Health (NIPC), a not-for-profit research and education institute, established in collaboration with the University of Galway. In 2019, Johnson founded Global Heart Hub, which has grown into a global alliance of almost 170 cardiovascular patient organisations across 44 countries, with a combined community reach of more than 28.7 million people. The network brings cardiovascular patient organisations together to strengthen the collective voice and leadership of people living with and affected by cardiovascular disease. Professor David A Wood, Honorary Professor of Preventive Cardiology, University of Galway; Director of Science, Strategy and Implementation at the National Institute for Prevention and Cardiovascular Health, said: “Neil leads with conviction because he is passionate about prevention of cardiovascular disease and, through his creation of the Global Heart Hub, he has become a leading international advocate.”
Neil Johnson
Accepting the award, Johnson said: “I am deeply honoured to receive this award from the World Heart Federation and to have this work in cardiovascular advocacy recognised in such a way. I am incredibly proud of what the Croí, NIPC and Global Heart Hub teams have achieved. Our vision is to continue building a stronger, more united voice for
people with lived experience of cardiovascular disease, ensuring that they are recognised as equal stakeholders in healthcare and that their insights and knowledge play a meaningful role in research, shaping healthcare policies, and the development of healthcare systems. This award is both an honour and a motivation to keep pushing for change.” NOVO LAUNCHES WEGOVY® 7.2 MG IN A SINGLE-DOSE PEN IN IRELAND, EXPANDING ACCESS TO THE HIGHEST APPROVED DOSE OF SEMAGLUTIDE FOR ADULTS WITH OBESITY Novo have announced the launch of Wegovy® (semaglutide) 7.2 mg in a single-dose p en in Ireland. It is indicated as an adjunct to a reduced-calorie diet and increased physical exercise for weight management, including weight loss and maintenance, in adults with an initial BMI of ≥30 kg/m2 (obesity). This treatment must be prescribed by a healthcare professional on prescription and will be dispensed through pharmacies. The clinical evidence for the 7.2 mg semaglutide is based on the STEP UP clinical trial, conducted by Novo, which has shown:
• From a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved an average weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo, when patients adhered to treatment. • In a sub-study in the trial, 84% of the weight lost with semaglutide came from fat mass loss, with tests confirming muscle function was preserved. • Gastrointestinal adverse events were more common with semaglutide 7.2 mg
(70.8%) versus 2.4 mg (61.2%) or placebo (42.8%), as was dysaesthesia (22.9% versus 6% versus 0.5%). • Serious adverse events were reported by 6.8% of participants with semaglutide 7.2 mg, 10.9% with semaglutide 2.4 mg, and 5.5% with placebo. General Manager of Novo Ireland Dilek Dogan Gurluk, said, “Obesity is a chronic disease that requires long-term, individualised management and support. By offering Wegovy® 7.2 mg in a single-dose pen, we can help reduce practical barriers for people living with obesity and the healthcare professionals who support them. We remain committed to improving access to obesity care in Ireland.” MAJOR NEW STUDY IDENTIFIES POTENTIAL NEW TREATMENT TARGETS FOR THE MOST COMMON TYPE OF BOWEL CANCER Major new research published recently identifies potential new ways to treat the most common type of bowel cancer in Ireland. The study conducted by an international research team led by RCSI University of Medicine and Health Sciences and The Institute of Cancer Research, London, provides a clear roadmap for repurposing existing drugs and developing new ones, to create more effective, personalised treatments for thousands of patients who currently have limited options. Of the 2,500 new bowel cancer cases diagnosed annually in the Ireland, Microsatellite stable (MSS) colorectal cancer accounts for 80-85% of these, but remains challenging to treat, with limited response to many newer therapies. Trials combining chemotherapy with newer targeted drugs or immunotherapies have delivered only modest improvements over current standard treatments.
IRISHPHARMACYNEWS.IE
82
Clinical Profiles
Now, researchers have discovered vulnerabilities in these tumours and have identified the drug combinations – including drugs already approved to treat other tumour types – that could be used to target them, leading to more effective treatments for bowel cancer. Using 2,000 patient tumour samples, the researchers analysed genetic, metabolic protein and clinical data with the help of artificial intelligence (AI) tools, revealing previously unrecognised ways in which the cancer cells divide, grow, adapt and interact with their environment. To do this, the team developed an AI approach called iPhenMap, which can create a biological map of the tumour. Using this map, they were able to spot connections between the different elements of the tumour – such as the genetic and metabolic features – that have been missed in previous studies that looked at the data in isolation. Importantly, they found previously unidentified vulnerabilities in the tumours. They then tested these vulnerabilities in laboratory models and showed that certain drug combinations could work well to target them and treat the cancer. For example, the targeted drug trametinib – approved to treat various cancers including melanoma, lung cancer, and thyroid cancer, with a specific mutation – was shown to significantly reduce tumour growth and extend survival in the laboratory models when combined with other drugs. The researchers hope this work will accelerate the path to clinical testing of new treatment strategies for bowel cancer, using drugs which have already been developed and approved. In addition, the team believe their AI approach could be used to identify more effective drugs for other tumour types. The research published in leading oncology journal Cancer Cell was jointly led by Professor Annette Byrne, Head of the RCSI Precision Cancer Medicine Group, Department of Physiology and Medical Physics and Professor Anguraj Sadanandam, Group Leader, Systems and Precision Cancer Medicine Group, The Institute of Cancer Research, London. Dr Rodrigo Dienstmann, Vall d’Hebron Institute of Oncology, Barcelona and University of Vic– Central University of Catalonia was co- senior author of the study. Professor Byrne said: “Patients with MSS RAS-mutant metastatic colorectal cancer urgently need better treatment options,
IRISHPHARMACYNEWS.IE
particularly when their disease no longer responds to standard therapy. "While these findings remain preclinical, they highlight promising therapeutic opportunities and provide a strong foundation for further development. The next step will be to identify the biological features that predict response and determine how these approaches can be advanced safely towards clinical evaluation.” Professor Sadanandam added: “A major strength of this research is the scale and diversity of the dataset, which was only possible through collaboration with European partners. By bringing together data from patients across multiple countries and integrating DNA, RNA, epigenetic, protein, metabolic, single-cell and clinical data at this scale, we were able to expose connections between tumour biology and therapeutic dependency that would otherwise be missed. “AI and machine learning will increasingly help cancer researchers to bring these complex data together, not just to classify tumours, but to understand how they behave, identify their vulnerabilities and guide the development and repurposing of treatments, so that patients can live longer and healthier lives.” Ensuring the patient voice was embedded throughout the project and that the findings were disseminated in an accessible format was a priority. This research was funded by the European Union’s Horizon 2020 Research and Innovation Programme through funding awarded to the COLOSSUS project (www.colossusproject. eu), and by a Research Ireland Project Award to Professor Byrne. COLOSSUS, led by Professor Byrne, brings together leading European and international academics, clinicians, private sector and not-for-profit partners. VHI HEALTH & WELLBEING FUND AWARDS ¤85,000 TO YOUTH MENTAL HEALTH PROJECTS ACROSS IRELAND Vhi and the Irish Youth Foundation (IYF) today announced the recipients of the Vhi Health & Wellbeing Fund, with grants totalling ¤85,000 awarded to nine youth organisations and community groups across Ireland. The funding will support programmes designed to strengthen young people’s mental health and wellbeing, helping more than 1,200 young people build resilience, manage anxiety and access vital supports within their communities.
Brian Walsh, Vhi CEO celebrates with grant winners The latest awards bring Vhi’s total investment through the Fund to ¤529,000 since its launch in 2020. Over the past six years, the Fund has supported 63 organisations and projects nationwide, positively impacting almost 39,000 young people through targeted programmes focused on early intervention, prevention, resiliencebuilding and emotional wellbeing. This year’s grant recipients span Dublin, Cork, Kilkenny, Galway, Limerick and Donegal, supporting young people from a wide range of backgrounds, including those experiencing addiction, disability, housing insecurity, social disadvantage and anxiety, as well as young refugees and those seeking international protection. Among this year’s recipients is Liquid Therapy in Donegal, which will deliver ‘A Day In The Ocean’ (ADITO), an innovative beach and ocean-based programme designed to promote positive wellbeing, social connection and confidence among young people who may face barriers to participating in mainstream sports. Developed by surfing practitioners, psychologists and psychotherapists, the initiative combines structured workshops with surfing and ocean-based activities to support physical and emotional wellbeing. In Cork, the Crann Centre will deliver a series of expressive arts workshops for young people with neuro-physical disabilities. Using art, music and meditation, the programme will create opportunities for self-expression, confidencebuilding and social connection while helping participants develop practical tools to support their wellbeing. Meanwhile, Galway Simon Community will deliver targeted supports for young people experiencing homelessness or at risk of housing insecurity, helping them develop confidence, resilience and the skills needed to navigate challenging circumstances.
Other organisations receiving funding include Southill Hub (Limerick), Mental Health Ireland (Galway, Kilkenny and Donegal), Aiséirí (Kilkenny), the Irish Refugee Council (Dublin) and Poppintree Youth Project (Dublin). The projects funded this year reflect the important role community organisations play in supporting young people across Ireland. Through trusted relationships, innovative programmes and accessible supports, these organisations are helping young people build confidence, strengthen wellbeing and develop the skills needed to navigate life’s challenges. Brian Walsh, Group CEO, Vhi, said: “At Vhi, we believe investing in young people’s health and wellbeing is one of the most meaningful ways we can contribute to healthier communities. Through the Vhi Health & Wellbeing Fund, we continue to see the positive impact that community-led initiatives can have in helping young people build confidence, develop resilience and access support when they need it most. We are proud to continue our partnership with the Irish Youth Foundation and support nine outstanding organisations whose work will make a real difference to the lives of young people across the country.” For more information about the Vhi Health & Wellbeing Fund visit https://iyf.ie/grants/. IRISH STUDY REVEALS SIGNIFICANT IMPROVEMENT IN OSTEOPOROSIS RATES A major Irish study has found a significant decline in the number of people diagnosed with osteoporosis in the hip and lower back over 26 years, based on bone-density scans from 66,681 people attending two hospitals in the Mid-West.
83 Published in Archives of Osteoporosis on 19 August 2026, the research looked at the first recorded bone-density scans of people attending University Hospital Limerick and St Camillus Hospital between 1998 and 2024.1 During this time, the proportion of people with osteoporosis at the hip fell from 19.4% to 7.4%. At the lower back, it decreased from 30.2% to 8.4%. The decline remained evident after researchers accounted for differences in the age and sex of those scanned, as well as changes in the number of scans carried out. The findings offer a new perspective on bone health over time and raise questions about what may be driving the decline in osteoporosis. Understanding whether this trend continues in future generations will be important as Ireland’s population ages and healthcare services prepare for the needs of an older population. The study also provides some evidence as to why longevity may be increasing. Osteoporosis is a condition associated with falls and fractures, which in many instances can contribute to death in the short to medium term. The substantial improvements in bone density described in the study will almost certainly result in a reduction in premature fracture rates, thereby allowing people to remain healthier and live longer. Osteoporosis is a chronic condition that weakens bones, making them more likely to break. It often develops without obvious symptoms, and some people only discover they have it after breaking a bone. Fractures can affect the hip, wrist and spine, sometimes leading to pain, reduced mobility and loss of independence, particularly in older people. The Irish Osteoporosis Society estimates that up to 300,000 people in Ireland have osteoporosis. The condition affects both men and women, although women are at greater risk after menopause. Professor Declan Lyons, HSE Director of Research in Limerick and co-author of the study, said, “As Ireland’s population ages, understanding how health changes over a lifetime is increasingly important. What is interesting about this study is the substantial decline in osteoporosis seen over the past 26 years among people attending these two hospitals. It raises important questions about whether people are reaching older age with better bone health than previous generations, and what that could mean for the future. “From a wider healthcare perspective, these findings highlight the importance of
understanding bone health as part of healthy ageing. Primary care plays an important role in identifying people at risk of osteoporosis and ensuring they can access appropriate assessment and support. Understanding the reasons behind the trend, and whether it is reflected in fracture rates, will help inform how we plan for the health needs of an ageing population.”
Roisin now checks her breast area on the first of the month, every month, and is sharing her story to encourage others to do the same and to go to their GP if they notice any changes. Alanna Kells, 28, from Cavan, found a small lump in her breast in October 2025. Commenting on how the lump in her breast felt, Alanna said: “I thought maybe it was just some muscle tissue. It felt like a pearl you’d get in boba tea. It was malleable and it wasn’t rock hard, which I assumed it would be if it was cancer. But I was able to move it around, and it blended into the surrounding tissue quite easily.
For more information about the risk factors, assessment and treatment of osteoporosis, visit https://www.osteoporosis. foundation/educational-hub/ material/patient-resources YOUNG BREAST CANCER PATIENTS URGE WOMEN TO ACT EARLY TO DETECT BREAST CANCER DURING THE IRISH CANCER SOCIETY’S PINK CAMPAIGN THIS BREAST CANCER AWARENESS MONTH Two breast cancer survivors in their 20s are urging women and men to know the signs of breast cancer, to understand their risk of breast cancer and to check their breasts. Breast cancer remains the most common cancer among women in Ireland, accounting for nearly one-third of all invasive female cancers. Around 13 per cent of all breast cancers occur in women aged between 15 and 44. Though the incidence is lower in younger women, notably, there has been a 25 per cent increase in breast cancer in this age group over the past decade. While breast cancer is significantly lower in younger women, when it does occur, the tumours tend to be more aggressive. Younger patients are also more likely to experience delays in getting diagnosed, and may face unique emotional, social, and long-term recovery challenges. Breast cancer patient, Roisin Molloy, 28, from Offaly, was living and working in New Zealand in September 2025 when she noticed a sore lump in her right breast. Explaining how she discovered the lump, Roisin said: “I was scrubbing off some fake tan when I noticed it. It was apple-sized, quite hard and close to the skin. There was some pain around it. I thought it was unusual but left it for four weeks to see if anything changed about it during my menstrual cycle.” After the four weeks had passed and the lump hadn’t changed, Roisin went to her GP who referred her for further tests. In November 2025, she was diagnosed with HER2 breast cancer. Speaking of the impact of the diagnosis while being so far away from home, Roisin said: "I felt like I was the loneliest person in
“I hummed and hawed about it for a day or two, but then I thought, ‘I should get this checked’.” Alanna went to her GP, who referred her to a Breast Clinic. In December 2025, Alanna received her diagnosis.
Alanna Kells the world. I was 20,000kms from home, and I was so scared and in disbelief. I was so healthy, I was eating so well, and I had no family history of cancer. I couldn’t understand why this had happened.” Three weeks after her diagnosis, Roisin flew back home to Ireland and prepared to start treatment. She had fertility treatment first, before undergoing chemotherapy and a mastectomy. She finished active treatment in late September, when she completed her course of radiotherapy. Reflecting on her experience of going through treatment for breast cancer, Roisin said: “I felt so vulnerable and like I was the only person in the world going through this and feeling this way, but I know I wasn’t. In June, two weeks after I had the mastectomy, I got the news that everything was clear – now I get to live again after all of this.” Roisin shared how the Irish Cancer Society supports and services helped: “I found the Irish Cancer Society booklets to be an important source of information. I got an Irish Cancer Society Support Pack on my first day in St James’s Hospital. “The nurse gave me the pack and said I could read everything in it in my own time. I liked that I could find out, piece by piece and when I was ready, more about what was happening.”
Speaking about her diagnosis, Alanna said: “The surgeon was straight to the point and told me I had cancer, specifically stage three invasive ductal carcinoma breast cancer, hormone positive and HR negative. “They told me the ultrasound found two tumours, and that the lymph nodes were inflamed. The breast MRI showed that I had cancer across all four quadrants of my breast. It ended up forming into one tumour that I could feel.” Her breast cancer diagnosis meant Alanna had to take on some huge, life-impacting decisions, at an extremely vulnerable time. Alanna said: “I started the process of fertility preservation, however after consulting with my oncologist, I decided the best action would be to stop the fertility preservation and start chemotherapy sooner.” Her chemotherapy was followed by a mastectomy, and she will soon start radiotherapy. Reflecting on her experience, and what she’d like others to know, Alanna said: “My genetic screening was all negative, so it just goes to show breast cancer can affect anyone at any age, even without a family history of it. It’s so important to be proactive about your health and to do regular breast checks, it can make a big difference.” Breast cancer is less common in younger women, but when it does occur, the tumours tend to be more aggressive. Younger patients are also more likely to experience delays in getting diagnosed, and may face unique emotional, social, and long-term recovery challenges.
IRISHPHARMACYNEWS.IE
mclernons.ie
MPS CCS MODULE
RUN COMMON CONDITIONS
CONSULTATIONS FROM ONE PLACE HSE-guided assessments, patient records, prescriptions and consultation management, all integrated with MPS.
One patient. One record. One consultation workflow. HSE protocol-driven
All eight Common Conditions Service assessments follow their HSE Pharmacist Assessment Form. Red flags warn, stop the consultation or guide the pharmacist to the right referral.
Full MPS integration
Patient medications, allergies and previous consultations are available directly alongside the assessment.
Prescriptions by Healthmail
Generate the Common Conditions Service (CCS) prescription template, preview it, then print or send it through Healthmail.
To find out more or book a demonstration contact your McLernons trainer or email us on servicedesk@mclernons.ie mclernons.ie